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Existing therapies for the treatment of glioma remain problematic while the 
incidence of malignant gliomas is growing, leading to an increasing demand for more 
effective treatment options.  Currently, patients diagnosed with malignant brain tumors 
have a very poor prognosis with a median survival rate of less than one year and an 
overall 5-year survival rate as low as 34.1%.  Brain tumors continue to be a challenge to 
treat because they are inherently diffuse, highly invasive, and non-localized.  For these 
reasons, it is imperative that treatments for brain and nervous system cancers are 
improved. 
Liposomal nanocarriers offer much promise in the delivery of chemotherapeutic 
drugs to solid tumors because they may be specifically targeted to tumors thereby 
shielding healthy organs from the toxic side effects of incorporated chemotherapeutics.  
Passive targeting of liposomes is achieved through the inclusion of PEG to evade the 
RES and prolong circulation in the bloodstream.  Since tumor vasculature exhibits 
increased permeability, prolonged circulation results in passive accumulation of 
liposomes to tumor.  Active targeting to tumor is accomplished through the inclusion of 
agents targeted to over-expressed receptors on tumor cells.  In vitro studies with a wide 
variety of targeting agents have demonstrated the potential for increased cytotoxicity of 
actively targeted liposomes due to specific uptake by tumor cells.  In vivo, however, 
actively targeted liposomal nanocarriers have failed to meet the expectations established 
by the promising outcomes of in vitro studies.  This is attributed to the fact that the 
xiv 
 inclusion of targeting agents results in accelerated clearance from the bloodstream and 
reductions in passive targeting to tumor thereby offsetting the benefits of active targeting.   
The central focus of this thesis was to engineer a multi-functional nanoscale drug 
delivery system which would enable active targeting without compromising RES evasion 
and passive accumulation to tumor.  It was shown that the use of folate targeting ligands 
in sterically stabilized liposomal formulations significantly reduced blood circulation 
times.  To address this issue and prevent RES recognition of folate on targeted liposomal 
formulations, a cysteine cleavable phospholipid-PEG conjugate was utilized to “mask” 
adjacent targeting ligands while liposomes were in circulation.  This system enabled 
controlled ligand presentation using an exogenous trigger.  Once passive accumulation at 
the tumor was achieved, cysteine was administered to detach PEG chains, expose folate, 
and promote uptake by tumor cells.  In vivo studies demonstrated that cleavable DSPE-
PEG5000 was capable of concealing folate on liposomes to maintain prolonged circulation 
times.  In vitro uptake and cytotoxicity studies verified the ability to conceal and expose 
folate on demand, permitting receptor mediated targeting and delivery of large drug 
payloads into the nucleus of target cells. Finally, studies conducted to analyze drug 
uptake by tumor cells in vivo confirmed that delivery was enhanced when tumor-
inoculated animals received targeted liposomes containing cleavable PEG chains 
followed by a cysteine infusion to expose folate. These results indicate that detachable 
PEG chains can be used in targeted liposomal formulations to enhance efficacy of 





 CHAPTER 1.  INTRODUCTION 
1.1.  STATEMENT OF PROBLEM 
Current approaches for the treatment of glioma are limited in their effectiveness 
because malignant brain tumors are characteristically diffuse, highly invasive, and non-
localized [1].  Upon diagnosis of malignant gliomas, surgical removal of the accessible 
tumor follows; however, due to the invasive nature of malignant gliomas, complete 
surgical resection is a rarity.  Therefore, conventional therapies include radiation therapy 
and chemotherapy after surgical resection.  Treatment regimens including radiation and 
systemic chemotherapy have been minimally effective [2, 3].  The success of systemic 
chemotherapy for intracranial tumors is critically dependent on the access that these 
agents have to tumors which is limited even with the so-called leaky vasculature across 
the blood-brain barrier (BBB).  Indeed BBB associated limitations restrict therapies to 
low molecular weight, uncharged, and lipophilic agents.  Use of implantable 
biodegradable drug depots is one strategy to localize delivery of chemotherapeutics and is 
currently used in clinical practice [4].  Gliadel®, an FDA approved BCNU-loaded 
polyanhydride polymer wafer, has resulted in improved survival rates [5].  However, the 
drug diffused from a central core usually cannot reach the tumor periphery where the 
most aggressive cancer cells persist, and median survival has only shown to be extended 
about 2.2-3.4 months for patients with newly-diagnosed high grade glioma [5, 6] and a 
mere 2 months for patients with recurrent disease [5, 7].  Conversely, drug delivery via 
systemic intravascular administration utilizes the tumor’s own blood supply for transport 
allowing for drug delivery throughout the tumor.  Systemic delivery of long circulating 
liposomal nanocarriers has exhibited increased chemotherapeutic drug delivery to solid 
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 tumors [8] due to the combination of prolonged circulation in blood and preferential 
accumulation in solid tumors by passive convective transport through leaky endothelium 
because of the discontinuity in the abnormal tumor vascular—the so called enhanced 
permeability and retention (EPR) phenomenon [9].  
Nanocarrier mediated therapy of gliomas shows promise because multi-functional 
nanocarriers can theoretically be designed not only to carry a range of chemotherapeutic 
or anti-invasive agents, but also to both passively and actively target intracranial tumors 
such as gliomas.  ‘Passive’ targeting results from prolonged circulation of nanocarriers 
allowing for accumulation at sites with abnormal, leaky vasculature.  In recent studies on 
a rat brain glioma, effective ‘passive’ tumor dosing was achieved by i.v. injections of 
drug-loaded liposomal nanocarriers [10].  It has been demonstrated in patients with 
glioblastomas and metastatic brain tumors that long circulating liposomal nanocarriers 
selectively overcome the BBB in the tumor lesions resulting in 13-19 times higher 
accumulation in the glioblastoma as compared to the normal brain [11].  However, 
passive targeting does not address uptake by tumor cells after extravasation. 
Therefore, for further increase in efficacy and specificity, liposomal nanocarriers 
can potentially be tagged with targeting molecules that bind to receptors over-expressed 
on tumor cells for ‘active’ targeting. The initial enthusiasm of the active targeting 
strategies has however been limited due to disappointing in vivo performance of the 
targeted nanocarriers compared to non-targeted nanocarriers.  It has been shown that the 
presence of targeting ligands compromises blood circulation time of nanocarriers [8, 12-
15] and decreases passive accumulation of carriers to tumors [16] as extravasation is 
directly proportional to circulation time and concentration in blood [17].  This is not 
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 unexpected as long circulation time of liposomal nanocarriers is due to a polyethylene 
glycol (PEG) shielding (3-10% of the lipid is typically PEGylated), and when targeting 
ligands are employed, they are usually conjugated on the free end of the PEG chain 
resulting in recognition by the reticulo-endothelial system (RES) and accelerated 
clearance by the liver.  As a result, fewer ‘targeted’ nanocarriers are able to reach the 
tumor site and consequently the gains from active targeting after extravasation into the 
tumor are compromised [16]. 
1.2.  HYPOTHESIS 
The ability to actively target systemically delivered drugs to tumors while 
retaining the full capability of passive accumulation remains an unresolved problem.   
Overcoming this challenge requires that circulation times be unaffected by the 
incorporation of targeting agents while the ability to actively target tumor cells at the 
target site is retained.  We believe that targeting ligands may be ‘masked’ by ‘burying’ 
them within adjacent longer PEG chains on the nanocarrier surface so that circulation 
times are not compromised as seen with non-masked ligand presenting nanocarriers.  To 
enable ligand binding to tumor cells after extravasation to tumor site, ligand-masking 
PEG chains may be fabricated to be susceptible to cleavage by a safe ‘cleaving agent’ 
(cysteine) that is administered intravenously after the nanocarriers have extravasated to 
the tumors.  The central hypothesis of this thesis is that the use of targeting ligands that 
are masked while in circulation, but unmasked after extravasation will significantly 
enhance targeted nanocarrier delivery to tumor compared to non targeted nanocarriers or 
targeted, unmasked nanocarriers.   
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 1.3.  OBJECTIVES 
The overall purpose of the work described in this thesis is to successfully 
optimize targeted drug delivery to tumors in vivo with an emphasis on achieving 
maximized drug accumulation at the target site with limited uptake by healthy organs.  
To do so, both passive and active targeting of chemotherapeutic agent to tumor should be 
employed where each method of targeting, while used concurrently, retains optimal 
performance. 
To meet this goal, the following objectives were set: 
1. To design and fabricate an actively targeted liposomal doxorubicin formulation 
and characterize in vivo performance.  
2. To reduce RES clearance of actively targeted liposomal formulations by masking 
targeting ligands with cleavable PEG chains.    
3. To demonstrate ligand activity masking and unmasking on targeted nanocarriers 
using cleavable PEG chains.   
a. Determine ability to modulate uptake and cytotoxicity of targeted 
formulations with cleavable PEG chains in vitro. 
b. Evaluate passive accumulation and active targeting of liposomal 
nanocarrier chemotherapeutics in vivo using a rat intracranial tumor 
model. 
Fulfillment of these objectives would also address some of the engineering 
challenges of nanoscale drug delivery to tumors.  In general, there are currently no means 
to control the introduction of ligands on targeted nanocarrier drug delivery systems after 
in vivo administration.  The scheme presented here would allow for precise control over 
4 
 an engineered nanoscale system for drug delivery.  Cleavable phospholipid-PEG 
conjugates would confer the ability to control the time and location of ligand presentation 
in vivo.  Masking and triggered unmasking of biological entities on targeted nanocarriers 
would serve to 1) prevent degradation of targeting agents to ensure that they are intact at 
the site of action, and 2) reduce the immunogenicity of incorporated agents to inhibit 
RES recognition and clearance.  Control over ligand presentation would ensure that 
targeted nanocarriers only act when necessary at the tumor site since activation would be 
initiated through an external trigger.      
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 CHAPTER 2.   CURRENT STATE OF GLIOMA THERAPIES 
2.1.  CURRENT TREATMENTS FOR BRAIN TUMORS ARE INSUFFICIENT 
Current therapies for the treatment of gliomas remain problematic while the 
incidence of malignant gliomas is growing, leading to an increasing demand for more 
effective treatment options [1].  It is estimated that there will be 21,810 new cases and 
13,070 deaths from cancers of the brain or nervous system in the United States in 2008, 
and 1 in 165 people will be diagnosed with cancer of the brain or nervous system in their 
lifetime [2].  Evidence suggests that the incidence of malignant brain tumors may be 
increasing particularly in the elderly [3], and gliomas are the second leading cause of 
death amongst children.  Patients diagnosed with malignant brain tumors have a very 
poor prognosis with a current overall 5-year survival rate of merely 34.1% [2].   
Brain tumors continue to be a challenge to treat because they are inherently 
diffuse, highly invasive, and non-localized.  These tumors exhibit aberrant proliferation, 
reduced apoptosis, evasion of external growth control and immunoregulation, and 
resistance to therapeutics [4].  Instead of completely and permanently eliminating a 
malignant brain tumor, current treatments have typically been shown to merely prolong 
patient survival [5, 6, 1].  For these reasons, it is imperative that treatments for brain and 
nervous system cancers are improved. 
2.2.  CURRENT TREATMENT MODALITIES 
Historically, the standard treatment of malignant gliomas has typically consisted 
of surgical resection followed by radiotherapy.  Chemotherapy has also been utilized in 
combination under certain circumstances.  Patient care is individualized on the basis of 
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 prognostic factors including patient age, Karnofsky Performance Status (KPS) score, and 
tumor size, location, and histology [7, 8].  Other treatment options currently in use or 
under investigation include localized radiotherapy, localized chemotherapy, and targeted 
systemic chemotherapy.  Novel treatment techniques continue to increase, and the 
National Cancer Institute reports over 400 clinical trials currently recruiting patients with 
brain tumors for the investigation of new treatment options [9].  In addition, the 
abundance of ongoing pre-clinical studies adds to the development of more effective 
treatments.  Current research studies, however, must ensure that newly developed 
treatments not only improve long term survival rates, but also address patient quality of 
life, specifically considering the drastic side-effects often associated with current 
treatments which serve to reduce patient compliance.  Here, the traditional treatment 
strategies as well as those recently developed or in development for the treatment of brain 
tumors are discussed. 
2.2.1.  SURGICAL RESECTION 
Surgical resection is often the first line of defense in the treatment of brain 
tumors.  It is performed to confirm tumor histology and to achieve maximal resection.  
Numerous studies have validated the benefit of surgery by comparing survival times 
between patients treated with radiation versus those undergoing craniotomy in addition to 
whole-brain radiotherapy [10, 11].   Patients who underwent surgery demonstrated a 
significant increase in median survival and experienced longer functional independence.  
Radical resection often leads to a better prognosis for patients [12, 13].  Surgical 
resection, however, is often incapable of completely removing deeply penetrating and 
diffuse brain tumors and typically results in tumor recurrence immediately adjacent to the 
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 site of removal.  It has been shown that greater than 95% of the brain tumor must be 
surgically excised to prevent progression of the disease [14].  Recurrence of tumors is 
common following surgical resection since it is often difficult to completely eradicate 
both the tumor and the invading tumor front without harming the adjacent healthy brain 
tissue, and recurrence of tumor invariably results in neurological deterioration and death.  
In addition, there are many risks associated with surgical resection since it is a highly 
invasive procedure.  Some reported risks include operative death, infection, seizures, 
brain fluid flow blockage, peritumoral edema, and impaired neurological functions [15].  
To reduce these risks, more effective and safer therapeutic procedures or adjuvant 
therapies must be developed for the treatment of malignant brain tumors. 
2.2.2.  RADIOSURGERY 
Surgical resection may not be an option for patients if the brain tumor is located 
in an unresectable location or if the glioma is recurrent.  In these cases, radiosurgery 
provides an acceptable treatment alternative [16].  Radiosurgery uses stereotaxy to 
precisely localize focal radiation typically delivered at doses between 54-60 Gy.  
Prescribed dose varies based on tumor size, location, and previous radiation treatments 
[16].  The target volume includes the tumor bed as well as an additional margin 
accounting for tumor infiltration into the surrounding healthy tissue [12].  Computed 
tomography (CT) or magnetic resonance imaging (MRI) is used to locate the tumor prior 
to radiosurgery.  The most commonly used radiosurgery system is the Gamma Knife, 
which centers converging gamma radiation beams at the desired target [16].  
Radiosurgery has proven effective at local tumor control and prolonging patient survival 
[17].  In addition, radiosurgery is less invasive than conventional surgical resection.  
10 
 Despite these advantages, tumor recurrence and side effects similar to those reported for 
surgical resection are often associated with radiosurgery.  In addition, stereotaxic 
radiosurgery often results in the development of late side effects due to the high radiation 
dose required per treatment [18]. 
2.2.3.  WHOLE-BRAIN RADIATION THERAPY 
Both surgical resection and radiosurgery typically require adjuvant postsurgical 
therapy due to the infiltrative nature of glioma.  Whole-brain radiation therapy (WBRT) 
is often utilized for this purpose at a dosage ranging between 10-30 Gy [19].  WBRT has 
also traditionally been used to treat glioma due to concerns of multicentricity.  While the 
use of WBRT has proven to provide swift attenuation of neurological symptoms, improve 
quality of life, enhance control of tumor progression, and decrease the likelihood of 
neurological death [19, 20], there still remain many complications associated with the 
procedure.  The penetration of radiation therapy is limited by the energy of the incident 
photons, and increasing the energy to allow for deeper penetration invariably results in 
irradiation of healthy tissue.  Resultant side effects may be either acute or late in 
occurrence and include fatigue, hair loss, scalp irritation, nausea, memory loss, mental 
deterioration, hormonal deficiencies, headaches, seizures, and possible death.  In 
addition, prognosis after treatment tends to be poor with a median survival of merely 12 
months following the combination of surgery and radiation therapy [1].       
2.2.4.  TRADITIONAL CHEMOTHERAPY 
Currently, systemic chemotherapy is not the primary treatment choice for 
malignant brain tumors; however it may be utilized as an adjuvant therapy.  
Unfortunately, systemic delivery of chemotherapeutics exposes healthy organs to the 
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 toxic side effects of the drug due to non-specific uptake.  As a result, a lower dosage of 
the drug must be administered, causing the overall efficacy of the treatment to be 
decreased offering only a marginal impact on patient survival.  In addition, brain tumors 
are unique from other types of cancer due to the presence of the blood brain barrier.  
Even though the BBB within the tumor environment is compromised exhibiting large 
inter-endothelial junctions (100-780 nm), delivery of traditional chemotherapeutics 
utilized as treatments for other types of cancer is limited.  Patients with recurrent or high 
grade glioma will typically be administered small, lipophilic chemotherapeutics capable 
of crossing the BBB as an adjuvant treatment.   
Temozolomide, as part of an adjuvant therapy, is the most commonly utilized 
chemotherapeutic drug for clinical treatment of glioma.  Temozolomide has recently 
gained popularity over the traditionally used BCNU because it can be administered in 
oral form.  Use of temozolomide (and other similar drugs) is primarily due to its physical 
properties (hydrophobicity and small size), which allow it to cross the BBB to reach 
tumor cells.  However, if other drugs could reach the tumor (i.e. cross the BBB), 
temozolomide would have no advantage over these drugs.  Primary toxicities associated 
with temozolomide include nausea and myelosuppression which result from non-specific 
drug uptake by healthy cells.  These side effects lower the drug therapeutic index which 
makes dosing more difficult and thereby reduces treatment efficacy.       
Theoretically, the BBB permeability of existing anticancer drugs utilized to treat 
other types of tumors could be increased by modifying them to be more lipophilic.  
However, clinical trials have demonstrated no significant increase in therapeutic efficacy 
using chemotherapeutics modified to increase lipophilicity [21].   Instead of altering the 
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 drug itself, other efforts have focused on altering the BBB by infusing hyperosmolar 
mannitol causing dehydration of the endothelial cells followed by their shrinkage [22].  
While hydrophilic drugs could penetrate better the disrupted BBB, the invasiveness of 
this method restricts its chronic use.  Encapsulation of traditional chemotherapeutics 
within long-circulating nanocarriers has been shown to circumvent the issues of transport 
across the BBB by increasing the number of passages through the microvascular bed 
thereby escalating the probability of extravasation into tumor [23-25].  In addition, 
entrapment of drug reduces associated side-effects by shielding non-target organs from 
exposure.  These nanocarriers may also be targeted to brain tumors to further increase 
treatment efficacy (See Section 2.2.3.2).   
2.3.  NOVEL TREATMENT APPROACHES 
2.3.1.  NOVEL RADIOTHERAPY TECHNIQUES 
Localized radiotherapy techniques have recently been developed in an attempt to 
avoid the typical side effects associated with WBRT resulting from healthy tissue 
exposure.  Brachytherapy involves interstitial delivery of radiotherapy.  In this process, 
radiotherapy is directed to tumor in order to spare nearby normal brain tissue.  This form 
of radiotherapy differs from radiosurgery because it involves the use of isotopes rather 
than gamma rays to treat the tumor.  Iodine-125 (I125) seeds have been studied most 
frequently and can be implanted permanently or temporarily at the tumor site.  
Unfortunately, studies have failed to demonstrate a significant advantage of this 
technique compared to WBRT, and reported complications such as isotope shift, 
neurologic decline, exacerbation of seizures, infection, and arterial occlusion, have made 
it so that this technique is rarely used today [26, 27]. 
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 A more promising development has been the GliaSite Radiation Therapy System.  
This temporary brachytherapy technique utilizes an expandable balloon filled with I125 
solution implanted at the tumor resection site.  The balloon adheres to the walls of the 
resection cavity and ensures a more homogeneous dose distribution of radiation [28].  
Preliminary studies show potential, demonstrating a median survival time of 12.7 months 
for patients with recurrent glioma [29]. 
Another approach to improve local dose intensification of radiation is to use 
systemically delivered radiosensitizers.  Many different agents have been reported 
including hypoxic sensitizers, s-phase sensitizers, and cytotoxic agents, however, with the 
exception of the cytotoxic agent, temozolmide, none of these treatments has 
demonstrated a distinct enhancement in therapeutic efficacy compared to radiotherapy 
alone [30].  In addition, systemic delivery of these radiosensitizers subjects non-target 
organs to the toxic effects of these drugs and delivery to tumor may be limited by the 
BBB.  For the radiosensitizers to be effective, large numbers of molecules per cell may 
be required, and this may not be feasible for gliomas without use of delivery vehicles. 
2.3.2.  LOCALIZED CHEMOTHERAPY 
Localized chemotherapeutic approaches are currently in use and under 
investigation in an attempt to circumvent the side effects associated with traditional 
systemic chemotherapy.  These techniques are used to deliver drug directly to the tumor 
site. 
2.3.2.1.  Intra-Arterial Delivery 
This technique was developed to deliver chemotherapeutics through the carotid 
artery to increase the amount of drug in contact with the BBB in an effort to enhance 
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 transport into the brain while reducing systemic toxicity.  The feasibility of drug transport 
across the BBB using this technique has been demonstrated with nitrosoureas; however, 
clinical studies have not yet demonstrated a clear advantage to this technique compared 
to traditional intravenous delivery.  Significant risks are associated with intra-arterial 
delivery including local infarctions, leukoencephalopathy, and heightened neurotoxic 
effects [31].  In addition, technical difficulty and inadequate drug distribution within the 
tumor have limited the success of this treatment method [32]. 
2.3.2.2.  Convection Enhanced Delivery 
In an attempt to localize chemotherapeutics to the delivery site, a method has been 
developed using catheter systems to deliver chemotherapeutics directly to the tumor site 
[33, 34].  The advantage of this method is that chemotherapeutics may be able to reach a 
large brain volume and delivered in a sustained fashion.  In addition, the BBB is 
bypassed and drug half-lives are prolonged.  This treatment must be reserved for patients 
with non-resected tumors because it relies on directional flow from the bulk tumor mass 
to the periphery.  This flow is reversed upon surgical removal of tumor due to the 
creation of an empty resection cavity.  Limitations of convection enhanced delivery 
include drug uptake by healthy cells, high invasiveness, and a limited delivery area 
without the placement of multiple catheters.  Despite successful results, associated risks 
such as infection, catheter blockage, inadequate drug distribution, elevated neurotoxic 
effects, and patient discomfort have limited clinical use of this technique.  
2.3.2.3.  Implantable Drug Depots 
Implantable biodegradable drug depots positioned within brain tumors are 
currently being used in clinical practice in an effort to prevent exposure of healthy organs 
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 to the toxic side effects of chemotherapeutics and to localize a chemotherapeutic and 
allow for prolonged and controlled drug delivery [35].  Gliadel® is an intracranial 
implantable polyanhydride polymer loaded with BCNU.  BCNU (carmustine) has been 
widely used as a systemic agent due to its lipophilicity but efficacy is restricted by the 
dose-limited side effects [21, 36].  On the other hand, Gliadel® has produced better 
results for patients with grade IV glioma extending the median survival by 13.4 weeks 
compared to placebo [37, 38].  This method, however, relies on drug diffusion from a 
central core and short diffusion distances from the wafer limit the drug’s accessibility to 
the entire tumor.  As a result, drug usually cannot reach the tumor periphery where the 
most aggressive cells persist.  In addition, BCNU released from the degradable wafer is 
non-specific and therefore cytotoxic to adjacent populations of healthy cells.  Possible 
risks of this system include infection and uncontrolled drug release after implantation 
leading to local neurotoxicity.  In addition, Gliadel wafers are unable to precisely 
conform to the resection cavity which could lead to incomplete exposure of the remaining 
tumor cells. 
2.3.3.  TARGETED SYSTEMIC DELIVERY OF CHEMOTHERAPEUTICS 
Local treatment strategies discussed thus far have been developed in an attempt to 
alleviate some of the side effects associated with traditional treatment of glioma.  While 
treatments are geographically localized to tumor, they remain non-specific and normal 
cells located within and/or near the tumor site will inevitably be affected by these 
treatment strategies.  In addition, these local treatment options do not address the 
invasiveness of gliomas.  Many of the treatments presents thus far suffer from diffusion 
limitations or simple inability to access the distant spread of tumor and the invasive cells 
16 
 located at the edge of the tumor lesion.  Chemotherapy via systemic intravascular 
administration utilizes the tumor’s own blood supply for transport allowing for drug 
delivery throughout the entire tumor and is minimally non-invasive.  The addition of 
targeting agents increases treatment specificity and reduces toxic side effects of the 
chemotherapeutic drugs.  As with traditional chemotherapy, the BBB may be a 
formidable obstacle; however, transport into the tumor may be facilitated by transient 
disruption of the BBB, through drug modifications to increase lipophilicity, or by 
prolonging drug circulation times to increase transport based on the enhanced 
permeability and retention effect.  The latter method is referred to as “passive targeting” 
and will be described in greater detail in Chapter 3.   
2.3.3.1.  Direct Drug Modification 
Chemotherapeutic drugs may be chemically modified to enable specific targeting 
to tumor.  Possible targeting agents include tumor-specific antibodies, antibody 
fragments, ligands, and peptides.  BBB transport may also be facilitated by creating 
lipophilic drug analogs.  The limitations of these approaches, however, include low drug 
payloads delivered to tumor, accelerated clearance due to binding of plasma proteins, 
reduced solubility in the brain interstitial fluid, and renal clearance due to small size of 
drug conjugates.  In addition, monoclonal antibody-drug conjugates utilized to target 
tumors have been shown to exhibit decreased potency compared to the parent drug [39].  
This may be attributed to heterogeneity of antigen expression within tumor, inefficient 
internalization of conjugated drug, inability to cleave the conjugate and release active 
free drug, or the development of drug resistance by cancer cells. 
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 2.3.3.2.  Targeted Nanocarriers  
The use of targeted nanocarriers to deliver chemotherapeutics allows for higher 
drug payloads, drug protection from degradation, increased drug solubility, ability to 
evade the immune system and prolong drug half-lives, multi-valent binding, and/or 
facilitated delivery across the BBB.  In particular, the delivery of increased drug payloads 
enables successful treatment of drug resistant cells due to saturation of drug efflux 
pumps.  These characteristics make targeted nanocarriers ideal candidates for specific 
delivery of chemotherapeutics to tumors.  Targeted nanocarrier drug delivery systems 
will be discussed in more detail in Chapter 3. 
2.4.  CONCLUSIONS 
Traditional treatments for brain cancer have failed to significantly alter the 
reported median survival rate over the past three decades.  The current median survival 
rate is less than one year with a reported 5-year survival rate of merely 34.1%.  Adjuvant 
treatments to surgical resection are mandatory; however, the main disadvantage of these 
therapies is that they are non-selective and subsequently toxic to healthy tissues.  
Localization of radiation or chemotherapeutics has been investigated, however, these 
approaches remain non-specific with the ability to injure normal cells, and these 
approaches limit treatment of the tumor periphery where the most aggressive cancer cells 
persist.  Tumor recurrence due to incomplete removal ultimately results in neurological 
deterioration and death.  For these reasons, it is imperative that current therapeutic 
efficacy is improved through the development of innovative, specifically-targeted 
systemic treatment strategies utilizing the tumor’s own blood supply given that the tumor 
is highly invasive and local therapies have demonstrated only limited enhancement in 
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 survival.  The use of targeted nanocarriers will allow for the protection of healthy tissues 
from the toxic effects of chemotherapeutics while enabling the delivery of large drug 
payloads to tumor.  
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 CHAPTER 3.   THERAPEUTIC NANOCARRIERS FOR DRUG 
DELIVERY TO TUMORS 
3.1.  INTRODUCTION 
Nanocarriers have been studied extensively for the targeted delivery of 
therapeutic drugs, genes, or imaging agents to tumors in an attempt to increase selectivity 
of these agents and to enable delivery of large drug payloads to the target site.  In contrast 
to large-scale drug delivery systems, nanocarriers enable easier penetration through 
biological and physiological barriers within the body due to their small size (at least one 
dimension between 1-100 nm) [1, 2].  Nanocarriers have been shown to improve drug 
stability in vivo and may serve to protect non-target organs from drug uptake.  There are 
many different types of systemically delivered nanocarriers that are either currently being 
investigated or are clinically approved for drug delivery to tumors.  Each class of 
nanoparticles encompasses different characteristics; however, the following essential 




4) physical stability in the blood 
3.2.  TYPES OF NANOCARRIERS USED FOR TARGETED DELIVERY TO TUMORS 
There exist numerous types of nanocarriers currently utilized for tumor targeted 
delivery applications.  This chapter will focus on those designed with the capability to 
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 transport chemotherapeutics to tumors.  While this is not an exhaustive list, some of the 
most commonly used types of nanocarriers are reviewed here (Table 3.1). 
 
Table 3.1.  Various Nanocarrier-Based Drug Delivery Platforms 
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 3.2.1.  POLYMERIC NANOPARTICLES 
Polymeric nanoparticles are produced from natural or artificial polymers and 
range in size from 10 to 1000 nm.  They can be formulated directly from polymers or 
from the polymerization of monomers.  Nanospheres are spherical in shape and 
composed of a polymer matrix.  Drugs are entrapped, encapsulated, or attached to the 
nanospheres for delivery to target sites.  Nanocapsules are hollow spheres composed 
from natural or artificial polymers.  The hollow central core may be utilized for drug 
encapsulation [4]. 
Many different polymers have been investigated for polymeric nanoparticles 
utilized for drug delivery due to intense research within the past decade.  These 
biodegradable and biocompatible polymers are degraded either enzymatically or non-
enzymatically within the body into inert compounds such as hydrogen, nitrogen, and 
water, removed by normal metabolic pathways, and then excreted.  Polymers can be 
either natural or synthetic.  Synthetic polymers typically degrade more slowly than 
natural polymers allowing for sustained drug delivery over a period of days to several 
weeks, however, harsher formulation conditions are often required involving organic 
solvents which must be thoroughly removed prior to patient administration [4].  Drug 
release rate is controlled through modulation of the polymers utilized in the nanoparticle 
formulation.  The most commonly utilized polymers include poly(lactide-co-glycolide) 
(PLGA) [5, 6], polylactide acid (PLA) [7], poly ε-caprolactone (PCL) [8, 9], chitosan 
[10, 11], and human serum albumin [12]. 
The periphery of polymeric nanoparticles may be modified with targeting agents 
or additional polymers.  Additional polymers may be used to further prolong circulation 
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 of the nanoparticles and thereby improve drug pharmacokinetics.  Specific targeting 
agents, such as those that bind to tumor receptors or tumor specific antigens, are often 
utilized to increase specificity of chemotherapeutics loaded in polymeric nanoparticles.   
For example, a recent study utilizing PLGA-PEG nanoparticles functionalized with an 
aptamer that binds to the prostate specific membrane antigen demonstrated a significant 
increase in delivery to prostate tumors in xenograft mouse models compared to non-
targeted controls [13].  These findings confirm the applicability of polymeric 
nanoparticles as tumor targeted drug carriers.    
3.2.2.  POLYMERIC MICELLES 
Micelles are structures formed by the spontaneous association of amphiphilic 
copolymers in an aqueous environment.  The driving force for formation is primarily 
hydrophobic interactions causing the non-polar segments of the copolymer molecules to 
form the micellar core and the relatively polar segments to form the micellar corona 
positioned between the hydrophobic core and the aqueous bulk phase.  The hydrophilic 
corona enables water solubility, prevents aggregation, and prevents protein absorption on 
micelles, while the hydrophobic core is used to encapsulate drugs and enables 
biodegradability [14].  Self-assembly is initiated when the block copolymers exceed a 
threshold concentration known as the critical micellization concentration (CMC).  Below 
the CMC, the copolymers exist as single chains dispersed within the bulk phase.  The 
CMC is an important factor in the design of micelles for drug delivery applications, 
because the stability of micelles, which are considerably diluted following i.v. 
administration to patients, is critically dependent on this number.  CMCs of 
pharmaceutical micellar nanocarriers typically range between 10-6 to 10-4 µM [15].  
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 Micelles with the lowest CMCs can withstand the greatest dilution which makes them 
better candidates for biomedical applications.   
The CMC of micellar formulations can be altered by changing the properties of 
the block copolymers comprising the micelles.  An increase in the hydrophobicity or size 
of the micelle core has been shown to result in a highly correlated decrease in the CMC 
[16].  In addition, an increase in the size of the hydrophilic segments serves to increase 
the CMC, albeit to a lesser extent.  Hydrophobic additives incorporated into the micelle 
core have been shown to lower the CMC and increase the number of copolymers 
associating to form each micelle.  The CMC is typically unaffected by temperature 
changes with the exception of micelles composed from poloxamers [17].   
The micelle shape is typically spherical or globular and primarily depends on the 
length of the hydrophobic segments of the amphiphilic copolymers [18].  The size of 
micelles ranges between 10-100 nm, depending on copolymer length, molecular weight, 
and relative proportion of hydrophobic and hydrophilic segments, which all determine 
how well the copolymers pack within the micelle.  The nanoscopic size of micelles 
facilitates sterile filtration prior to patient administration.  In addition, the typical mass of 
an intact micelle varies between 100-1000 kDa which allows them to penetrate capillaries 
within the body and bypass glomerular filtration and excretion by the kidneys with a 
renal threshold of 42-50 kDa [19].  If diluted below the CMC, however, individual 
copolymers are rapidly removed by the kidneys [20]. 
The most commonly studied compounds used for the hydrophobic segment of 
copolymers comprising micelles can be classified into 3 groups: polyethers, polyesters, 
and polyamides.  Hydrophobic polyesters, such as poly(L-lactide) (PLA), poly(lactide-
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 co-glycolide) (PLGA), and poly(ε-caprolactone) (PCL), are used most frequently.  
Polyesters are sensitive to hydrolytic degradation making them suitable biodegradable 
candidates for the micelle core.  Poly(propylene oxide) (PPO) is an example of a 
commonly used polyether, and poly(L-histidine), poly(L-aspartic acid) derivatives, and 
poly(L-glutamic acid) derivatives are examples of polyamides utilized for the micelle 
core.  Polyamides are often degraded by enzymes within the body; therefore, they are 
also considered to be biodegradable.  The most commonly used polymer for the 
hydrophilic corona of micelles is polyethylene glycol (PEG) of molecular weight ranging 
from 1-15 kDa [21].  PEG is completely soluble in water, inexpensive, non-toxic, and 
uncharged.  It also serves as an efficient steric barrier between micelles and plasma 
proteins responsible for removing foreign particles from the bloodstream promoting 
prolonged circulation times.  Micelles using PEG in the corona have exhibited plasma 
half-lives of 18 hours after intravenous administration [22].  Alternatives to PEG for the 
hydrophilic portion of micelles include poly(N-vinyl pyrrolidone) (PVP) [23] and 
poly(vinyl alcohol) (PVA) [24].  Poloxamers are copolymers of PEG and PPO oriented in 
a PEG-PPO-PEG configuration.  Also referred to as Pluronics, these polymers micellize 
with the PPO segments localizing in the hydrophobic core and the PEG segments 
forming the hydrophilic corona.  Poloxamer micelles have been studied extensively and 
have been investigated for the delivery of doxorubicin [25-27], vinblastine [28], 
cisplatine [28], and nystatin [29]. 
The hydrophobic core of polymeric micelles makes them useful for the delivery 
of water insoluble drugs.  Drugs may be encapsulated within the core [30] or covalently 
conjugated to the polymers comprising the micelles [31].  The corona serves to protect 
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 the associated drugs from degradation prior to delivery.  Sustained release of drug may be 
achieved if the drugs entrapped within the micelle possess extremely small (10-16 to 10-18 
cm2/sec) diffusion coefficients [32].  Micellar drugs may be targeted to specific drug 
delivery sites by chemical conjugation of target-specific molecules to the micelle corona.  
In addition, micelles may be functionalized to allow triggered drug delivery.  Various 
formulations have been studied including those sensitive to pH [33], temperature [34], 
and ultrasound [35].     
3.2.3.  DENDRIMERS 
Dendrimers are nanocarriers composed of multiple highly-branched monomers 
forming a three dimensional treelike structure emerging from a central core.  Dendrimers 
are typically globular or spherical in shape with diameters ranging from 1-200 nm 
although the most commonly utilized dendrimers composed from polyamidoamine 
typically do not exceed 15 nm in diameter [36].  Dendrimers tend to have high molecular 
weights despite their nanoscale size.  Synthesis of dendrimers is stepwise producing 
highly regular branching patterns with repeated units and a distinct number of peripheral 
groups.  Polymerization may proceed from the periphery and terminate at the central core 
or initiate from the core and terminate at the external surface.  Branch lengths are limited 
by steric hindrance.  The low polydispersity associated with these nanocarriers allows for 
reproducible pharmacokinetic behavior in vivo.  The branching pattern of dendrimers 
enables the attachment of many drugs, targeting agents, and/or solubilizing groups to the 
periphery of a single carrier.  As a result, dendrimers have been investigated for a variety 
of biological applications including gene delivery [37], magnetic resonance imaging [38], 
and anticancer therapeutics [39]. 
30 
   Dendrimers for the delivery of pharmaceuticals may be formulated from a 
variety of compounds.  The most widely used dendrimer scaffolds in biology are those 
prepared from polyamidoamine.  To avoid toxicity and liver accumulation, the surface 
amine groups of these dendrimers must be modified with neutral moieties.  Other 
dendrimer formulations have been made from polyethylene oxide, glycerol, succinic acid, 
phenylalanine, or lactic acid [36].   
The versatile nature of dendrimers allows them to deliver either hydrophobic or 
hydrophilic agents to a target site.  Drugs may be covalently attached to functional groups 
on the dendrimer or simply associated with the internal core of the sphere by electrostatic 
interactions, hydrogen bonding, or hydrophobic interactions [40], however, studies 
investigating the noncovalent encapsulation of doxorubicin and methotrexate within 
polyamidoamine dendrimers showed that drugs were not readily retained in isotonic 
solutions and loading efficiencies were relatively low.  A maximum of merely 6.5 DXR 
and 26 methotrexate molecules were loaded per dendrimer [41], therefore, this loading 
method has yet to be utilized as a common strategy. Covalent attachment of drugs is also 
limited since each drug molecule requires a functionalized branch of the dendrimer for 
attachment.  Nonetheless, covalent attachment of chemotherapeutics such as DXR and 
cisplatin to dendrimers has been investigated and shown to be successful.  Covalent 
association of DXR to PEO dendrimers resulted in a 9-fold increase in tumor delivery 
compared free DXR when administered to mice bearing subcutaneous C-26 tumors.  In 
addition, survival was significantly enhanced for these animals compared to those 
receiving free DXR therapy.  The reported antitumor effect was comparable to that 
achieved with Doxil®, a clinically approved liposomal DXR treatment [39].  Tumor 
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 targeting may be achieved with dendrimers through the covalent attachment of targeting 
agents.  For example, it has been shown that the attachment of folic acid to 
polyamidoamine dendrimers carrying covalently attached methotrexate enhances uptake 
by human epithelial carcinoma (KB) cells in vitro [42].  Dendrimers serve as good 
candidates for anti-cancer therapy due to their monodispersity, multivalency, water 
solubility, and capability for surface modification. 
3.2.4.  CARBON NANOTUBES 
Carbon nanotubes are cylinders formed from benzene rings and are single or 
multi-walled with a cage like structure.  Single walled carbon nanotubes (SWNT) consist 
of a layer of graphene rolled into a cylinder while multi-walled carbon nanotubes 
(MWNT) are composed of multiple concentric layers of graphene rolled into cylinders 
spaced approximately 0.34 nm apart [43].  Diameters of SWNTs typically range from 
0.4-3 nm, while MWNT diameters may reach up to 100 nm.  Nanotube lengths vary from 
10 nm up to several millimeters [44].  Without surface modification, carbon nanotubes 
are completely insoluble; however, the nanotubes may be covalently or non-covalently 
modified through the attachment of polymers, such as PEG, to increase solubility for 
biological applications.  The external surface of carbon nanotubes may also be 
functionalized for the attachment of drugs or targeting agents to facilitate specific uptake 
by target cells [45].  Conversely, drugs, fullerenes, porphyrins, or metals may be trapped 
inside the nanotubes due to hydrophobic interactions for delivery to target sites.  Due to 
the large available surface area of nanotubes, multiple types of targeting agents and/or 
drugs may be simultaneously attached providing a functional advantage in cancer therapy 
[46].  The tips at the ends of the nanotubes are best described as fullerene hemispheres 
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 and are more reactive than the sidewalls of the nanotubes.  As a result, most reactions 
typically occur at the tips of the nanotubes and at sidewall imperfections before occurring 
at the intact sidewalls [47].    
Recent studies have demonstrated the ability to utilize carbon nanotubes in the 
treatment of cancer.  Since carbon nanotubes intrinsically absorb near infrared (NIR) and 
radio waves resulting in the local generation of heat, they have been investigated in 
attempts to thermally ablate cancer cells.  Experiments have been conducted using 
targeted [48, 49] or locally delivered non-targeted [50] nanotubes followed by the 
application of radiofrequency or NIR radiation to examine the effects on cancer cells.  
Kam, et al., absorbed phospholipid-PEG-folate conjugates to carbon nanotubes and 
observed selective cancer cell death after exposing cultures to the targeted nanotubes and 
NIR light [48].  Another study demonstrated selective cancer cell death after targeting 
PEG coated carbon nanotubes to breast cancer cells using antibodies against insulin-like 
growth factor 1 receptor and human endothelial receptor 2 and applying NIR radiation 
[49].  Radio waves were utilized instead of NIR in another study since they can penetrate 
deeper through the body.  Non-targeted carbon nanotubes were injected directly into a 
liver tumor before applying the radio waves.  This resulted in cell death at the target site 
with slight damage to the neighboring healthy cells [50]. 
Carbon nanotubes have also been studied in the delivery of chemotherapeutics 
such as doxorubicin [51, 52] and methotrexate [53, 45] to directly kill cancer cells.  
Pastorin, et al. demonstrated efficient uptake of carbon nanotubes covalently loaded with 
methotrexate by Jurkat cells [53].  Another study investigated DXR loaded PEGylated 
carbon nanotubes and discovered that noncovalent association of DXR was highly 
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 efficient due to Π-stacking and that binding efficiency and release rates were dependent 
on both pH and nanotube diameter.  Nanotubes were targeted to tumor cells through 
covalent attachment of RGD peptide and after administering to U87MG cells, enhanced 
uptake and cytotoxicity was observed.  In fact, IC50 values of the targeted nanotubes (3 
µM) approached values obtained with free DXR (2 µM) [52]. 
The use of carbon nanotubes for the delivery of therapeutic molecules is a 
relatively new concept.  Limited data exists regarding biocompatibility; however, the 
potential advantages of these nanocarriers compel further investigation of their use.  
Carbon nanotubes are highly stable due to their mechanical properties.  In addition, they 
have been shown to effectively penetrate target cells, and their large surface area and 
internal volume allows for multiple functionalization and entrapment of therapeutic 
molecules [54, 55].  Disadvantages to their use include the fact that they are non-
biodegradable, their large surface area may increase the probability of protein 
opsonization, chemical modification is required to ensure solubility in biological fluids, 
and they possess a strong tendency to aggregate.  Despite these challenges, carbon 
nanotubes present a promising option for delivery of chemotherapeutics to tumors. 
3.2.5.  LIPOSOMES 
Liposomes are closed spherical nanoscale vesicles composed of lipid bilayers.  
Multilamellar liposomes are composed from several lipid layers with alternating regions 
of hydrophobicity and hydrophilicity.  Unilamellar liposomes consist of a single bilayer 
enclosing an aqueous core.  Cholesterol is often incorporated into liposomes used for 
biological applications to enhance physical stability.  Formed in a manner similar to 
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 micellar formation, hydrophobic interactions play a central role in the self-assembly of 
liposomes from amphiphilic lipids. 
3.2.5.1.  Formulation Components 
Liposomes may be composed from a variety of phospholipids, the most common 
being either natural (egg or soy) or synthetic phosphocholine.  The phospholipid content 
typically varies anywhere from 55-100% (molar) of the liposome components.  The 
chemical structure of a common formulation component, 1,2-distearoyl-sn-
glycerophosphocholine (DSPC), is shown in Figure 3.1a.  This molecule represents the 
typical structure of an amphipathic liposomal component and is composed of a polar 
phosphate head group bound to hydrocarbon chains.  The hydrocarbon chains make up 
the hydrophobic portion of the molecule which forms the interior of the liposome bilayer.  
The polar head group forms the exterior of the bilayer and is in direct contact with the 
exterior and interior buffers.  The level of fatty acid saturation on the selected lipids has 
an affect on the overall stability because it determines the susceptibility to oxidation.  
Typically, the more saturated a lipid the less vulnerable it is to oxidation.  Phospholipids 
derived from biological sources, such as egg or soybean, tend to contain substantial levels 
of polyunsaturated fatty acids making them less stable than the synthetic equivalents.  
The phospholipid head group may be substituted by a functional group to allow 
attachment of other components such as polyethylene glycol and/or targeting moieties.  
1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) is an example of a functional 
phospholipid used to conjugate such agents (Figure 3.1b). 
It is these phospholipids which primarily dictate the ultimate shape of the 
liposomes.  Packing of the phospholipids to constitute the liposome bilayer is dependent 
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 on the total length of the molecule and the respective sizes of the head groups and 
hydrocarbon chains.  A so-called “packing factor” (P) may be determined from the lipid 
tail region volume (v) divided by the product of the cross-sectional area of the polar head 
group (a) and the total length of the phospholipid molecule (l) given by Equation 3.1 
[56]:   
  
la
vP ×=    
 
(Equation 3.1) 
Packing factors ranging between 0.5-1 typically lead to spherical bilayer vesicles. 
Another characteristic to consider in the selection of phospholipids for liposome 
formulation is the phase transition temperature.  The phase transition temperature is 
defined as the temperature at which the lipid physical state converts from an ordered gel 
phase to a disordered liquid crystalline phase and is depended on hydrocarbon chain 
length, degree of saturation, charge, and head group species.  In the gel-like phase, 
hydrocarbon chains are fully extended and tightly packed while they are randomly 
oriented and fluid in the liquid phase [57].  Lengthened hydrocarbon chains and increased 
levels of saturation result in elevated phase transition temperatures due to stronger van 
der Waals interactions.  The use of phospholipids with higher phase transition 
temperatures generates bilayers which are more stable [58].  This decreases the 
possibility for premature leakage of encapsulated components; however, considerations 
must be made to ensure that encapsulated drugs can still escape the liposomes once they 
reach the target site of action.  In addition, the phase transition temperature of the 
liposome bilayer dictates the temperature above which sizing, drug loading, and insertion 
of additional components should occur since these processes are most efficient when the 
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 bilayer is in the crystalline fluid state.  If the phase transition temperature of the selected 
phospholipids is too high, denaturation of proteins and/or drugs may occur during the 
sizing, loading, and/or insertion processes.  Therefore, a careful balance must be met to 
ensure that the selected lipids have phase transition temperatures that prevent premature 
leakage of components but enable processing to occur at temperatures that are harmless 
to all liposomal components.   
Cholesterol is often included into the liposomal formulation at a percentage of 30-
45% (molar) to help modulate membrane fluidity, elasticity, and permeability and to 
instill stability (Figure 3.1c).  Within the lipid bilayer, the polar head of cholesterol is 
aligned with the polar head of the phospholipids.  As in biological cell membranes, the 
hydrophobic properties of cholesterol ensure that it resides in the interior portion of the 
bilayer where it serves to fill the gaps created by imperfect packing to inhibit flip-flop of 
membrane components and prevent movement of components within the bilayer.  
Cholesterol also adds rigidity to the liposomes by preventing phase transitions of the 
bilayer thereby decreasing leakage of components encapsulated within the liposomes or 
trapped within the bilayer [59].  In this manner, the amount of cholesterol utilized also 
has an effect on the ultimate phase transition temperature of the bilayer.  Finally, some 
studies have shown that the inclusion of cholesterol may help to protect the bilayer from 
hydrolytic degradation by demonstrating that the water penetration depth into lipid 
bilayers is reduced when cholesterol is present [60]. 
Other components are often included in liposomal formulations depending on the 
final application.  If rapid release of internal components at altered pH is desired, pH 
sensitive lipids such as dioleoyl phosphatidyl ethanolamine (DOPE) and pH stabilizers 
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 such as cholesteryl hemisuccinate (CHEMS) may be incorporated [61].  Cationic lipids 
are often used in liposomes intended for the delivery of DNA or gene products [62-64].  
PEG is typically incorporated to enable RES evasion and prolonged circulation times 
while targeting agents may be inserted to facilitate specific targeting to tumor cells.  
Passive and active targeting of liposomes using these components will be discussed 







Figure 3.1.  Chemical structures of DSPC (A), DSPE (B), and cholesterol (C). 
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 3.2.5.2.  Preparation Techniques 
There exist numerous preparation techniques for liposomal formulations including 
detergent removal, emulsion removal, ethanol injection, and solvent removal.  A more 
detailed discussion of these techniques may be found elsewhere [65].  Choice of 
preparation technique dictates final liposome size and number of bilayers.  Solvent 
removal is one of the most commonly used techniques [66].  Lipids are dissolved in 
organic solvents such as chloroform or a mixture of chloroform and methanol to ensure a 
homogeneous mixture.  Lipid solutions are typically prepared at a concentration ranging 
between 10-20 mg/ml depending on the lipid solubility.  Solvent is subsequently removed 
by evaporation to produce a thin film of lipids.  Hydration of the dry lipid film is 
accomplished through the addition of an aqueous medium (typically prepared at 
physiological osmolarity for in vivo applications) at a temperature above the highest 
phase transition temperature (Tc) of the lipids.  Hydration produces large (200-1000 nm), 
multilamellar vesicles (LMV).  Interlamellar spacing is dictated by the level of 
electrostatic repulsion between the polar head groups of the phospholipids.   
Sizing of multilamellar liposomes is typically performed via sonication or 
extrusion.  Sonication is performed at temperatures above the lipid Tc where sonic energy 
serves to disrupt the LMV and produce small unilamellar vesicles (SUV) ranging 
between 15-50 nm in diameter.  Many factors help to determine final size including lipid 
composition, concentration and suspension volume, and sonication time and power.  
Unfortunately, sonication often results in size variations between batches.  Extrusion 
involves forcing the LMV through etched polycarbonate filters with defined pore sizes.  
This process is typically performed under high pressure and at a temperature above the 
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 lipid Tc.  Diameters of the liposomes after extrusion tend to be close to the filter pore 
size.  Extrusion through filters with 100 nm pores yields large, unilamellar vesicles 
(LUV) of reproducible size.  Final diameter depends on lipid composition and the filter 
pore size. 
3.2.5.3.  Drug Loading 
Drugs or other agents may be loaded within the liposomal bilayer or within the 
aqueous core.  Drug loading within liposomes provides protection from degradation and 
elimination from the body while shielding non-target organs from the toxic effects of the 
drug.  In particular, chemotherapeutic drugs, such as doxorubicin (DXR), are known to 
be myelosuppressive, GI toxic, and cardiotoxic.  Encapsulation within liposomes 
alleviates some of these effects by primarily confining the drug to the vascular fluid 
thereby sparing healthy organs from exposure.  Liposomal encapsulation of DXR has 
been shown to reduce the volume of distribution in humans from approximately 900 L/m2 
(for free DXR) to merely 2.75 L/m2 (for liposomal DXR) verifying that liposomal DXR 
is primarily restricted to the vascular fluid volume [67].   
Initially, the only option for liposomal encapsulation of therapeutic agents was 
through passive loading.  A new advancement allowing for more efficient drug loading 
involves the use of transmembrane ion gradients and is termed ‘remote’ or ‘active’ 
loading.  Both methods of liposomal drug encapsulation are discussed in the following 
sections.   
3.2.5.3.1.  Passive Loading 
Passive drug entrapment is process where loading occurs during liposomal 
formulation.  Aqueous drugs to be loaded within the internal core of the liposomes may 
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 be mixed with the solution used to hydrate the lipid film prior to sizing.  Lipophilic drugs, 
which will localize within the liposomal bilayer, are simply mixed with the lipids before 
solvent evaporation and subsequent hydration.  Nonincorporated material is removed 
from loaded liposomes by dialysis or gel-filtration chromatography [68, 69].   
Passive loading of aqueous compounds is an inefficient process.  The amount of 
drug loaded is proportional to the initial drug concentration and the total inner volume of 
the liposomes.  The available inner volume for loading is only a small fraction of the 
whole liposome suspension causing this loading method to be inefficient.  The total inner 
volume of the liposomes available for passive encapsulation is a function of the initial 
lipid concentration and the liposome diameter [70].  Increasing the lipid concentration 
allows for an increase in the volume available for loading, however, this typically 
increases the viscosity of the liposomal formulation, and sizing is often more difficult 
when dealing with viscous solutions.  An alternative approach is to preformulate and size 
the liposomes and subsequently concentrate the solution via diafiltration or rotary 
evaporation.  The agent to be encapsulated is then introduced into the liposomes through 
several freeze-thaw cycles serving to transiently rupture the liposomes [71].  This 
method, however, may alter the liposome size distribution creating a heterogeneous 
solution with poor reproducibility [72].  In addition, highly viscous solutions which often 
result from passive encapsulation are not biocompatible for injection and passively 
loaded agents are more susceptible to leakage after dilution and/or liposome purification. 
3.2.5.3.2.  Remote Loading 
The discovery of ‘remote’ loading techniques has provided a superior alternative 
to the inefficient process of passive drug loading.  Remote loading allows for efficient 
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 drug entrapment and stable retention of small molecules.  This process is driven by an 
electrochemical potential created by pH or ion gradients established across the lipid 
bilayer of the liposomes.  Gradients are established by preparing the liposomes in a buffer 
of specified pH and ion strength to be used as the internal volume buffer.  The external 
phase is then exchanged for another buffer via dialysis, diafiltration, or size exclusion 
chromatography.  Encapsulation is performed by mixing the liposomes with the 
compound of interest typically at a temperature above the phase transition temperature of 
the lipid bilayer to ensure fluidity and efficient transport across the bilayer.  Interaction 
with ions within the liposomes effectively traps the drug within the core.  This method 
enables encapsulation efficiencies approaching 100% and sustained entrapment of small 
molecules. 
Remote loading has been reported most often with DXR, a small, weakly basic, 
amphiphilic drug (pKa ~ 8.3).  Liposomes are prepared in ammonium sulfate buffer and 
the external phase is exchanged for a non-acidic buffer.  Uncharged DXR passively 
diffuses across the lipid bilayer to enter the liposome core where it interacts with 
dissociated ammonium sulfate forming a gel-like precipitate with the SO42- anions 
(Figure 3.2).  This precipitate is effectively trapped within the liposome creating a sink 
for accumulation of additional uncharged DXR [73].   To ensure that release of DXR 
upon entry into tumor cells can be achieved, a study designed to collapse the ammonium 
sulfate gradient through the use of the ionophore nigericin was conducted to ensure that 
the loading process is reversible.  Fortunately, it was shown that when the gradient is 
collapsed, DXR, with full biological activity, is rapidly released from the liposomes [74]. 
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 Using an ammonium sulfate gradient DXR can be actively loaded into liposomes 
yielding high drug:phospholipid ratios.  Amounts as high as 15,000 DXR molecules per 
liposome can be stably encapsulated through this method [75].  When liposomes are 
targeted through the inclusion of a few targeting moieties, the efficient loading of DXR 
attained through remote loading techniques allows for the delivery of high amounts of 
DXR per targeting vector.  This is in stark contrast to the 1:1 targeting molecule to drug 
ratio attained through direct drug conjugation to individual targeting vectors confirming 
that targeted liposomes are a superior alternative to targeted drug conjugates. 
 
Figure 3.2. Ammonium sulfate driven remote loading of doxorubicin. 
 
(NH4)2SO4 







2DXR-NH2 + 2H+ + 2Cl-
2NH3 
Liposome Interior
Adapted from Bolotin et. al., J Liposome Res.  4(1), 1994 [3]. 
 
Liposome Exterior
PermeabilitiesPerm abilities (cm/s) 
NH3            1.3x10-1 
H+             10-3-10-5 
NH4+          10-6-10-7 
Cl-              10-11 
SO42-          <10-12 
(NH4)2SO4   very low 
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 3.2.5.4.  Passive Targeting with Liposomes 
A major advantage of using long circulating liposomes came from the observation 
that carriers of relatively small size (~100 nm) can preferentially accumulate in solid 
tumors by passive convective transport [76] through the “leaky” vascular endothelium of 
tumors.  The abnormal tumor vascular has been shown to be discontinuous with pores 
varying from 100 to 780 nm in size [77, 78].  Because tumor blood vessels are inherently 
leaky marked by compromised endothelial junctions, and lymphatic vessels of tumors are 
scarce, prolonged circulation of liposomes in the bloodstream allows for sustained drug 
accumulation at the tumor site.  Due to longer blood residence time, repeated passage 
through the microvascular bed results in high levels of nanocarriers within the tumor 
which is known as the enhanced permeation and retention (EPR) phenomenon (Figure 
3.3).  Gabizon et al. have shown that the longer the blood circulation of liposomes, the 
higher their accumulation in the tumor [79].  When drugs are encapsulated in liposomes 
that are modified with flexible, water soluble polymers such as polyethylene glycol 
(PEG) chains to increase their surface hydrophilicity and prevent the adsorption of blood 
proteins and phagocytic uptake, the circulation time in the bloodstream is significantly 
prolonged.  Coating liposomes with such polymers to inhibit protein opsonization is 
termed “steric stabilization”, and the resulting “Stealth” liposomes have been shown to 
evade clearance by the RES.  For example, free DXR is cleared 450 times faster than 
PEGylated liposomal DXR [80].  The increased concentrations at the tumor site achieved 
through this method of passive targeting can greatly improve treatment efficacy. A recent 
study explored the performance of DXR-loaded liposomes in an orthotopic 9L rat brain 
glioma model [81].  Increased drug concentrations were observed in the brain tumor 
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 consistent with passive accumulation of liposomes via the EPR phenomenon.  In another 
study on patients with brain glioblastoma treated with DXR-loaded liposomes, the 
intratumoral drug accumulation was 13-19 times that recorded in normal brain [82].  
Compared to long-circulating micelles, PEG coated liposomes have been shown to 
exhibit longer half-lives giving them a distinct advantage with regard to passive 
accumulation in tumors [83].  In studies, Doxil®, the clinically approved PEGylated 
liposomal form of DXR, has exhibited prolonged circulation, sustained drug release, a 
higher tendency for extravasation into tumors, enhanced therapeutic index, and increased 
antitumor activity over free DXR. The clearance of liposomal DXR in humans has been 
reported as 0.041 L/h/m2 whereas free DXR has been shown to clear at a much faster rate 
ranging from 24 to 35 L/h/m2.  This reduction in clearance results in an AUC for 
liposomal DXR which is approximately 2-3 orders of magnitude larger than that of free 
DXR [67].   
6-7nm 100-780 nm 
 Normal Tissue Tumor Site 
Figure 3.3. Passive accumulation of long-circulating liposomal nanocarriers into 
tumors via the EPR effect. 
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 3.2.5.5.  Active Targeting with Liposomes 
To further increase uptake by tumor cells, targeting agents can be incorporated 
into liposomes to allow targeting to cells over-expressing tumor associated antigens or 
certain plasma membrane receptors (Figure 3.4).  The incorporation of targeting ligands 
corresponding to specific cell markers, such as plasma membrane receptors, not only 
facilitates targeting to the cell but also drug retention at the target site by preventing 
retrograde movement of liposomes into the bloodstream.  Targeting ligands can be 
chosen to bind receptors that undergo receptor-mediated endocytosis to facilitate drug 
uptake by cells [84, 85].  Targeting agents may be bound directly to lipid anchors on the 
liposomal bilayer or attached with a linker such as PEG.  Attachment via PEG is 
preferable over direct attachment to lipid anchors because studies have shown that 
adjacent PEG chains, which must be incorporated for RES evasion for in vivo 
applications, inhibit binding to target cells when targeting ligands are grafted directly to 
the liposome surface [86-88].  Studies have even demonstrated interference in cell 
association when small targeting ligands, such as folate (441 Da), are attached to 
liposomes via PEG chains of the same length as adjacent PEG chains incorporated for 
steric stabilization.  Therefore, most efficient active targeting to cells is attained when 
targeting agents are bound to liposomes by longer PEG chains [84]. 
Targeting agents may be incorporated into liposomal formulations by various 
methods.  If the liposomes are formulated using functionalized lipids or PEG chains, 
targeting agents may be reacted with the end groups after the liposomes are formulated 
[89-91].  Another method involves the prefabrication of conjugates of the targeting agent 
either bound directly to a phospholipid (i.e. DSPE-ligand) or bound to a phospholipid via 
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 PEG (i.e. DSPE-PEG-ligand).  These conjugates may be included with the liposomal 
components during formulation [92, 93], or insertion of the conjugates may be conducted 
into preformed liposomes by mixing micelles of the conjugate with the liposomes at a 
temperature above the phase transition temperature of the liposome bilayer [94].  The 
latter method, termed “post-insertion”, is desirable because it provides increased 
flexibility regarding the choice of liposomal drug and ligand(s), it allows for greater 
control over the number of incorporated conjugates per liposome, and it provides the 
most economical use of the conjugates by preventing targeting ligands for being 
sequestered to the internal side of the bilayer [95].  
Delivery of drug using actively targeted liposomes is preferable over direct 
conjugation to targeting moieties because (1) the drug-ligand conjugates have lower 
cytotoxic potencies [96] and (2) encapsulation yields a much higher drug cargo [73].  In 
addition, liposomes are typically larger than drug-ligand conjugates preventing  
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Figure 3.4. Active targeting of liposomal nanocarriers to tumors using ligands 




 glomerular filtration in the kidneys.  This is advantageous because clearance is decreased, 
and the luminal side of the kidneys is spared exposure to drug.  Finally, since single 
liposomes can be formulated to present multiple targeting ligands, multivalent binding 
results in increased avidity to tumor cells as shown by competitive binding assays [97].   
3.2.5.5.1.  Targeting Agent Selection 
A number of agents have potential as liposomal targeting moieties for active 
targeting to tumors including antibodies or antibody fragments targeted to tumor 
antigens, ligands directed toward tumor cell plasma membrane receptors, or small 
peptides known to bind tumor cell surface determinants.  Selection criteria may be based 
on a number of characteristics, however, foremost consideration should be given to 
immunogenicity of targeting agents, facilitation of entry into cells (i.e. via receptor-
mediated endocytosis), and ability to enable nuclear localization of the entrapped drug 
cargo.  In addition, targets should be easily accessible, have negligible expression in 
healthy tissues, and expression by tumor cells should be elevated, stable, and 
homogeneous [98].   
Antibodies are highly specific and bind target antigens with high affinities, 
however, attachment of antibodies to liposomes has been shown to stimulate uptake by 
the RES, therefore, more recent studies have focused on the use of antibody fragments as 
an alternative to prevent premature clearance by Fc-receptor mediated uptake by the RES 
[77, 99].  Common tumor targets using liposomes functionalized with antibodies or 
antibody fragments include HER2 [86, 85, 100], disialoganglioside (GD2) [101], CD19 
[102, 103], prostate-specific membrane antigen (PSMA) [104, 105], transferrin receptor 
[106-108], and epidermal growth factor receptor (EGFR) [109, 97].  Another drawback to 
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 the use of antibodies or antibody fragments is that they are expensive to produce.  The 
incorporation of small peptides into liposomes has been investigated to target 
aminopeptidase N [110, 111], matrix metalloproteinase (MMP) [112], and integrin [113, 
114] on or around tumor cells.  Liposomal incorporation of ligands associated with 
receptors over-expressed by tumor cells has also been studied extensively.  Many 
different cell membrane receptors have been investigated as possible targets for 
liposomes using receptor associated ligands including transferrin receptors [115, 116], 
hyaluronan receptors [117], sigma receptors [118], and most commonly, folate receptors 
[84, 119, 75, 120-122, 93, 123-126, 97, 127, 128], which serve as the tumor associated 
target on which this thesis will focus.  
The folate receptor (FR) is one of the numerous transmembrane receptors known 
to be over-expressed by tumors [129].  This 38,000 Da glycosylphosphatidylinositol-
linked membrane protein exhibits restricted expression in normal adult epithelial tissues 
including the choroid plexus, bladder, testes, colorectum, and lung, however, expression 
is limited to the apical surface of cells placing FR out of direct contact with the 
bloodstream.  The kidneys serve as an exception to this rule since FR is expressed by the 
proximal tubules, however, only those agents which are small enough to undergo 
glomerular filtration will come into contact with FR in the kidneys [130]. 
The primary biochemical role of folate in mammals is to mediate the transfer of 
one-carbon units in reactions that are important for DNA synthesis and replication, cell 
division, survival, and growth [130].  Methyl tetrahydrofolate derived from folate is 
essential for the regeneration of methionine from homocysteine.  Methionine, in turn, is 
utilized for protein production or is converted to S-adenosylmethionine which serves as a 
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 methyl donator in over 80 biological methylation reactions including the methylation of 
DNA, RNA, proteins, and phospholipids.  Alternatively, folate may be used for de novo 
synthesis of deoxynucleoside triphosphates required for DNA synthesis [131].  As a 
result, FR is often over-expressed in rapidly dividing cells with increased demands for 
folate.   
FR is an ideal tumor target because it is over-expressed by a wide variety of 
tumors including tumors of the ovary, lung, colon, endometrium, brain, breast, and 
kidney [132].  Upregulation is attributed to an increased cellular demand for folate due to 
elevated DNA synthesis and biological methylation reactions required for cellular 
division.  The use of FR as a target for drug delivery systems is ideal since expression in 
normal tissues is restricted to the apical surface preventing exposure of non-target organs 
to intravenously delivered FR-targeted drugs.  Folate has a high binding affinity for FR 
(Kd<1 nM), and folate covalently bound to drugs has been shown to retain this high 
affinity as well as the ability to undergo receptor mediated endocytosis [133].  In 
addition, folic acid drug conjugates are delivered to the cytoplasm in a functionally active 
form.  Unlike other receptor mediated drug delivery systems, since recovery of intact 
folate is essential to cells, the normal uptake mechanism bypasses lysosomes which 
would otherwise degrade folate prior to release into the cytoplasm [134, 135, 132].   
FR-targeted formulations have been studied extensively and represent an ideal 
targeting system since FR is known to undergo receptor-mediated endocytosis facilitating 
drug delivery [119, 120, 122, 123, 136, 125, 63, 127, 137, 138, 128, 139].  Several in 
vitro liposomal studies utilizing FR as a target have demonstrated significantly higher 
cytotoxicities from FR-targeted formulations compared to non-targeted resulting from 
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 increased uptake of drug by target cells [75, 123, 126].  Confocal microscopy has verified 
that drugs delivered via FR-targeted liposomes are rapidly transferred to the nuclei of 
target cells [75].  Others have shown that targeting to this receptor also confers the ability 
to overcome drug resistance, a common problem associated with chemotherapy [121].  
3.2.5.5.2.  Targeting Agent Incorporation Decreases Circulation Times and 
Passive Targeting to Tumor 
Unfortunately, numerous studies have shown that targeting ligand attachment to 
PEG chains anchored in liposomal membranes results in accelerated plasma clearance 
even when additional PEG chains are included to prolong circulation [119, 75, 139].  The 
inability to extend circulation with traditional targeted formulations is due to the fact that 
PEG chains employed are either the same length or shorter than those used to tether 
targeting ligands to the nanocarriers, since longer adjacent PEG chains have been shown 
to inhibit binding to target cells.  Decreased plasma concentrations of targeted 
formulations have been reported whether the targeting moiety is an antibody, receptor 
ligand, or small peptide.  It is believed that targeting moieties anchored with similar 
length or longer PEG on the liposome surface retain the ability to interact with plasma 
proteins responsible for RES clearance.  Specifically, folate receptor (FR)-targeted 
liposomes have been shown to suffer from rapid clearance due to the recognition of folate 
by the RES because folate was conjugated to a longer PEG3350 chain than the adjacent 
PEG2000 chains in an effort to overcome steric interference of PEG on binding of folate to 
target cells [84]. Studies investigating therapeutic efficacy of targeted nanocarriers often 
demonstrate no clear therapeutic advantage due to reduction in circulation times.  In fact, 
when circulation is only slightly reduced, for example in immune-deficient animals, FR-
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 targeted liposomal treatments have demonstrated greater success on solid tumors [136]. 
In addition, a study utilizing an in vivo adoptive tumor growth assay, which is unaffected 
by pharmacokinetics, exhibited a distinct advantage of FR-targeted formulations over 
non-targeted in inhibiting tumor growth [121].  When admininstered to immuno-
competent animals, studies have demonstrated no therapeutic advantage between non-
targeted and FR-targeted formulations administered to mice bearing subcutaneous 
carcinomas [75].  Mice with FR-expressing ascites tumors, however, have been shown to 
survive longer on FR-targeted liposomal treatments [75, 125].  In another study, i.p. 
injections of FR-targeted liposomes into nude mice with a KB carcinoma prohibited 
tumor growth and increased survival greater than non-targeted formulations [136], 
whereas both the FR-targeted and non-targeted liposomes exhibited the same blood 
clearance profiles in the nude mice.  These results make it clear that decreased circulation 
time of FR-targeted liposomal nanocarriers needs to be further investigated with an 
emphasis on discovering methods to address the negative consequences of folate 
inclusion within liposomal formulations before therapeutic advantages are realized.    
3.2.5.6.  Use of Cleavable Phospholipid-PEG Chains in Liposomes 
In recent years, conjugates containing reversible disulphide linkages have been 
used by numerous investigators in drug delivery [140, 141].  Cleavable PEG conjugates 
have been utilized previously as mediators capable of destabilizing nanoparticles and 
promoting release of contents at the target site [142-144].  Some groups have investigated 
the use of cleavable PEG to stabilize pH sensitive liposomes to prolong circulation time 
in the bloodstream and demonstrated that these conjugates retain the ability to enable 
RES evasion in vivo [144].  Removal of the PEG coating was shown to destabilize the 
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 liposomes promoting fusion and rapid release of liposomal contents in a pH dependent 
manner [142, 143, 145, 144].  In other studies, thiolytically cleavable PEG conjugates 
were used to trigger the release of drugs from inhalable agglomerated liposomes [146, 
147].   
Many different cleavable cross-linkers have been employed including those 
cleavable by matrix metalloproteinase [148, 149], acids [150], and most commonly, 
cysteine or other thiol reducing agents [142, 146, 147, 143, 151, 152, 145, 144].  Many 
conjugates containing reversible disulfide linkages have been studied to bind PEG to 
liposomal phospholipids including diothiobenzyl (DTB) [146, 145], 
dithiobis(succinimidyl propionate (DTSP) [142-144], and N-succinimidyl-3-(2-
pyridyldithio) propionate (SPDP) [151, 152].  Thiol reducible cross-linkers offer the 
advantage of precise control over cleavage since they require an externally delivered 
reducing agent such as cysteine, which is only present in the unbound, reduced form at 
low concentrations in the body (~10 µM in blood), to sever the linkage.  In addition, 
cysteine is innocuous to the body at the doses administered for cleavage (~1 mmol/kg).   
It has long been established that PEG chains are capable of creating a hydrophilic 
barrier around liposomes preventing binding of opsonins by steric hindrance and thereby 
preventing RES recognition.  It is expected that binding to opsonins responsible for RES 
clearance will be prevented and protein deposition decreased in the same manner when 
targeting ligands are attached to PEG chains of shorter length than adjacent PEGs.  By 
inhibiting the binding of plasma proteins to targeting ligands, longer PEG chains can 
effectively ‘mask’ targeting ligands and prevent clearance by the RES.  In recent years, 
conjugates containing reversible disulphide linkages have been shown to enable 
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 prolonged liposome circulation in vivo [144].  In addition, studies have demonstrated that 
cleavage of these conjugates in vitro completely restores binding to target cells due to 
exposure of targeting moieties promoting cell association [75, 151, 149]. This suggests 
that cleavable PEG conjugates could also be utilized to mask targeting ligands to prevent 
RES recognition and clearance while the liposomes are in circulation and then allow 
binding to cells after cleaving the PEG chains at the tumor site to expose the targeting 
ligands.  By maximizing the passive accumulation of actively targeted liposomes to 
tumor while still retaining the ability to actively target tumor cells, the negative impact of 
targeting ligand insertion into liposomes can be addressed to realize the full potential of 
actively targeted formulations.  
3.3.  CONCLUSIONS 
The inadequacy of current treatments for glioma needs to be addressed through 
the development of new alternatives providing improved treatment efficacy.  Specifically, 
traditional systemically delivered chemotherapeutics are incapable of adequately 
accumulating in brain tumors and do not spare healthy tissues from the drug toxicity.  
Targeted chemotherapy using nanocarriers provides the opportunity for increased drug 
accumulation in tumor and minimized delivery to non-target organs.   
Liposomal nanocarriers offer much promise in the delivery of chemotherapeutic 
drugs to solid tumors because they are biocompatible, they exhibit efficient and stable 
drug loading allowing for the delivery of large drug payloads to tumors and bypass of 
multidrug resistance efflux pumps [27], and they protect encapsulated drugs from 
premature degradation while shielding healthy organs from the toxic side effects of 
incorporated chemotherapeutics.  Liposomes have been shown to favorably alter the 
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 pharmacokinetics of encapsulated drug cargo.  Most importantly, because hydrophilic 
barriers may be created through the inclusion of polymers such as PEG and targeting 
agents are easily incorporated, both passive and active targeting of chemotherapeutic 
drugs to tumors may be achieved using liposomal nanocarriers. 
Since FR is known to be over-expressed by various tumors, numerous studies 
have investigated the use of incorporating folate as a targeting ligand into liposomal 
delivery vehicles loaded with DXR.  There are problems, however, associated with this 
approach that have not yet been addressed.  First, the incorporation of PEG is essential to 
allow prolonged circulation of FR-targeted liposomes, but the addition of this polymer 
hinders target cell association if it is longer than the PEG chains used to tether folate to 
the liposome, and drug uptake at the tumor site may be negatively affected as a result.  
Conversely, if shorter PEG chains are utilized, the attachment of folate to the exterior 
surface of liposomes has been shown to result in accelerated clearance of targeted 
formulations from plasma.   
Cleavable PEG chains provide a potential solution to the issue of folate exposure 
on liposomes.  They have been extensively studied for other liposomal applications and 
have demonstrated a proven ability to retain RES evasion capabilities of liposomes in 
vivo.  In addition, in vitro studies have verified that removal of cleavable PEG chains 
restores the targeting capacity of liposomal nanocarriers.  This suggests that the 
incorporation of a longer cysteine cleavable PEG conjugate into liposomal formulations 
should allow for enhanced control over folate exposure.  When the liposomes are in 
circulation, the long cleavable PEG chains will inhibit binding of plasma proteins and 
effectively ’mask’ the folate targeting ligands reducing RES clearance.  After 
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 extravasating into the target site, liposomes will be treated with systemic cysteine, which 
should localize to tumors due to its small size, to cleave the PEG chains and expose the 
targeting ligands, thereby promoting target cell uptake due to receptor binding.  In this 
manner, folate is only exposed at the tumor site where it is needed and will not interfere 
with prolonged circulation of liposomes.  Ultimately, tumor drug accumulation should 
improve since circulating drug levels will be maintained and subsequent receptor binding 
and uptake will prevent retrograde movement of drug from tumor.  The following 
chapters further explore the consequences of folate inclusion within liposomal 
formulations and this novel approach to allow control at the nanoscale level by 
modulating the exposure of folate on liposomal nanocarriers.   
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 CHAPTER 4.  EVALUATION OF ALTERNATIVE TARGETING 
AGENTS TO IMPROVE TREATMENT EFFICACY 
4.1.  INTRODUCTION 
Liposomal nanocarriers show vast potential in the field of chemotherapy 
particularly due to the demonstrated ability to passively accumulate to tumors increasing 
delivery to the target site while preventing uptake by non-target organs and reducing the 
side-effects commonly associated with traditional chemotherapeutics.  Passive targeting 
to tumors is due to increased vascular permeability at the tumor site combined with the 
prolonged circulation of liposomes in the bloodstream.  Elevated permeability results 
from the presence of enlarged interendothelial gaps along the emergent tumor 
vasculature, and an increased number of passages through the ‘leaky’ microvascular bed 
at the tumor site facilitates passive extravasation of liposomes.  Prolonged circulation 
times are achieved through steric stabilization of liposomes upon the attachment of 
polyethylene glycol (PEG) to the external surface preventing RES recognition and 
clearance of the nanocarriers.  While passive targeting of nanocarriers increases the 
delivery of chemotherapeutics to the tumor site, it does not facilitate uptake by the target 
cells after extravasation, therefore, active targeting agents are often incorporated to 
promote binding and uptake by tumor cells.  Unfortunately, the exposure of targeting 
agents on the liposomal surface has been shown to increase RES recognition of 
nanocarriers thus reducing passive targeting to tumors.  To address this issue, we have 
proposed controlling the exposure of targeting agents on the liposomal surface to enable 
both RES evasion and active tumor targeting.  An alternative approach to maintain the 
RES evasion capability of targeted liposomes involves the use of small peptides as 
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 targeting agents.  Numerous studies have demonstrated that circulation times of 
PEGylated liposomes remain prolonged when small targeting agents such as peptides [1, 
2] or antibody fragments [3, 4] are utilized in lieu of their larger counterparts.  To further 
investigate the impact of targeting agent size on RES evasion and liposomal treatment 
efficacy, we have evaluated 2 targeted liposomal formulations.  The targeting agents 
utilized were a small peptide (1984 Da) targeted to aminopeptidase N and a large 
antibody (~150 kDa) targeted to the transferrin receptor. 
Aminopeptidase N (APN) is an ecto-enzyme involved in the activation of 
collagenase utilized for extracellular matrix degradation during tumor cell invasion [5].  
APN has also been identified to play an essential role in capillary tube formation during 
angiogenesis [6].  APN is an ideal target for chemotherapeutics because it has been 
shown to be expressed by angiogenic vessels, whereas expression is absent or minimal in 
established blood vessels [7].  In addition, a peptide motif (NGR) has been identified 
which binds the APN isoform expressed by tumor vessels and not the isoforms present in 
normal epithelial or myeloid cells [8] and delivery of numerous agents to angiogenic 
vessels has already been proven to be successful with this targeting agent [7, 9].  
Targeting to the tumor vasculature not only aids in the localization of drug at the tumor 
site but has also been shown to treat tumors indirectly through vascular damage and anti-
angiogenic effects making vascular targets ideal for liposomal delivery of 
chemotherapeutics [9, 10].  For the studies reported here, we have utilized a 19 amino 
acid peptide containing a NGR residue sequence targeted to aminopeptidase N (APN) as 
the targeting agent for liposomal DXR.  This longer sequence allowed for accessibility of 
the NGR motif for target cell binding while attached to the liposomal surface via 
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 PEG3350.  A terminal cysteine was selected to allow for conjugation to maleimide groups 
on PEG chains bound to DSPE.  NGR was incorporated into the liposomal formulations 
so that it would be present on the external surface of the nanocarriers to enable active 
targeting to angiogenic vessels within tumor.  Formulations containing this small 
targeting peptide were investigated in vivo to determine the effects on circulation times in 
the bloodstream and treatment efficacy.   
In addition, we also investigated liposomal formulations targeted to the transferrin 
receptor (TfR), which is also known to be over-expressed by tumor vasculature [11-13].  
TfR is involved in the endocytosis and transcytosis of transferrin, the blood plasma 
protein for iron ion delivery [14].  It serves as an ideal target for liposomal 
chemotherapeutics because it has been shown to be expressed on both the tumor 
vasculature and tumor cell membranes [15, 16].  In addition, TfR has been shown to be 
selectively expressed by the brain capillary endothelium [12] and has been demonstrated 
to facilitate transcytosis of TfR-targeted liposomal drugs across the BBB [17].  The agent 
utilized to target TfR in these studies was a large antibody, OX26, conjugated to the 
distal ends of PEG2000.  Formulations targeted with this antibody to TfR were investigated 
in vivo to explore the effects on circulation times and biodistribution and the ability to 
prolong survival in tumor-inoculated animals.           
4.2.  MATERIALS AND METHODS 
4.2.1.  SYNTHESIS AND MICELLE FORMATION OF DSPE-PEG3350-NGR 
1,2-Distearoyl-sn-glycerophosphoethanolamine (DSPE)-PEG3350-NGR peptide 
was synthesized by methods similar to those described previously. Briefly, 6.06 µmol 
DSPE-PEG3350-maleimide and 6.55 µmol NGR peptide (GNGRGGVRSSSRTPSDKYC) 
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 were dissolved in 600 µL DMSO before adding 5.4 mL deionized water and reacting at 
room temperature for 5 hours.  The micellar product was dialyzed to remove unreacted 
peptide and the final concentration was determined using a modified Lowry method (DC 
protein assay, Bio-Rad, Hercules, CA).   
4.2.2.  PREPARATION OF APN-TARGETED LIPOSOMAL NANOCARRIERS 
A 62:35:3 molar ratio of 1,2-distearoyl-sn-glycero-phosphocholine (DSPC, 
Genzyme, Cambridge, MA)/cholesterol (Sigma, St. Louis, MO)/DSPE-PEG2000 (Avanti 
Polar Lipids, Birmingham, AL) was dissolved in 1 mL of ethanol at 60 °C.  0.005% 
(mol) of fluorescent phospholipid (β-DPH, Invitrogen, Carlsbad, CA) was used to track 
phospholipid content. The lipids were hydrated with 9 mL 400 mM ammonium sulfate 
and extruded five times through a 0.2 μm and 10 times through a 0.1 μm Nucleopore 
membrane.  Liposome size was determined by dynamic light scattering (90 Plus Particle 
Size Analyzer, Brookhaven Instruments, Holtsville, NY). Liposomes were dialyzed 
against a phosphate-buffered saline solution to establish an ammonium sulfate gradient 
for doxorubicin loading.  NGR liposomes were prepared by adding DSPE-PEG3350-NGR 
peptide micelles to liposomes and heating at 60 °C for 1 h. Unincorporated micelles were 
removed through dialysis.  Liposomal NGR was determined using a DC protein assay 
(BioRad, Hercules, CA).  The number of NGR peptides per liposome was determined by 
a ligand to phospholipid ratio, assuming 120,000 phospholipid molecules per liposome 
where phospholipid content was quantified by DPH fluorescence, yielding a bulk average 




 4.2.3.  PREPARATION OF OX26 LIPOSOMAL NANOCARRIERS 
To fabricate OX26 liposomes, OX26 was thiolated with a 4:1 molar excess of 2-
iminothiolane (Sigma) by reacting at room temperature for 1 hour similar to methods 
described elsewhere [18].  OX26-thiol was added to liposomes formulated as described 
above from a 62:35:2:1 molar ratio of DSPC/cholesterol/DSPE-PEG2000/DSPE-PEG2000-
maleimide an allowed to react overnight with terminal maleimide groups on PEG2000.  
Unreacted OX26 was removed by size exclusion chromatography.  Amount of liposome-
coupled OX26 was determined by a Bradford dye-binding procedure (protein assay, Bio-
Rad, Hercules, CA) after lysis of liposomes with 20% SDS.  The number of OX26 
antibodies per liposome was determined by an antibody to phospholipid ratio as 
described above for APN peptide.   
4.2.4.  ACTIVE LOADING OF DOXORUBICIN INTO LIPOSOMES 
Following ligand incorporation or coupling, liposomes were loaded with 
doxorubicin (DXR, Henry Schein Inc., Melville, NY) via the ammonium sulfate gradient 
[19].  In brief, liposomes were mixed with DXR reconstituted in phosphate buffered 
saline and heated for 1 hour at 60°C.  Unencapsulated DXR was removed by dialysis.  
Loading efficiency was determined by a 480 nm absorbance reading after lysis with 5% 
TritonX100.   
4.2.5.  TUMOR CELL CULTURE 
9L cells (a kind gift from the University of California at San 
Francisco/Neurosurgery Tissue Bank) were maintained in MEM/EBSS supplemented 
with 10% FBS and 0.05 mg/mL gentamicin under conditions of 5% CO2 and 95% 
humidity.  9L cells were harvested with 0.05% trypsin/0.53 mM EDTA.  Cells were 
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 counted with Trypan blue and a hemacytometer.  Prior to implantation, cells were 
resuspended in serum-free Leibovitz’s L-15 medium to a concentration of 2x108 cells/ml.  
4.2.6.  TUMOR INOCULATION  
All animal studies were conducted under a protocol approved by the Institutional 
Animal Care and Use Committee (IACUC) at Georgia Institute of Technology.  A rat 
glioma model was established by surgically implanting 2x106 9L glioma cells into the 
frontal lobe of 11-12 week old male Fisher 344 rats.  During surgery, anesthesia was 
maintained through the administration of 2-3% inhalant isoflurane.  The incision site was 
shaved and the animal mounted in a stereotaxic frame.  The scalp was opened to expose 
the skull, and a burr hole was drilled 2 mm anterior and 2 mm lateral to the bregma.  9L 
glioma cells in 10 μl of Leibovitz’s L-15 medium were slowly injected into the frontal 
lobe through a 21-gauge needle at a depth of 3 mm.  The burr hole was then sealed with 
bone wax, and the scalp was sutured.   
4.2.7.  IMMUNOHISTOCHEMISTRY FOR CHARACTERIZATION OF APN EXPRESSION  
To ensure that inoculated 9L glioma tumors upregulate APN, explanted brains 
were examined for APN expression.  Twelve days after tumor inoculation, rats were 
anesthetized by an IP injection of 50, 10 and 1.67 mg/kg respectively of 
ketamine/xylazine/acetylpromazine and perfused with phosphate-buffered saline (PBS) 
containing heparin (1000 units/L) followed by 4% paraformaldehyde in PBS. Brains were 
explanted and stored in 4% paraformaldehyde for approximately 24 hours prior to being 
embedded in paraffin. Paraffin embedded tissues were sliced into 5 μm sections using a 
rotary microtome. Representative sections containing tumor were immunostained for 
APN. In brief, sections were deparaffinized and rehydrated using xylene and a graded 
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 series of alcohols and then washed in PBS. Antigen retrieval was performed by 
incubating the slides in a citrate buffer (19.7 mM citric acid, 8.2 mM sodium citrate, pH 
6.0) at 80°C for 20 minutes and then treating with 0.1% trypsin in Tris buffered saline 
(136.9 mM NaCl, 20 mM Tris-HCl, pH 7.2) for 15 minutes at 37°C.  Sections were then 
washed with 0.1% Tween 20 in Tris buffered saline (TBST).  Endogenous peroxidase 
was blocked by treating with 1% H2O2 in PBS. After washing with TBST, sections were 
exposed to a mouse monoclonal antibody to APN (1 μg/ml) in TBST containing 4% 
normal goat serum overnight at 4°C.  Sections were then washed with TBST before 
applying anti-mouse poly horseradish peroxidase (Chemicon, Temecula, CA) for 30 
minutes at room temperature.  After washing with TBST, sections were exposed to DAB 
chromogen-buffer (Chemicon, Temecula, CA) for 20 minutes, washed with TBST, and 
counterstained with Harris’ hematoxylin.  
4.2.8.  SURVIVAL STUDIES EVALUATING TREATMENT EFFICACY 
Four days or 12 days after tumor inoculation, animals were treated with either a 
saline sham, non-targeted ‘Stealth’, or targeted liposomal DXR i.v. injection (10 mg/kg 
doxorubicin; ~60 mg/kg lipid) via tail vein. Equivalent volumes of 0.9% sterile saline 
solution were administered to animals receiving sham injections.  Animals selected to 
receive multiple treatments were administered either non-targeted or APN-targeted 
liposomal DXR (10 mg/kg) 7 days after receiving the initial treatment.  Tumor growth 
was allowed to progress until the animal showed signs of morbidity, at which point, 
interventional euthanasia was administered. Time of death was determined to be the 
following day.  
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 4.2.9.  IN VIVO CIRCULATION STUDIES 
Adult, male Fisher 344 rats were given an i.v. injection of liposomal DXR (10 
mg/kg DXR; ~60 mg/kg lipid).  Each group of animals received one of the following 
formulations: non-targeted with 3% DSPE-PEG2000, APN-targeted with DSPE-PEG3350-
NGR and 3% DSPE-PEG2000, or TfR-targeted with DSPE-PEG2000-OX26 and 3% DSPE-
PEG2000.  Number of targeting agents incorporated within targeted liposomes was varied 
to determine the effect on circulation time.   Blood was collected from the orbital sinus 
immediately before injection and at various time points after injection.  Plasma was 
isolated from each blood sample by centrifuging at 2,200g for 15 minutes.  Plasma was 
diluted 1:4 with deionized water before mixing 200μl with 100μl of 10% Triton X-100, 
200μl of water, and 1500μl of acidified isopropanol (0.75N HCl).  Mixtures were stored 
overnight at -20°C to extract the drug and then warmed to room temperature and vortexed 
for 5 minutes.  The samples were then centrifuged at 15,000g for 20 minutes.  
Fluorescence of supernatants was analyzed to determine doxorubicin content (λex=485, 
λem=590).  Plasma samples obtained immediately prior to injection were used to correct 
for background fluorescence.  
4.2.10.  BIODISTRIBUTION IN TUMOR INOCULATED ANIMALS  
Thirteen days after glioma inoculation, when tumor was deemed large enough for 
explantation, an orbital blood sample was collected from each animal prior to treating 
with either a saline sham, non-targeted ‘Stealth’, or TfR-targeted liposomal DXR i.v. 
injection (10 mg/kg doxorubicin; ~60 mg/kg lipid) via tail vein. At each of two 
designated time points following injection (20 or 50 hours), DXR biodistribution was 
assessed.  Animals were anesthetized with an IP injection of 50, 10 and 1.67 mg/kg 
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 respectively of ketamine/xylazine/acetylpromazine, and a cardiac blood sample was 
obtained.  Animals were then perfused with heparinized PBS (1000 units/L) to remove 
the blood.  The spleen, brain, heart, lungs, liver, and kidneys were explanted, washed 
with PBS, and blotted dry.  Tumor, identified by discoloration and variation in tissue 
texture, was dissected from the brain using a dissecting microscope at 7x magnification. 
Organs were weighed and frozen at -20°C until ready to be processed.  
Plasma was isolated from each cardiac blood sample obtained prior to perfusion 
by centrifuging at 2,200g for 15 minutes.  Plasma samples were stored at -20ºC until 
ready to be analyzed.  Doxorubicin was extracted from plasma and tissue samples in a 
manner similar to that described elsewhere [20].  Plasma was diluted 1:4 with water. 
Organs were homogenized in distilled, deionized water (20% wt/vol) using a Polytron 
Homogenizer (Brinkmann Instruments, Westbury, NY).  Homogenates and 25% plasma 
samples (200μl) were mixed with 100μl of 10% Triton X-100, 200μl of water, and 
1500μl of acidified isopropanol (0.75N HCl).  Mixtures were stored overnight at -20°C to 
extract the drug and then warmed to room temperature and vortexed for 5 minutes. The 
samples were then centrifuged at 15,000g for 20 minutes.  Fluorescence of supernatants 
was analyzed to determine doxorubicin content (λex=485, λem=590).  Organ samples from 
an animal treated with a saline sham i.v. injection and plasma samples obtained prior to 
doxorubicin injection were used to correct for background fluorescence.  
4.3.  RESULTS 
4.3.1.  IMMUNOHISTOCHEMISTRY FOR CHARACTERIZATION OF APN EXPRESSION  
While it has been previously established that APN is expressed by endothelial 




Figure 4.1.  Aminopeptidase N is selectively over-expressed by 9L glioma tumors in vivo.  
Immunohistochemical analysis reveals expression of APN in tumor 12 days after inoculation.  Brown 
horseradish peroxidase marks the location of APN in the fixed tissue.  (a) Normal brain tissue serves as a 
negative control.  (b) Tumor section obtained from Fisher 344 rat 12 days after intracranial 9L glioma 
tumor inoculation exhibiting elevated expression of APN.  Scale bars represent 100 μm. 
glioma.  To evaluate in vivo expression, an intracranial tumor model was developed and 
APN expression was examined through immunohistochemistry on explanted brain 
tumors.  The results confirmed that APN expression is elevated in intracranial 9L glioma 
compared to normal brain tissue (Figure 4.1).  The established tumor, 12 days after 
implantation, demonstrated uniformly distributed APN expression while APN was not 
detected in normal brain tissue.   
4.3.2.  SURVIVAL STUDIES EVALUATING TREATMENT EFFICACY 
Studies were performed to evaluate the therapeutic efficacy of non-targeted 
liposomal DXR compared to liposomal DXR targeted to APN or TfR.  Using non-
targeted and APN-targeted liposomes, the effect of treatment administration time point 
was examined.  APN-targeted liposomes were equivalent to non-targeted liposomes with 
approximately 500 NGR peptides incorporated for targeting to APN.  Animals received 
liposomal DXR either 4 or 12 days after tumor inoculation to determine the impact on 
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Figure 4.2.  Use of NGR peptide to target liposomal DXR to APN does not prolong survival of tumor-
bearing rats.  Animals received saline sham ( ), non-targeted ( ), or APN-targeted liposomal DXR ( ) 
i.v. 4 days (a) or 12 days (b) after tumor inoculation.  There was no difference in survival of animals 
receiving non-targeted or targeted liposomal DXR at either time-point.  Both liposomal treatments were 
able to prolong survival of tumor-bearing rats compared to saline-treated controls when administered 4 
days after tumor inoculation, however, when treatment was delayed to 12 days after tumor inoculation, no 
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Figure 4.3.  Use of OX26 antibody to target liposomal DXR to TfR does not prolong survival of 
tumor-bearing rats.  Animals received a single dose of non-targeted ( ) or TfR-targeted liposomal DXR 
( ) i.v. 4 days after tumor inoculation.  A subset of animals received an additional dose of non-targeted 
( ) or TfR-targeted ( ) liposomal DXR 11 days after tumor inoculation.  There was no difference in 
survival of animals receiving non-targeted or targeted liposomal DXR under either treatment regimen.  The 
addition of a second treatment administration doubled the cumulative dose of DXR and had a detrimental 
effect on survival times.  Data represents mean ± SEM. 
animals received treatments 4 days after tumor inoculation, survival times of liposomal 
DXR treated animals were improved compared to saline-treated controls, however, there 
was no significant difference in survival between the groups receiving either non-targeted 
or APN-targeted liposomal DXR (Figure 4.2(a)).  When treatments were delayed and 
administered 12 days after tumor inoculation, survival times of treated animals did not 
demonstrate any improvement over saline-treated controls (Figure 4.2(b)).  In addition, as 
seen with animals receiving treatments 4 days after tumor inoculation, there was no 
significant difference in survival times between animals receiving non-targeted or APN-
targeted liposomal DXR 12 days after tumor implantation.    
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 To investigate the impact of the use of larger targeting agents on therapeutic 
efficacy and to explore the effect of multiple treatment administration, additional survival 
studies were conducted on tumor bearing rats receiving either non-targeted or TfR-
targeted liposomal DXR.  Animals received treatments 4 days after tumor inoculation, 
and a subset of animals received an additional treatment 11 days after tumor inoculation.  
Survival was monitored, and the results of this study are exhibited in Figure 4.3.  No 
improvement in survival resulted upon the inclusion of OX26 for TfR targeting of 
liposomal DXR as demonstrated by the absence of a change in survival times between 
animals receiving non-targeted liposomal DXR compared to those receiving TfR-targeted 
liposomal DXR.  In addition, increasing the number of treatments administered to tumor-
bearing rats actually had a detrimental impact on survival times.   
4.3.3.  IN VIVO CIRCULATION STUDIES 
In vivo circulation studies were performed on rats receiving non-targeted, APN-
targeted, or TfR-targeted liposomal DXR to further explore the impact of targeting agent 
size and possibly elucidate the reason why an improvement in treatment efficacy was not 
observed in survival studies for animals receiving actively-targeted treatments.  Figure 
4.4 displays the results from the circulation study on rats receiving either non-targeted or 
APN-targeted liposomal DXR.  Circulation data were fitted to bi-exponential curves.  
Areas under the curves (AUCs) and plasma half-lives were determined for each 
formulation and are reported in the table inset of Figure 4.4.  Overall, the incorporation of 
APN-targeting NGR peptide into sterically stabilized liposomal DXR formulations had 
little effect on circulation times.  The AUCs were not significantly different between the 
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a t1/2 (hours) AUC  
NT Stealth 38.1±0.67 5456.3±219.7
500 NGR 39.8±1.21 5601.0±179.0
1000 NGR 33.0±1.64 4846.0±236.0*
 
Figure 4.4.  APN-targeted liposomes retain the ability to evade the RES.  Circulating levels of DXR in 
the bloodstream, expressed as a percentage of initial DXR concentration, over time in animals receiving an 
i.v. injection of Stealth NT ( ) (n=3) or APN-targeted liposomal DXR containing 500 ( ) (n=3) or 1000 
( ) (n=3) NGR peptides.  Data were fit to exponential curves to determine half-lives and AUC’s.  
Inclusion of targeting agents did not have a significant effect on calculated AUC.  A significant decrease in 
half-life was observed when the number of NGR peptides inserted was increased from 500 to 1000 
(*p=0.0192, ANOVA), although there was no significant difference in half-life between liposomes targeted 
with 1000 NGR peptides and Stealth NT liposomes.  Data represent mean ± SEM.     
targeted liposomes compared to either APN-targeted formulation.  There was a 
significant decrease in half-life when the number of NGR peptides was increased from 
500 to 1000; however, the latter formulation displayed a half-life that was comparable to 
that obtained with non-targeted liposomes demonstrating that this formulation retained 
the ability to evade the RES. 
A dramatic difference in the circulation study results was observed when a larger 
targeting agent, OX26, was employed in liposomal formulations targeted to TfR (Figure 
4.5).  After fitting circulation data to bi-exponential curves, plasma half-lives and AUCs 
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a  t1/2 (hours) AUC 
NT Stealth 18.46±3.099* 2931.4±551.6†
4 OX26 0.780±0.062 736.12±72.18 
6 OX26 0.658±0.052 732.59±100.7 
10 OX26 0.417±0.026 513.32±34.41 
45 OX26 0.462±0.203 76.509±19.22 
 
Figure 4.5.  Inclusion of OX26 antibody to facilitate active targeting of sterically stabilized liposomes 
to TfR significantly decreases circulation times.  Circulating levels of DXR in the bloodstream, 
expressed as a percentage of initial DXR concentration, over time in animals receiving an i.v. injection of 
Stealth NT ( ) (n=3) or TfR-targeted liposomal DXR containing 4 ( ) (n=3), 6 ( ) (n=3), 10 ( ) (n=3), 
or 45 ( ) (n=3) OX26 antibodies.  Data were fit to exponential curves to determine half-lives and AUC’s.  
Inclusion of targeting agents had a significant and detrimental impact on calculated AUCs and plasma half-
lives (*p<0.0003, †p<0.007, ANOVA).  Data represent mean ± SEM.     
formulation tested exhibited a significant decrease in both plasma half-life and AUC 
compared to non-targeted liposome treated controls.  The addition of as few as 4 OX26 
antibodies decreased circulation half-life from 18.5 hours to a mere 47 minutes, and the 
AUC was reduced by a factor of 4.  Liposomes formulated with higher levels of OX26 
demonstrated even further reductions in half-lives and AUCs.          
4.3.4.  BIODISTRIBUTION IN TUMOR INOCULATED ANIMALS 
Additional studies were performed to determine biodistribution of DXR in tumor-
bearing animals after receiving either non-targeted or TfR-targeted liposomal DXR.  
Initially, studies were conducted on rats without tumors to determine ability to achieve  
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 Figure 4.6.  Targeting to TfR with OX26 alters the biodistribution of liposomal DXR 20 hours after 
treatment administration.  Overall organ distribution (A) and brain uptake (B) of non-targeted liposomal 
DXR ( ) or TfR-targeted liposomal DXR containing 45 ( ) or 60 ( ) OX26 is shown.  *Statistically 
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tion studies were performed on tumor-bearing animals 50 
hours a  
on-
ke 
in 50 hours after treatment administration 
was investigated using lower amounts of OX26 (4, 6, and 10 OX26 per liposome) for 
TfR-targeted liposomes to determine whether an improvement in delivery to the brain  
antibodies to target TfR (Figure 4.6).  Biodistribution was examined 20 hours after 
treatment administration.  As predicted by the circulation study, plasma DXR levels
significantly reduced in animals receiving TfR-targeted liposomes compared to those 
treated with non-targeted liposomes.  This reduction in plasma levels was reflected by 
significant increase in lung, liver, and brain levels of drug uptake.  The formulation 
containing 60 OX26 antibodies demonstrated a significant reduction in uptake by the
spleen compared to the 2 other formulations.  Levels of uptake by the heart were 
comparable for all 3 formulations.  Delivery to the brain was significantly increas
animals receiving TfR-targeted liposomes compared to those treated with non-targeted 
liposomes (Figure 4.6(b)).   
Additional biodistribu
fter the administration of either non-targeted liposomal DXR or TfR-targeted (45
OX26) liposomal DXR (Figure 4.7).  At this time point, in contrast to the 20-hour study, 
levels of TfR-targeted drug detected in the spleen were significantly increased compared 
to non-targeted controls.  Once again, there was a significant increase in uptake of 
targeted formulations by the brain compared to non-targeted liposomes.  For both n
targeted and targeted liposomes, uptake at the tumor site was significantly increased 
compared to brain uptake, however, there was no significant difference in tumor upta
between the 2 formulations (Figure 4.7(b)).      

































Figure 4.7.  Targeting to TfR with OX26 alters the biodistribution of liposomal DXR 50 hours after 
treatment administration.  Overall organ distribution (A) and plasma, brain, and tumor uptake (B) of non-
targeted liposomal DXR ( ) or TfR-targeted liposomal DXR containing 45 OX26 ( ) is shown.  
*Statistically significant differences to non-targeted liposomes (Student’s t-test), p<0.05.  Values represent 











































could be achieved (Figure 4.8).  There was no significant difference in brain delivery of 
liposomes targeted with 4 OX26 compared to non-targeted controls, however uptake was 
significantly increased when liposomes containing either 6 or 10 OX26 antibodies per 
liposomes were administered.  It should be noted that brain uptake of these 2 
formulations was about half that observed at the same time point for targeted 
formulations composed with 45 OX26 per liposome (Figure 4.7(b)). 
4.4.  DISCUSSION  
The overall goal of these studies was to evaluate alterations in treatment 
performance in response to the incorporation of different targeting agents in liposomal 
 
Figure 4.8.  Targeting to TfR with lower levels of OX26 exposes the minimum number of antibodies 
necessary to achieve selective delivery to the brain 50 hours after treatment administration.  Brain 
uptake of non-target ed liposomal DXR ( ) or TfR-targeted liposomal DXR containing 4 ( ), 6 ( ), or 1
( ) OX26 per liposome is shown.  *Statistically significant differences to non-targeted liposom






























 DXR formulations.  Two different targeting agents were investigated; the first, a small 
peptide, was presented as an alternative solution to the issue of targeting agent 
recognition and accelerated clearance by the RES reported for actively targeted 
liposomes.  This peptide containing the APN-targeting motif, NGR, has been reported to 
exhibit minimal immunogenicity in vivo and therefore, served as an ideal candidate in 
these attempts to maintain prolonged circulation of actively targeted liposomal 
nanocarriers.  In addition, immunohistochemistry verified that APN is upregulated within 
9L glioma tumors after implantation.  The presence of APN within tumor 12 days after 
tumor inoculation in our model verifies that this target is available for tumor cell 
targeting in addition to vascular targeting of liposomal formulations.  Survival studies 
8 days in this tumor model, completely eradicated the benefits of treatment.  In addition, 
hese 
formulations was also unable to im  tumor-bearing animals receiving 
a single ltiple 
utilizing APN-targeted liposomal DXR emphasized the importance of liposomal 
treatment administration time point in tumor-inoculated animals.  Delaying treatment by 
it was shown that the inclusion of NGR peptide intended to facilitate targeting to APN on 
both the tumor vasculature and the tumor cell membranes did not have a significant 
impact on survival times of glioma tumor-bearing animals receiving a single dose of 
liposomal DXR. 
An antibody to TfR, OX26, was the other targeting agent selected for t
studies.  Unfortunately, the inclusion of OX26 targeting agents in liposomal DXR 
prove the survival of
 dose of liposomal DXR.  In an effort to enhance treatment efficacy, a mu
treatment regimen was adopted, however, increasing the treatment administration 
frequency from a single to a double dose was actually detrimental to animal survival.  
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 This may have been due to the treatment dose (10 mg/kg DXR) chosen for these
experiments.  Instead of maintaining a constant cumulative dose of 10 mg/kg, an
receiving two doses of DXR actually received a cumulative dose of 20 mg/kg.  Even 
though DXR was encapsulated within liposomes to decrease toxicity of the drug, this 
dosage may have been above the tolerable level for these animals.  To address th
a longer period between treatment administrations should be utilized to ensure that the 
original dose is entirely cleared and recovery from non-target damage is complete or the
individual doses should be reduced to maintain an equivalent cumulative treatmen
In an effort to determine why a positive impact on treatment efficacy was not 
achieved through the incorporation of APN-targeting peptides or TfR-targeting 
antibodies, in vivo circulation studies were performed to ensure that adequate circulating 
levels of drug were maintained in the bloodstream preserving the ability to passively 
target tumors.  It was shown that NGR peptides did not impact circulation times of 
liposomal nanocarriers.  This result was surprising given the inability of APN-targete









rmine the reason why survival was not prolonged.  First and foremost, 
in vitro ieved 
elivery 
 of drug 
 uptake studies must be performed to verify that nuclear delivery may be ach
with APN-targeted liposomes.  Biodistribution studies would serve to ensure that d
across the BBB is possible using NGR peptides.  Finally, alternative treatment regimens 
may be explored determine whether an improvement in treatment efficacy may be 
achieved with APN-targeted liposomal DXR. 
While the inclusion of NGR peptides had little effect on the circulation of 
liposomes, OX26 antibodies had a severe detrimental impact on circulating levels
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 in the bloodstream.  As few as 4 OX26 antibodies per liposome were shown to cause a 
significant reduction in both AUC and half-lives of TfR-targeted liposomes compared
non-targeted control liposomes.  Of these 2 targeting agents, the most obvious differen
is size.  In fact, there is a 75-fold difference in molecular weight between the NGR 
peptide and the OX26 antibody.  Presumably, however, it is not size alone which 
determines the ability to evade the RES particularly since other targeting agents smaller 








-targeted liposomes.  Many investigators 
have ut
h 
tions from the bloodstream upon incorporation [21, 22].  Other factors such as
polarity, hydrophobicity, overall surface charge, and targeting agent configuratio
other characteristics must also play a role in the ability of the RES to recognize these 
molecules on the surface of liposomal formulations and accelerate clearance from the
bloodstream.  The NGR motif has been shown in these studies and by others to be 
minimally immunogenic.  The primary reason suggested for the low immunogenicity of
NGR has been its ability to mimic natural proteins in the bloodstream.  The NGR motif is
present in natural proteins such as fibronectin which contains 4 NGR sequences [23].  
Structural similarities between the NGR motif and naturally present proteins may explain 
its ability to evade the RES [24].  Conversely, OX26 is much larger in size, presumably 
extending beyond the hydrophilic PEG barrier at the liposome surface, but more 
importantly, the antibody is of murine origin which most likely contributes to the 
triggered acceleration in RES clearance of TfR
ilized antibody fragments in lieu of entire antibodies to avoid Fc receptor-
mediated clearance [3, 4] and the results presented here emphasize this need, however, 
opting for antibody fragments may result in a reduction in antigen binding affinity whic
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 should also be taken into consideration.  The entire OX26 antibody was utilized for these 
particular studies to ensure a vast difference in targeting agent size enabling comparison 
between 2 extremes. 
TfR-targeted formulations were further investigated in biodistribution stud
investigate the true impact of drastically reduced circulating levels of drug on the ability 
to achieve delivery to target sites.  Twenty hour biodistribution studies performed in t
absence of tumor demonstrated a significant reduction in circulating levels of drug in th
bloodstream when 45 or 60 OX26 antibodies were utilized for TfR targeting.  The 
primary clearance route accounting for these reductions appeared to be through the liv
which demonstrated a significant increase in uptake of targeted formulations.  An 
increase in delivery to the lungs was observed and may be attributed to binding to lu
TfR since uptake was incrementally increased as the number of OX26 antibodies was 
increased.  Uptake by the spleen was significantly reduced for liposomes targeted with 60 
OX26 compared to non-targeted formulations and TfR-targeted formulations containin
45 OX26 antibodies.  This may be due to RES recognition of maleimide at the terminal 
ends of unconjugated PEG chains and clearance via the spleen.  This difference in uptake
by the spleen was reversed 30 hours later when TfR-targeted liposomes surpassed
uptake of non-targeted liposomes.  This was accompanied by a reduction in liver le
targeted liposomes and may be due to either coagulation of TfR-targeted liposomes over 
time in the bloodstream which would favor RES clearance via the spleen or may b
to saturation of factors responsible for clearance via the liver forcing an increase in 












 The major finding of the biodistribution studies was that brain levels of drug were
elevated (approximate
 







very was achieved compared to non-targeted controls.  
The ina
he 
ed to non-targeted controls at both 20 hours and 50 hours, although brain uptake 
was relatively low in comparison to delivery to all of the other organs studied.  The fact 
that delivery across the BBB to the brain was significantly increased despite the dramatic
reduction in circulating levels of drug suggests that the presence of OX26 must 
significantly facilitate transcytosis across the BBB.  If plasma clearance issues coul
resolved, then delivery may be further improved.  Unfortunately, we showed that 
decreasing the number of OX26 antibodies to as low as 4 per liposome does not 
significantly improve circulation times and the biodistribution study performed after 
reducing the number of targeting antibodies from 45 to 4, 6, or 10 OX26, therefore, did
not demonstrate any further improvement in delivery to the brain.  Formulations with 6 
and 10 OX26 per liposome, however, did exhibit a significant increase in brain delivery 
compared to non-targeted controls and, as with liposomes containing 45 OX26, may hav
potential for targeting of liposomal nanocarriers to the brain if RES evasion can be 
restored for these formulations.  Liposomes formulated with 4 OX26 performed the worst 
in vivo since they still exhibited accelerated clearance by the RES and failed to achieve a 
significant increase in delivery to the brain.  
Unfortunately, uptake by the tumor was not enhanced by the inclusion of 45 
OX26 even though the maximum brain delivery was attained with this formulation a
significant increase in brain deli
bility of TfR-targeted liposomes to surpass tumor uptake of non-targeted 
liposomes despite significant increases in delivery to the brain is most likely because t
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 transport mechanism is different between these 2 sites.  In healthy brain where the BBB 
is intact, delivery occurs through transcytosis via TfR; however, delivery to glioma, 
where the BBB is discontinuous, results primarily from the passive process of 
extravasation through the leaky vasculature at the tumor site.  This process is cri
dependent on circulating levels of drug, and therefore, the impact of accelerated clearanc
was more apparent in the case of delivery to the tumor. 
tically 
e 
4.5.  CONCLUSIONS 
These studies have emphasized the importance of careful consideration of 
targeting agent selection upon formulation of actively targeted liposomal nanocarriers.  
The small peptide investigated for APN targeting had no impact on liposome circulation 
times in the bloodstream, whereas the inclusion of as few as 4 OX26 antibodies had a 
severe detrimental effect on liposome performance in vivo.  Unfortunately, neither the 
inclusion of NGR peptide or OX26 targeting agents in liposomal DXR formulations was 
able to improve the survival of tumor-bearing animals receiving a single dose of 
liposomal DXR.  This result is explained by reduced circulating levels of drug in the case 
of TfR-targeted liposomes; however, additional studies with APN-targeted liposomes 
must be performed to determine why this formulation was unable to extend survival of 
tumor-bearing animals despite maintenance of prolonged circulation times.  We have 
successfully achieved an enhancement in drug delivery to the brain using TfR-targeted 
liposomes, which is significant considering the drastic reductions in circulation time upon 
inclusion of OX26 antibody as a targeting agent.  These results further stress the need to 
address reductions in circulation times of actively targeted liposomal formulations and 
demonstrate that the use of smaller targeting agents or those able to mimic naturally 
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 occurring substances in the body may provide an option to allow both RES eva
active targeting in vivo. 
sion and 
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 CHAPTER 5.  DECREASED CIRCULATION TIME OFFSETS 
INCREASED EFFICACY OF PEGYLATED NANOCARRIERS 
TARGETING FOLATE RECEPTORS OF GLIOMA 
 
As published with A.V. Annapragada and R.V. Bellamkonda, Nanotechnology, 18, 
(2007) 385101. 
5.1.  ABSTRACT 
Liposomal and other nanocarrier based drug delivery vehicles can localize to 
tumors through passive and/or active targeting.  Passively targeted liposomal nanocarriers 
accumulate in tumors via ‘leaky’ vasculature through the enhanced permeability and 
retention (EPR) effect.  Passive accumulation depends upon the circulation time and the 
degree of tumor vessel “leakiness”.  After extravasation, actively targeted liposomal 
nanocarriers efficiently deliver their payload by receptor-mediated uptake.  However, 
incorporation of targeting moieties can compromise circulation time in the blood due to 
recognition and clearance by the reticuloendothelial system, decreasing passive 
accumulation.  Here, we compare efficacy of passively targeted doxorubicin-loaded 
PEGylated liposomal nanocarriers to actively targeted liposomal nanocarriers in a rat 9L 
brain tumor model.  Although folate receptor (FR)-targeted liposomal nanocarriers had 
significantly reduced blood circulation time compared to PEGylated liposomal 
nanocarriers; intratumoral drug concentrations both at 20 and 50 h after administration 
were equal for both treatments. Both treatments significantly increased tumor-inoculated 
animal survival by 60-80% compared to non-treated controls, but no difference in 
survival was observed between FR-targeted and passively-targeted nanocarriers.  
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 Therefore, alternate approaches allowing for active targeting without compromising 
circulation time may be important to fully realize the benefits of receptor-mediated active 
targeting of gliomas. 
5.2.  INTRODUCTION 
In the past few decades, liposomal nanocarriers have been extensively 
investigated as drug carriers for cancer therapy and have been found to offer many 
benefits when utilized for drug delivery.  One of the major benefits of PEGylated 
liposomal nanocarriers is their ability to evade the reticuloendothelial system (RES) and 
extend the circulation time of encapsulated drugs in the bloodstream.  PEG chains on the 
outer leaflet of the liposomal bilayer are thought to provide a steric barrier to opsonin 
binding resulting in RES evasion [1-8].  Prolonged circulation in the bloodstream results 
in enhanced extravasation at sites exhibiting increased vasculature permeability [9-12].  
For this reason, liposomal nanocarriers have shown increasing promise as drug delivery 
vehicles with the characteristic ability to passively accumulate in tumors and areas of 
injury.   
Circulation time is an important factor for nanocarrier therapy of tumors and 
consequently much effort has gone into designing and optimizing liposomal nanocarriers 
to exhibit prolonged circulation times.  Numerous studies have examined the effects of 
liposome size [13-15], charge [16], pH dependence [17], lipid composition [15, 18], 
cholesterol percentage [19], polymer incorporation [11], and degree of phospholipid 
saturation [20].  The results of these studies have confirmed that prolonged circulation is 
vital for passive targeting of liposomal nanocarriers at sites with “leaky” vasculature. 
Passive targeting is achieved when liposomal nanocarriers are formulated to evade the 
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 RES and subsequently accumulate in areas with characteristic “leaky vasculature”, such 
as tumor sites or sites of injury.  Drainage in tumors is typically limited, and the 
liposomal nanocarriers are retained at the site.  This well-documented phenomenon has 
been designated the enhanced permeability and retention (EPR) effect and results in 
passive accumulation of liposomal nanocarriers at sites with compromised vasculature [9-
12].  
To further increase the efficacy of liposomal nanocarriers that reach the sites of 
interest, active targeting of drugs through the incorporation of targeting moieties on the 
exterior of nanocarriers has been explored.  Active targeting offers many benefits 
including decreased side effects due to reduced accumulation in non-target organs [21-
23].  When targeting moieties are included in the liposomal formulation, these carriers 
can be made to bind specifically to target cells and/or accumulate in areas of interest [24-
28].  Several studies have examined the use of ligands [29-33], small peptides [34, 35], or 
antibodies [26, 36-38] to target over-expressed agents present on or around target cells.  
Although active targeting of liposomal nanocarriers to tumors through the 
incorporation of targeting moieties has shown great promise in vitro, numerous in vivo 
studies utilizing targeting ligands designed to direct formulations to extravascular sites 
have not been as successful.  FR-targeted studies, in particular, have shown very little 
success on solid tumors in vivo [39, 40].  Limited success has been achieved with FR-
targeting in ascitic tumor models, but the increase in efficacy has been attributed to the 
fact that the tumors are disperse and do not limit drug diffusion or receptor binding [39, 
41-44].  It has been suggested that solid tumors are more difficult to treat because drug 
delivery is impeded by the local tumor environment.  High interstitial pressures 
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 characteristic of tumors are known to prohibit transport of liposomal drugs beyond the 
perivascular space [45].  We suggest, and this study confirms, that while limited transport 
is a viable culprit, decreased circulating levels of drug also plays a substantial role in 
diminishing the success of these formulations.  In fact, when circulation is not 
compromised, for example in immune-deficient animals, FR-targeted liposomal 
treatments have demonstrated greater success on solid tumors [46].  In addition, a study 
utilizing an in vivo adoptive tumor growth assay, which is unaffected by pharmacokinetic 
parameters, exhibited a distinct advantage of FR-targeted formulations over non-targeted 
in inhibiting tumor growth [47]. 
Therefore, long circulation times and receptor-targeted uptake comprise the 2 
major facets of liposomal drug delivery, passive targeting and active targeting.   
Numerous studies have successfully documented the ability of targeted liposomal 
nanocarriers to bind specifically to target cells in vitro [29-31, 33, 47]; however, others 
have shown that the addition of targeting moieties often has a detrimental impact on RES 
evasion in vivo even when passive targeting methods, such as the inclusion of PEG, are 
used in combination [34, 39, 46, 48-50].  The liposomal drug delivery strategy to achieve 
the highest drug accumulation at the target site with limited uptake by non-target organs 
would ideally incorporate both active and passive methods of targeting where each 
method of delivery retains optimal performance.   
In the present study, we attempted to specifically target a chemotherapeutic drug, 
doxorubicin, to a folate receptor (FR) over-expressing intracranial tumor in 
immunocompetent rats using a liposomal delivery vehicle.  We chose a brain tumor 
model to perform these studies as it represents an invasive, non-localized tumor that is 
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 difficult to treat by conventional methods such as surgical resection and/or radiation 
therapy.  These tumors typically exhibit projections into the brain demonstrating the 
diffuse and invasive nature of the disease.  The standard chemotherapeutic agents for 
brain tumors, nitrosoureas, have not been very effective as single agents and have failed 
to significantly improve survival times of patients compared with radiotherapy alone [51-
54].  For this reason, targeted chemotherapeutics are desirable.  We have chosen to target 
a chemotherapeutic, doxorubicin, to glioma using liposomal nanocarriers.  Doxorubicin 
was selected for encapsulation since it is fluorescent, allowing for ease of detection, and 
it can be actively and stably loaded into liposomal nanocarriers, allowing for large drug 
payloads.  In addition, doxorubicin has been shown to be more potent than nitrosoureas 
against glioma cells in vitro [55].  Liposomal doxorubicin has been investigated by 
several groups in the treatment of gliomas with promising results [56-58].  FR-targeted 
formulations have been studied extensively and represent an ideal targeting system [31, 
39-44, 46, 49, 59-61].  Numerous tumors have been identified that over-express FR, and 
FR-targeted liposomal nanocarriers have been shown to actively bind these malignant 
cells and subsequently undergo endocytosis.  Cellular uptake of FR-targeted liposomal 
nanocarriers has been shown to be dependent on the presence of adjacent PEG chains.  
Gabizon, et al. demonstrated that cell association of FR-targeted liposomal nanocarriers 
due to FR binding was completely inhibited when adjacent PEG chains were the same 
length as the folate-bearing PEG chains.  Lengthening the folate-bearing PEG chains 
allowed for a dramatic increase in binding of FR-targeted liposomal nanocarriers to target 
cells [62].  In previous studies, we have investigated the liposomal delivery of 
doxorubicin to glioma cells in vitro utilizing FR as a target.  We have previously 
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 demonstrated that preferential uptake of doxorubicin by glioma cells can be achieved 
using FR-targeted liposomal nanocarriers containing an optimal number of targeting 
ligands [29].  For this study, folate-PEG conjugates were inserted into the bilayer of 
liposomal nanocarriers carrying doxorubicin to facilitate targeting to FR.  We 
investigated whether this technique increases the doxorubicin dosage received by tumor 
cells while reducing non-specific delivery to tissues, which do not over-express FR 
receptor.  In addition to dosage obtained at the tumor site, we evaluated delivery to non-
target organs, clearance times, and overall increase in survival of tumor inoculated 
rodents relative to non-targeted or untreated control rodents.  Ultimately, we examined 
the effect of converting a passively targeted formulation to actively targeted to determine 
whether the accompanying negative impact on passive accumulation offsets the benefit of 
active targeting.  The resultant data emphasize the need to consider the effects, both 
beneficial and detrimental, of active targeting when formulating targeted liposomal 
nanocarriers to tumors. 
5.3.  MATERIALS AND METHODS 
5.3.1.  MATERIALS 
A 9L glioma cell line was received as a generous donation from the Neurosurgery 
Tissue Bank at UCSF.  Minimal essential medium containing Earle’s balanced salt 
solution (MEM/EBSS) was purchased from Hyclone (Logan, UT).  Gentamicin (50 
mg/ml), fetal bovine serum (FBS), and Leibovitz’s L-15 medium were obtained from 
Gibco (Carlsbad, CA).  Trypsin-EDTA (0.05% trypsin, 0.53 mM EDTA) in Hanks’ 
balanced salt solution was purchased from Mediatech (Herndon, VA).  Heparin (1000 
USP units/ml), isoflurane, and doxorubicin were obtained from Baxter Healthcare 
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 (Deerfield, IL).  Ketamine (100 mg/ml) was purchased from Fort Dodge Laboratories 
(Madison, NJ).  Marcaine (0.5%) was obtained from Abbott Laboratories (Abbott Park, 
IL).  Flunixin meglumine was purchased from Phoenix Scientific (San Marcos, CA).  
Xylazine (100 mg/ml) was purchased from The Butler Company (Dublin, OH).  
Acetylpromazine (10 mg/ml) was obtained from Boehringer Ingelheim (Ingelheim, 
Germany).  Trifluoroacetic acid (TFA) and triethylamine (TEA) were obtained from 
Fisher Scientific (Pittsburgh, PA).  Cholesterol, paraformaldehyde, and Triton X-100 
were purchased from Sigma (St. Louis, MO).  1,2-Distearoyl-sn-glycerophospho-choline 
(DSPC), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and 1,2-distearoyl-
sn-glycerophosphoethanolamine poly(ethylene glycol)2000 (DSPE-PEG2000) were obtained 
from Avanti Polar Lipids (Birmingham, AL).  t-Boc-HN-PEG3350-succinimidyl 
propionate (t-Boc-HN-PEG3350-SPA) was obtained from Shearwater Polymers (San 
Carlos, CA).  A monoclonal antibody to nestin (mAb 353, IgG1) was purchased from 
Chemicon (Temecula, CA).  Dialysis tubing (10,000 and 100,000 molecular weight cut-
off) was purchased from Spectra/Por (Dominguez, CA).  All animals were purchased 
from Harlan (Indianapolis, IN) and maintained on a folic acid deficient diet (<0.05 ppm) 
containing 1% succinylsulfathiozole obtained from Purina TestDiet (Richmond, IN).  A 
stereotaxic frame was purchased from Kopf Instruments (Tujunga, CA) and utilized for 
tumor inoculation surgeries. 
5.3.2.  LIPOSOME FORMULATION 
Liposomal nanocarriers were formulated using methods similar to those described 
elsewhere [63, 64].  In brief, a 62:35:3 molar ratio of DSPC:cholesterol:DSPE-PEG2000 
was dissolved in ethanol (60ºC) and then hydrated with 400 mM ammonium sulfate 
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 buffer.  The addition of 3% DSPE-PEG2000 was to enable RES evasion.  The solution was 
extruded 5 times through a 0.2 μm filter and then 10 times through a 0.1 μm filter using a 
10 ml Lipex Thermoline extruder (Northern Lipids, Vancouver, British Columbia, 
Canada) at 60ºC.  Liposomal nanocarriers were then dialyzed against decreasing 
concentrations of sodium chloride buffer to remove ethanol and establish an ammonium 
sulfate gradient used to facilitate doxorubicin loading.  The average diameter of extruded 
liposomal nanocarriers was verified by dynamic light scattering (Brookhaven Instruments 
Corporation, Holtsville, NY) and determined to be approximately 110-115nm. 
5.3.3.  DSPE-PEG3350-FOLATE CONJUGATE SYNTHESIS 
Since folate was to be utilized as a targeting ligand, it was necessary to formulate 
a DSPE-PEG3350-folate conjugate to allow insertion into the liposomal bilayer.  A longer 
PEG chain (PEG3350) than those used to confer steric stabilization (PEG2000) was utilized 
to avoid the documented interference with FR binding when shorter PEG chains are used 
[62].  First, a DSPE-PEG3350-amine was synthesized according to methods described 
elsewhere [65].  Briefly, t-Boc-HN-PEG3350-SPA was dissolved in chloroform and mixed 
with DSPE followed by TEA (~1:1:3 molar ratio).  The solution was heated to 60ºC for 5 
minutes and then mixed overnight at room temperature.  The chloroform was rotary 
evaporated, and the residue was taken up with acetonitrile.  The unreacted DSPE was 
precipitated by storing the mixture at 4°C for 6 hours.  The solution was then centrifuged 
to remove the unreacted DSPE, evaporated, and dried over P2O5 under vacuum.  A 10% 
solution of TFA in methylene chloride was added to the DSPE-PEG3350-t-Boc product 
and mixed at 0°C for 2 hours.  The mixture was then washed 4 times with chloroform to 
remove the TFA and rehydrated with water.  The solution was dialyzed (100,000 
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 MWCO) against water to remove unreacted Boc-PEG3350-amine and then lyophilized to 
yield the DSPE-PEG3350-amine product.         
Next, the DSPE-PEG3350-Folate conjugate was formed by previously described 
methods [29, 62].  Briefly, 36.8 mg of folate was dissolved in 1.415 ml of dry DMSO 
before adding 190 mg of DSPE-PEG3350-amine, 600 µl of pyridine, and 46 mg of 
dicyclohexyl carbodiimide (DCC).  The mixture was allowed to react for 4 hours at room 
temperature.  The solution was rotary evaporated to remove pyridine and rehydrated with 
17.5 ml water.  Insoluble by-products were removed by centrifugation at 10,000g.  The 
supernatant was dialyzed (100,000 MWCO) twice against 2 L 50 mM NaCl and three 
times against 2 L water.  The retentate was then lyophilized to yield the final product, 
which was analyzed by thin-layer chromatography, 1H NMR, and mass spectroscopy.  
Rf=0.49 in 1.48 N ammonium hydroxide.  1H NMR (CDCl3 solvent): DPPE [0.84 ppm 
(t), 1.2, 1.5(d), 2.25(d), 2.9(t), 3.1(t), 5.04(m)], PEG [3.3 ppm], and folic acid [1.91, 2.03, 
2.3(t), 4.33(m), 4.48(d), 6.5(d), 6.93(t), 7.64(d), 8.12(d), 8.6(s)].  MW=3144Da.  
5.3.4.  DSPE-PEG3350-FOLATE INSERTION INTO PREFORMED LIPOSOMAL 
NANOCARRIERS 
Folate-conjugates were inserted into preformed liposomal nanocarriers to create 
FR-targeted liposomal formulations.  Non-targeted liposomal nanocarriers did not receive 
conjugates for insertion.  Conjugate insertion was performed according to methods 
previously described [29, 66].  Briefly, DSPE-PEG3350-folate conjugates were micellized 
by dissolving in DMSO (60°C) to a concentration of 28 mM and then diluting 1:10 with 
water for a final concentration of 2.8 mM conjugate in 10% DMSO.  Micelles were 
dialyzed (10,000 MWCO) twice against 1 L water to remove DMSO.  Folate content of 
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 the retentate was determined by measuring UV absorbance at 285 nm wavelength of 
micelles lysed in 10% SDS using a UV-visible spectrophotometer (Shimadzu Scientific 
Instruments Model 1601, Columbia, MD).  Folate-conjugate micelles were then mixed 
with liposomal nanocarriers to achieve a concentration of 0.15% of the total lipid 
formulation.  Our previous in vitro studies have demonstrated that maximum 
differentiation in drug uptake between malignant and cortical cells was achieved with 
0.2% folate-conjugate insertion in the absence of adjacent DSPE-PEG2000 chains [29].  
0.15% folate-conjugate was inserted to generate the FR-targeted formulations for these in 
vivo studies since the insertion of higher numbers was partially hindered by adjacent 
DSPE-PEG2000 chains and this number allowed for consistent insertion efficiencies.  
Previous in vitro studies from our lab have also demonstrated that FR-targeted 
formulations containing as little as 0.05% folate-conjugate bind efficiently to malignant 
cells, consequently this reduction in targeting ligand insertion would still promote 
targeting to tumor cells [29].  The micelle/liposome mixture was then heated to 60°C for 
1 hour to allow insertion.  Afterwards, the liposomal nanocarriers were cooled on ice and 
then dialyzed (100,000 MWCO) to remove any ammonium sulfate or unincorporated 
folate-conjugates from the external phase of the liposomal nanocarriers.  To verify 
adequate insertion, the folate content in the liposomal formulation was then analyzed by 
measuring the UV absorbance at 285 nm after lysing the liposomal nanocarriers with 
10% SDS. 
5.3.5.  REMOTE LOADING OF DOXORUBICIN 
Doxorubicin was loaded into the liposomal nanocarriers using an ammonium 
sulfate gradient as previously described [64].  In brief, liposomal nanocarriers were 
111 
 mixed with doxorubicin reconstituted in PBS (15 mg/ml) at a ratio of 0.16 mg 
doxorubicin to 1 mg of lipid and heated to 60°C for 1 hour.  The liposomal nanocarriers 
were then immediately cooled on ice and subsequently dialyzed to remove any remaining 
doxorubicin. The formulations were sterilized by passing through a 0.2 μm filter.  Final 
doxorubicin content was assessed by lysing the liposomal nanocarriers with 5% Triton X-
100 at 60°C and measuring the UV absorbance at 480 nm. 
5.3.6.  PLASMA CLEARANCE 
In an effort to separate the effects of RES clearance and extravasation into tumor, 
these studies were performed in animals without tumors.  Animals were given an 
intravenous (IV) injection of either non-targeted (n=5) or FR-targeted liposomal 
doxorubicin (n=5) via tail vein (10 mg/kg doxorubicin; ~60 mg/kg lipid).  Blood was 
collected from the orbital sinus immediately before injection and at 1, 3, 12, 16, 22, 48, 
and 92 hours after injection.  Plasma was isolated by centrifugation (2,200g, 15 min).  
Liposomal nanocarriers were lysed by treating with 5% Triton X-100 and heating to 60ºC 
for 20 minutes.  To accurately detect low levels of doxorubicin, fluorescent readings were 
obtained.  Total doxorubicin content of each sample was analyzed (λex=485, λem=590) 
using a fluorescence spectrometer (BIO-TEK, Synergy HT, Winooski, VT).  Plasma 
samples obtained immediately prior to injection were used to correct for background 
fluorescence.   
5.3.7.  9L GLIOMA CELL CULTURE 
A 9L glioma cell line was maintained in MEM/EBSS medium supplemented with 
10% fetal bovine serum and 0.05 mg/ml gentamicin.  Cells were passaged by 
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 trypsinization and washed with growth medium.  Prior to implantation, cells were 
resuspended in serum-free Leibovitz’s L-15 medium to a concentration of 2x108 cells/ml. 
5.3.8.  TUMOR INOCULATION 
A rat glioma model was established by surgically implanting 2x106 9L glioma 
cells into the frontal lobe of 11-12 week old male Fisher 344 rats.  All procedures were 
conducted under a protocol approved by the Institutional Animal Care and Use 
Committee (IACUC) at Georgia Institute of Technology.  Animals were fed a folate-free 
diet containing 1% succinylsulfathiozole for approximately 18 days prior to surgery.  
Folate was eliminated from the diet in an attempt to prevent competitive binding of 
dietary folate to the folate receptors on tumor cells and to avoid possible down regulation 
of tumor FR after implantation.  Although other studies have shown exclusion of dietary 
folate to have no effect on tumor uptake of exogenous folate, a succinylsulfathiozole 
supplement was not utilized to eliminate production of folate by the enteric microflora 
[39].  In addition, a study utilizing J6456 lymphoma in vivo demonstrated a quick down 
regulation of tumor FR expression when animals were kept on a normal folate-enriched 
diet [46].  Therefore, in our study, animals were maintained on the folate deficient diet 
for a minimum of 3 weeks prior to treatment as this has been proven adequate to 
sufficiently lower folate concentrations to a level comparable to that of humans [46].  
During surgery, anesthesia was maintained through the administration of 2-3% inhalant 
isoflurane.  The incision site was shaved and the animal mounted in a stereotaxic frame.  
The scalp was opened to expose the skull, and a burr hole was drilled 2 mm anterior and 
2 mm lateral to the bregma.  2 x 106 9L glioma cells in 10µl of Leibovitz’s L-15 medium 
were slowly injected into the frontal lobe through a 21-gauge needle at a depth of 3 mm 
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 below the brain surface.  The burr hole was then sealed with bone wax, and the scalp was 
sutured closed.  Animals received 5 ml Lactated Ringer’s solution through intraperitoneal 
(IP) injection and a subcutaneous injection of 0.5% marcaine at the wound site.   Flunixin 
meglumine (2.5 mg/kg) was administered through an intramuscular injection to alleviate 
pain as needed.     
5.3.9.   IMMUNOHISTOCHEMISTRY FOR CHARACTERIZATION OF ANGIOGENESIS 
To ensure that the injection of liposomal nanocarriers would occur after the onset 
of angiogenesis, explanted brains were examined for new blood vessel formation.  Four 
days after tumor inoculation, rats were anesthetized by an IP injection of 50, 10 and 1.67 
mg/kg respectively of ketamine/xylazine/acetylpromazine and perfused with phosphate-
buffered saline (PBS) containing heparin (1000 units/L) followed by 4% 
paraformaldehyde in PBS.  Brains were explanted and stored in 4% paraformaldehyde for 
approximately 24 hours prior to being embedded in paraffin.  Paraffin embedded tissues 
were sliced into 5 μm sections using a rotary microtome.  Representative sections 
containing tumor were immunostained for nestin, a marker of angiogenesis.  In brief, 
sections were deparaffinized and rehydrated using xylene and a graded series of alcohols 
and then washed in PBS.  Endogenous peroxidase was blocked by treating with 1% H2O2 
in PBS, and the sections were treated with proteinase K (1 μg/ml) for antigen retrieval.  
After washing with PBS and permeabilizing with 0.5% saponin in PBS, sections were 
exposed to a mouse monoclonal antibody to nestin (1 μg/ml) in PBS containing 1% horse 
serum for 1 hour.  Sections were then washed twice with PBS before applying the 
biotinylated secondary antibody in 0.5% saponin in 1% normal horse serum in PBS for 1 
hour at room temperature.  Slides were washed with PBS and incubated for 45 minutes 
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 with Vectastain Elite ABC Reagent.  Afterwards, sections were washed with PBS and 
then sterile deionized water and exposed to the Vector DAB substrate (0.067% in tris 
buffered saline with 0.024% H2O2).  The reaction was terminated by washing with PBS, 
and the sections were then counterstained with Harris’ hematoxylin.        
5.3.10.    BIODISTRIBUTION IN TUMOUR INOCULATED ANIMALS 
Thirteen days after glioma inoculation, when tumor was deemed large enough for 
explantation, an orbital blood sample was collected from each animal prior to treating 
with either a saline sham, non-targeted ‘Stealth’ (20 hrs: n=8; 50 hrs: n=8), or FR-
targeted (20 hrs: n=7; 50 hrs: n=10) liposomal doxorubicin IV injection (10 mg/kg 
doxorubicin; ~60 mg/kg lipid) via tail vein.  At each of two designated time points 
following injection (20 or 50 hours), doxorubicin biodistribution was assessed.  
Numerous investigators have reported liposomal accumulation in tumor to peak around 
48 hours [39, 67, 68], which lead to the selection of the 50 hour time point for this study.  
The earlier time point (20 hours) was selected since it has been reported that FR-targeted 
liposomal nanocarriers may have an increased accumulation in tumor compared to non-
targeted liposomal nanocarriers at earlier time points [39].  At each time point after 
doxorubicin administration, animals were anesthetized with an IP injection of 50, 10 and 
1.67 mg/kg respectively of ketamine/xylazine/acetylpromazine, and a cardiac blood 
sample was obtained.  Animals were then perfused with heparinized PBS (1000 units/L) 
to remove the blood.  The spleen, brain, heart, lungs, liver, and kidneys were explanted, 
washed with PBS, and blotted dry.  Tumor, identified by discoloration and variation in 
tissue texture, was dissected from the brain using a dissecting microscope at 7x 
magnification.  Organs were weighed and frozen at -20°C until ready to be processed.  
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 Plasma was isolated from each cardiac blood sample obtained prior to perfusion by 
centrifuging at 2,200g for 15 minutes.  Plasma samples were stored at -20ºC until ready 
to be analyzed.  Doxorubicin was extracted from plasma and tissue samples in a manner 
similar to that described elsewhere [69].  Plasma was diluted 1:4 with water.  Organs 
were homogenized in distilled, deionized water (20% wt/vol) using a Polytron 
Homogenizer (Brinkmann Instruments, Westbury, NY).  Homogenates and 25% plasma 
samples (200µl) were mixed with 100µl of 10% Triton X-100, 200µl of water, and 
1500µl of acidified isopropanol (0.75N HCl).  Mixtures were stored overnight at -20°C to 
extract the drug and then warmed to room temperature and vortexed for 5 minutes.  The 
samples were then centrifuged at 15,000g for 20 minutes. Fluorescence of supernatants 
was analyzed to determine doxorubicin content (λex=485, λem=590).  Organ samples from 
an animal treated with a saline sham IV injection and plasma samples obtained prior to 
doxorubicin injection were used to correct for background fluorescence. 
5.3.11.    SURVIVAL STUDIES 
Four days after tumor inoculation, animals were treated with either a saline sham 
(n=5), non-targeted ‘Stealth’ (n=6), or FR-targeted (n=6) liposomal doxorubicin IV 
injection (10 mg/kg doxorubicin; ~60 mg/kg lipid) via tail vein.  Equivalent volumes of 
0.9% sterile saline solution were administered to animals receiving sham injections.  
Tumor growth was allowed to progress until the animal showed signs of morbidity, at 
which point, interventional euthanasia was administered.  Time of death was determined 




 5.4.  RESULTS   
5.4.1.  PLASMA CLEARANCE STUDIES 
Analysis of doxorubicin in plasma samples obtained from treated rats revealed 
that the insertion of 0.15% folate-conjugates into liposomal nanocarriers resulted in 
accelerated clearance from blood plasma (Figure 5.1).  ANOVA revealed that the plasma 
clearance was significantly different between the two formulations (p<0.001).  Within the 
first hour, the rapid reduction in circulating FR-targeted liposomal doxorubicin resulted 
in a 20% difference in plasma levels of FR-Targeted doxorubicin compared to non-
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Non-Targeted 3785.8 18.1 
FR-Targeted 2202.2 6.7 
 
Figure 5.1.  Plasma clearance of liposomal doxorubicin formulations.  Accelerated clearance of FR-
targeted liposomal formulations was exhibited by the rapid decrease of doxorubicin in the blood following 
an IV injection of 10 mg/kg liposomal doxorubicin.  Plasma clearance of FR-targeted formulations was 
significantly higher than clearance of non-targeted liposomal nanocarriers as determined by ANOVA 
(p<0.001).  Both formulations included 3% DSPE-PEG2000 to promote RES evasion.  Blood samples were 
collected from the orbital sinus at various time-points, and drug concentration was determined by 
fluorometry.  Error bars represent standard error of means. Areas under the curves and plasma half-lives 
were calculated for each formulation and are reported in the inset table. 
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and plasma half-lives were determined for each formulation and are reported in Figure 
4.1.  The incorporation of 0.15% folate-conjugates resulted in a 41.8% reduction in AUC.  
Formulations containing 0.2% folate-conjugates were also investigated and found to 
exhibit a further decrease in circulation times demonstrated by a 61.9% reduction in AUC 
compared to non-targeted liposomal doxorubicin (data not shown). 
5.4.2.  TUMOR GROWTH CURVE 
A growth curve was established to record tumor progression over time in 
untreated rats (Figure 5.2).  The growth curve data was used to determine inter-animal 
variability in tumor growth and to verify our ability to consistently inoculate tumor.  
Tumor volume was shown to increase exponentially with a doubling time of 1.7 days for 
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 Figure 5.2.  9L glioma growth curve in Fisher 344 rats.  Tumor volumes were determined through 
histological analysis.  Representative slices stained with cresyl violet from brains explanted at each time 
point show tumor cross-sections (dark areas).  Data is fitted to an exponential curve.  Error bars represent 
standard error of means. 
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following stereotaxic implantation.  Histological examination revealed that the tumors 
were infiltrative into normal brain tissue (data not shown).  
5.4.3.  NESTIN EXPRESSION 
Angiogenesis is necessary for effective IV delivery of drug to tumors.  For brain 
tumors, in particular, the formation of new blood vessels is critical because it disrupts the 
blood-brain barrier.  Therefore, we performed immunohistochemistry to determine the 
onset of angiogenesis in our intracranial tumor model.  Immunohistochemistry results 
confirmed that angiogenesis initiates as early as 4 days following tumor inoculation 
(Figure 5.3).  Nestin, an intermediate filament protein expressed by neuroepithelial stem 
cells, was present in the tumor at this time point indicating the formation of new 
microvessels (Figure 5.3(b),(c),(d)).  This protein was not detected in normal brain tissue 
(Figure 5.3(a)).  The presence of new vessels 4 days after tumor inoculation in our model 
makes liposomal drug delivery to tumor feasible at this time point.  Since treatments are 
typically most effective at an early time point, day 4 was chosen to be the treatment day 
for survival studies.   
5.4.4.  ORGAN DISTRIBUTION STUDIES 
Organ analysis for doxorubicin content showed that the majority of drug was 
cleared by the liver and spleen for both formulations (Figure 5.4).  RES saturation is 
unlikely since the lipid levels did not exceed those reported to cause saturation [70].  In 
addition, we did not observe an acceleration of clearance as the plasma levels dropped, 
which would have been indicative of RES saturation.  Doxorubicin levels in the kidneys 





Figure 5.3.  Nestin expression in normal brain and 9L glioma tumor.  Immunohistochemical analysis 
reveals expression of nestin, a marker for angiogenesis, in tumor 4 days after inoculation.  Brown 
horseradish peroxidase marks the location of nestin in the fixed tissue.  (a) Normal brain tissue serves as a 
negative control.  (b) Tumor section obtained from Fisher 344 rat 4 days after intracranial 9L glioma tumor 
inoculation exhibiting elevated expression of nestin.  Scale bars represent 200 μm.  (c,d) Magnifications of 
tumor image (b) displaying nestin staining along microvessel walls.  Scale bars represent 20 μm. 
however, were significantly different between the two formulations at each time point.  
FR-targeted formulations showed lower plasma levels compared to non-targeted 
formulations at both 20 and 50 hours confirming the data obtained from our plasma 
clearance study.   Plasma doxorubicin levels decreased significantly over time for both 
formulations.  Spleen doxorubicin levels also decreased over time, however, the 





Figure 5.4.  Biodistribution of liposomal doxorubicin formulations in Fisher 344 rats with 9L glioma 
tumor.  Animals received 10 mg/kg doxorubicin IV in either non-targeted or FR-targeted liposomal 
nanocarriers.  Fisher 344 rats were euthanized (a) 20 hours or (b) 50 hours after doxorubicin 
administration.  Doxorubicin content in each organ (ng/mg) and within the plasma (µg/ml) was determined 
through fluorometric analysis.  At both time points, plasma doxorubicin concentrations in animals treated 
with FR-targeted doxorubicin were significantly lower (p<0.01, p<0.001) and liver concentrations were 
significantly higher (p<0.01, p<0.002) than animals receiving non-targeted formulations (Student’s t-test).  
Inset graphs illustrate tumor and brain doxorubicin levels.  At 50 hours, both groups exhibited significantly 











































































 Tumor doxorubicin levels were not significantly different between the two 
formulations at each time point despite the significantly lower amount of FR-targeted 
doxorubicin in the plasma.  Doxorubicin tumor levels for non-targeted formulations 
decreased 6.5% from 20 to 50 hours, which was accompanied by a 27% reduction in 
plasma levels.   In contrast, a 3% increase in tumor levels was observed over the same 
time period for FR-targeted formulations despite the corresponding 65% reduction in 
plasma doxorubicin levels.  Both formulations exhibited higher doxorubicin content in 
the tumor compared to normal brain tissue at 20 and 50 hours, however, elevated 
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Figure 5.5.  Survival of Fisher 344 rats with 9L glioma tumor in response to treatment.  Intracranial 
tumor implantation occurred on day 0, and treatments were administered 4 days later.  Liposomal 
doxorubicin was administered IV at a dose of 10 mg/kg.  Animals in the saline sham group received 
equivalent volumes of 0.9% saline IV.  Survival was monitored daily as described in Materials and 
Methods.  Survival of animals receiving liposomal doxorubicin was significantly increased over saline 
treated animals (p<0.02), however there was no significant difference in survival between animals 
receiving either non-targeted or FR-targeted liposomal doxorubicin (Student’s t-test). 
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 5.4.5.  SURVIVAL STUDIES 
The therapeutic effect of the non-targeted and FR-targeted treatments was 
determined by comparing the respective survival times in response to treatment type 
(Figure 5.5).  Treatments were administered IV at a doxorubicin dosage of 10 mg/kg four 
days after tumor inoculation when new blood vessels have begun to emerge.  Equivalent 
volumes of saline were administered for untreated animals.  The data show a statistically 
significant increase in survival time for both non-targeted (p=0.004) and FR-targeted 
(p=0.01) treatments when compared to a saline sham injection as determined by 
Student’s t-test.  However, there was not a significant difference in survival between the 
non-targeted and FR-targeted liposomal treatments. 
5.5.  DISCUSSION 
The present study was designed to explore the relative benefits of actively 
targeted FR compared to passively targeted ‘Stealth’ liposomal nanocarriers.  Numerous 
in vitro studies have reported gains in targeting efficiency of liposomal nanocarriers to 
tumor cells through the inclusion of folate [29, 31, 41-44, 46, 49, 71].  While in this study 
tumor accumulation and survival were no different when compared to passively targeted 
Stealth liposomal nanocarriers, the fact that this occurred in spite of significantly 
compromised circulation time points to the advantages of active targeting on tumor 
states.  We hypothesize that the increase in clearance exhibited by FR-targeted liposomal 
nanocarriers was due to recognition of folate by the RES.  Exposure of folate on the 
liposomal surface is believed to elicit an interaction between liposomal nanocarriers and 
factors responsible for RES clearance.  This interaction occurs even though PEG is 
included in the liposomal formulation.  Increasing the numbers of PEG chains beyond 3% 
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 in the liposomal formulation was not attempted because we have previously determined 
that increasing the number of PEG molecules tends to hinder insertion of folate-PEG3350-
DSPE conjugates into the liposome bilayer and might compromise the access of folate to 
its receptor on tumor cells.  The observed marked reduction in circulation times of FR-
targeted formulations, while significant,  was not as dramatic as that reported for 
formulations utilizing antibodies as targeting moieties [37, 50], but was slightly higher 
than that reported in a similar study utilizing a higher lipid dose in mice [39].  
Survival studies verified that the inclusion of folate in the liposomal formulations 
did not extend survival beyond that achieved by passively targeted ‘Stealth’ liposomal 
nanocarriers. While this is consistent with the equivalent accumulation of doxorubicin in 
tumors in both cases, it is also possible that survival as the ultimate endpoint of this study 
is not sufficiently sensitive to assess differences in behavior of single doses. It is possible 
that because this tumor model exhibits exponential growth, a single injection may not be 
capable of halting growth enough to cause a substantial increase in survival.  Tumor 
growth probably recovers rapidly following a single injection of chemotherapeutic 
making it impossible to see an effect weeks later.  Even if tumor size was reduced to a 
larger degree by the targeted formulations, the aggressiveness of the tumor to recur and 
the ease to expand within an empty void may have made it impossible to ultimately 
resolve a difference in survival times.  Numerous studies, in fact, have demonstrated 
greater success in extending survival times of animals and tumor accumulation of drug 
when multiple treatments are administered [67, 72].  The administration of multiple 
treatments may have revealed a difference in efficacy between the targeted and non-
targeted liposomal treatments in the current study; however, this was not attempted 
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 because our ultimate goal was to compare passively targeted and actively targeted 
formulations using a single treatment regimen to examine the effects of active targeting 
more closely. 
To determine why survival times remained unaffected despite the inclusion of 
folate, biodistribution studies were performed to evaluate drug content in the vital organs.  
A significantly higher liver accumulation of FR-targeted over non-targeted liposomal 
nanocarriers (20 hours: p<0.01, 50 hours: p<0.001) obtained from this study suggests that 
the liver is primarily responsible for the accelerated plasma clearance observed for FR-
targeted formulations.  This is either due to specific targeting to the folate receptors on 
hepatic cells or a result of opsonization of FR-targeted formulations resulting in clearance 
through the liver.  Since kidney levels were comparable for both formulations, we are 
confident that both formulations are equally stable and do not ‘leak’ doxorubicin. 
Therefore, significant reduction in plasma levels of FR-targeted drug compared to non-
targeted observed at each time point was due to accelerated RES clearance.   
Comparable amounts of drug were attained in the tumor for both formulations 
despite significantly lower plasma levels of FR-targeted drug at each time point.  Passive 
accumulation of liposomal nanocarriers at pathological sites has been shown to be a 
function of circulation kinetics [73].  This is true up to a certain lipid dose, at which 
saturation of tumor with liposomal nanocarriers would occur.  The fact that FR-targeted 
liposomal nanocarriers demonstrated decreased plasma levels suggests that tumor 
accumulation of doxorubicin should have been proportionately lower compared to non-
targeted, however, this was not the case.  Saturation of tumor with doxorubicin is an 
unlikely cause of this result since tumor levels continued to increase over time, and even 
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 at the maximum accumulation levels, it is estimated that only 18% of the tumor 
interstitial volume would have been occupied by liposomal nanocarriers.  Total percent of 
interstitial volume occupied by liposomal nanocarriers was calculated assuming a tumor 
density close to 1 g/cm3 and an interstitial volume fraction of 0.4 as determined by 
previous investigators [74].  
Since it is assumed that the tumor input of doxorubicin is decreased for FR-
targeted formulations due to lower circulating levels, the fact that comparable drug levels 
were discovered in the tumors suggests that FR-targeted formulations may have been 
retained to a better degree within the tumor due to the presence of the folate ligand. 
While we acknowledge the fact that direct evidence for active targeting and enhanced 
retention is not reported in this study, others have demonstrated that active targeting to 
cells obtained from solid mass tumors with FR-targeted liposomal formulations is 
achievable in vivo [44].  In addition, the relationship between circulation time and passive 
targeting of liposomes to tumor sites is well established [70, 73, 75].  Decreased 
circulating levels of liposomes have been proven to lead to decreased tumor uptake; 
however, this was not the case in our studies presumably due to active targeting and 
improved retention of targeted formulations at the tumor site.  Altering the dosage of 
lipids (number of nanocarriers) administered was not attempted because higher dosages 
would have led to RES saturation and lower dosages would have resulted in a further 
reduction in passive targeting to tumor.  We did attempt to increase the amount of 
targeting ligand present on the liposomes in an effort to enhance the ability to actively 
target tumor and overcome the loss in circulation time, however, this simply resulted in 
even lower circulating levels of liposomes in the bloodstream further strengthening our 
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 thesis that the presence of folate causes the accelerated clearance.  Decreasing the amount 
of folate present on the liposomes was not attempted because our previous in vitro studies 
have indicated that this would lead to a reduction in tumor targeting [29].  These studies 
reinforce the central finding of this report: while active targeting and retention at the 
tumor site confers a major advantage of FR-targeted over non-targeted formulations, 
decreases in nanocarrier circulating time effectively offset the gain in drug retention 
resulting in comparable survival times with both treatments.   
The results obtained from these experiments stress the importance of carefully 
considering all of the effects related to active targeting.   There exists a definite need to 
properly balance the effects of passive and active targeting when preparing liposomal 
formulations.  Potential therapeutic formulations must be tailored so that the benefits of 
active targeting are not offset by a potential decrease in circulating levels of drug.  To 
address this need, special considerations must be made upon the inclusion of targeting 
moieties to not only allow for adequate drug targeting, but also ensure that time spent in 
circulation is not compromised. 
5.6.  CONCLUSIONS 
To date, the majority of studies utilizing FR-targeted formulations have shown 
very modest, if any, improvements in treatment efficacy.  Lack of success achieved with 
FR-targeted formulations has been attributed to the limitations on the transport of 
liposomal nanocarriers within solid tumors.  We believe, however, that the inability to 
improve treatment efficacy with targeted liposomal nanocarriers in vivo may also be due, 
in part, to the losses in passive accumulation in tumors due to compromised circulation 
times associated with actively targeted formulations.  This information contributes to the 
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 current understanding of how potential therapeutic formulations may be tailored to 
address the combined effects of drug retention in tumor and time spent in circulation.  If 
plasma clearance issues can be resolved, the ability to specifically target 
chemotherapeutics to malignant brain tumors would alleviate some of the issues 
associated with current therapies and possibly allow for improved prognoses. 
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 CHAPTER 6.  MASKING AND TRIGGERED UNMASKING OF 
TARGETING LIGANDS ON NANOCARRIERS IMPROVES DRUG 
DELIVERY TO BRAIN TUMORS 
 
As prepared for submission to Nature Materials with E. Karathanasis, A.V. Annapragada 
and R.V. Bellamkonda. 
6.1.  ABSTRACT 
Long-circulating nanocarriers have been extensively studied to deliver 
chemotherapeutics, however, inclusion of targeting agents compromises circulation times 
and passive accumulation at tumors thereby offsetting the benefits of active targeting.  
Here, we utilize cysteine cleavable phospholipid-polyethylene glycol (PEG) to ‘mask’ 
targeting ligands on nanocarriers, prolong circulation times, enhance passive tumor 
targeting, and, after cysteine infusion to detach PEG and expose folate, promote active 
targeting to tumor cells.  In vivo blood circulation studies verified the ‘masking’ ability of 
cleavable phospholipid-PEG, and modulation of uptake and cytotoxicity of nanocarriers 
using cleavable phospholipid-PEG was demonstrated through in vitro studies.  Finally, 
studies analyzing uptake by tumor cells in vivo confirmed enhanced delivery when 
tumor-inoculated animals received targeted liposomes containing cleavable PEG 
followed by a cysteine infusion to expose folate. These results indicate that cleavable 
phospholipid-PEG can be used in nanocarrier formulations for controlled masking and 
unmasking of targeting ligands to enhance efficacy of targeted chemotherapeutics. 
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 6.2.  INTRODUCTION 
The ability to specifically target systemically delivered chemotherapeutics to 
tumors offers potential advantages over conventional non-targeted chemotherapy, most 
notably a reduction in toxic drug side effects due to decreased delivery to non-target 
organs [1-3].  Receptor-targeted nanocarriers can be used to package drugs and facilitate 
delivery of high drug payloads to tumors while shielding healthy organs and limiting 
degradation of drug [4, 5].  Long circulating nanocarriers, in particular, have been studied 
extensively as delivery vehicles for chemotherapeutics due to the inherent ability to 
preferentially accumulate in solid tumors by passive convective transport through leaky 
endothelium (a process termed extravasation) [6-9].  The long blood residence time and 
repeated passage through the microvascular bed results in high intratumoral 
concentrations.  The efficacy of these passively targeted nanocarriers is dependent on the 
extent of their extravasation to tumors.  The degree of passive accumulation in turn is 
dependent on the nanocarrier circulation time [10].  While passive targeting of 
nanocarriers results in accumulation of drug at the target site, in vitro studies have shown 
that uptake by cells is limited unless a targeting agent is utilized to promote active 
targeting to cells [11-15].  Unfortunately, we have recently demonstrated that there is an 
inherent optimization problem as the properties that confer prolonged nanocarrier 
circulation times, such as the sphere of hydration made possible by incorporation of 
polyethylene glycol (PEG), are compromised by the presence of receptor targeting 
ligands on nanocarrier surface [16].  As a result of the incorporation of targeting moieties 
into nanocarriers, reduced circulation times substantially decrease passive dosing of 
tumors [16-22].  This consequence partially accounts for the limited success of receptor-
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 targeted nanocarriers in vivo despite the promising results of in vitro experiments [18, 
23].  In this study, we demonstrate an elegant solution that masks the targeting ligands 
while in circulation, and unmasks the ligands after extravasation to the tumors solving the 
optimization conundrum (Figure 6.1). 
 
 
Figure 6.1.  Schematic depicting FR-targeted nanocarrier options.  A) When attached to PEG chains 
longer than those incorporated for RES evasion, folate targeting ligands are readily recognized by the RES 
resulting in accelerated clearance.  These liposomes are often removed from circulation before 
extravasation to the target site is achieved.  B) Longer PEG chains conceal folate from the RES but hinder 
receptor-mediated uptake by target cells over-expressing the folate receptor.  C) Long cysteine-cleavable 
PEG-phospholipid conjugates mask folate during circulation to enable passive targeting to tumor but may 
be removed through the administration of cysteine at a later time after a majority of the nanocarriers have 
extravasated to the target site.  Resultant exposure of folate enables targeting to cells over-expressing the 
folate receptor.   
 
Here, we report a novel multifunctional nanocarrier system using a cleavable 
PEG-lipid conjugate to allow for precise control over ligand access beyond the stealth 
PEG layer on the nanocarrier surface.  PEG chains are capable of creating a hydrophilic 
barrier around liposomes preventing binding of opsonins by steric hindrance and thereby 
preventing recognition by the reticuloendothelial system (RES) which consists of 
phagocytic cells responsible for clearance of nanoparticles from circulation [24-28].  
Therefore, protein deposition and the binding of opsonins responsible for RES clearance 
should be prevented and the targeting ligands ‘masked’ when they are presented on PEG 
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 chains shorter than adjacent PEG chains conferring the hydrophilic, stealth coating on the 
nanocarriers.   
The cleavable conjugate reported consists of a phospholipid bound to PEG5000 via 
a disulfide bridge and is incorporated into the bilayer of receptor-targeted liposomes.  
While present, the cleavable PEG5000 conjugates conceal the targeting ligands (folate), 
which are conjugated to PEG2000, from the immune system allowing for prolonged 
circulation times and passive targeting to tumor.  Once the desired amount of drug is 
passively delivered to the tumor, active targeting is initiated through cleavage of the 
disulfide bridge and removal of PEG5000 from the liposomes.  Targeting ligands are then 
exposed to promote active targeting and uptake by tumor cells.  This distinct ability to 
control the method of targeting using a cleavable PEG conjugate allows for maximization 
of both passive and active targeting while reducing the detrimental effects of targeting 
ligand incorporation. 
Many strategies have been employed to develop conjugates for triggered drug 
delivery systems cleavable by mild acidic pH [29-31], thiols [29-36] or matrix 
metalloproteinase [37, 38]. Thiol reducible cross-linkers offer the advantage of precise 
control over cleavage since they require an externally delivered reducing agent such as 
cysteine, which is only present in the unbound, reduced form at low concentrations in the 
body (~10 µM in blood), to sever the linkage.  In addition, cysteine is innocuous to the 
body at the doses administered for cleavage (~1 mmol/kg).  For these reasons, a cysteine-
cleavable phospholipid PEG conjugate was selected as the ideal candidate for this 
‘triggerable’ receptor-targeting liposomal system.  As a test system, we chose folate as 
the targeting ligand, targeting folate receptors on a rat glioblastoma model.  Folate is a 
140 
 versatile tumor targeting ligand, and the folate receptor has been shown to be over-
expressed in tumors of the ovary, lung, colon, endometrium, brain, breast, and kidney 
[39]. 
 The following data demonstrate our ability to design these multifunctional 
nanocarriers with the ability to 1) conceal targeting ligands, 2) expose targeting ligands 
on demand, 3) enable receptor mediated targeting, and 4) deliver large payloads of drug 
into the nucleus of target cells.   
6.3.  RESULTS AND DISCUSSION 
To test this liposomal system, we first synthesized a cysteine-cleavable conjugate 
by linking a lipid, distearoyl-phosphatidyl ethanolamine (DSPE), to a PEG5000 via a 
disulfide bridge using methods similar to those described elsewhere [34, 36, 40, 41].  
NMR and mass spectroscopy verified the structure of the final conjugate, DSPE-S-S-
PEG5000, which had a purity of 85% with the remaining being inert compounds (see 
methods for details on characterization).   
The thiolytic cleavability of the conjugate was confirmed by treating micellar 
conjugate with cysteine. Upon exposure to cysteine, the parent spot on thin layer 
chromatography (Rf=0.25) disappeared while the native lipid (Rf=0.05) and PEG 
(Rf=0.5) appeared. The degree of cleavage was quantified via normal-phase HPLC 
analysis which confirmed that treatment with a 10-fold excess of cysteine resulted in 
fragmentation of 86% of the conjugate (data not shown).  
In vivo plasma clearance studies were performed to determine the minimal 
percentage of DSPE-S-S-PEG5000 required to adequately mask DSPE-PEG2000-folate on 
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Conventional NT 0 0 0 0 0 
Conventional FRT 0 0 0 0.15 0 
Noncleavable NT 0 8 0 0 0 
Noncleavable FRT 0 8 0 0.15 0 
Cleavable NT 0 0 8 0 0 
Cleavable FRT 0 0 8 0.15 0 
Stealth NT 3 0 0 0 0 
Traditional FRT 3 0 0 0 0.15 
 
 
 the surface of the liposomes and achieve circulation times comparable to those obtained 
with non-targeted ‘Stealth’ formulations.  All procedures were conducted under a 
protocol approved by the Institutional Animal Care and Use Committee (IACUC).  Male 
Fisher rats received different types of liposomal nanocarriers encapsulating a 
chemotherapeutic, doxorubicin (DXR), intravenously (i.v.) and orbital blood samples 
were obtained at various time points and analyzed for doxorubicin content.  Table 6.1 
contains details regarding formulation components for all treatments used in these 
studies.  The cleavable FRT formulation containing 8 mol% DSPE-S-S-PEG5000 
demonstrated optimal in vivo circulation performance compared to other percentages of 
DSPE-S-S-PEG tested and is included in Figure 6.2 which displays the percentage of 
initial DXR in plasma over time for animals receiving either non-targeted liposomes 
(Stealth NT), masked folate-targeted liposomes (Cleavable FRT), or traditional folate-
targeted liposomes (Traditional FRT).  This plot clearly shows that cleavable FRT 
formulations circulate better than traditional FRT liposomes having a significantly longer 
plasma half-life (p<0.0001) and greater AUC0..25 (p<0.0001) and AUC0..∞ (p=0.0001) as 
determined by ANOVA.  These results indicate that this level of cleavable conjugate is 
capable of concealing DSPE-PEG2000-folate from the RES.  In fact, the circulation profile 
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 of this ‘masked’ FRT formulation is comparable to that of Stealth NT liposomes actually 
outperforming the Stealth NT nanocarriers for the first 25 hours after injection.  The slow 
acceleration in plasma clearance over time exhibited by the cleavable FRT formulation is 
presumably due to the low levels (~10 µM) of reduced thiols naturally present in the 
bloodstream slowly cleaving some the PEG chains from the liposomes and gradually 
exposing folate which accelerates RES clearance.  The AUC and half-life of cleavable 
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Formulation Half Life (hrs) AUC (0..25) AUC (0..∞) a
Stealth NT 30.3±1.64 1832.8±50.0 5267.4±333.8 
Figure 6.2. Inclusion of 8% DSPE-S-S-PEG5000 prolongs circulation of FR-targeted nanocarriers.  
Circulating levels of DXR in the bloodstream, expressed as a percentage of initial DXR concentration, over 
time in animals receiving an i.v. injection of Stealth NT ( ) (n=3) or cleavable FRT ( ) (n=3) liposomal 
DXR.  Data were fit to exponential curves to determine half-lives and AUC’s.  The cleavable FRT 
formulation shown contained 8% DSPE-S-S-PEG5000 and demonstrated improved circulation time 
compared to the traditional FRT formulation reported in Chapter 5 exhibiting a significant increase in both 
AUC and half life (ANOVA).  The half-lives and AUC’s from t=0 to 25 hours of Stealth NT and cleavable 
FRT nanocarriers were similar demonstrating the ability of DSPE-S-S-PEG5000 to adequately mask folate 
from the RES duing this timeframe, however, the AUC calculated from t=0 to infinity for Stealth NT 
liposomes was significantly greater than the AUC of cleavable FRT liposomes (ANOVA).  Data represent 
mean ± SEM.     
 
Cleavable FRT 27.4±1.42 1911.6±45.8 3868.2±186.0 




liposomes despite this gradual cleavage of PEG.  These data prove that DSPE-PEG2000-
folate can be concealed by DSPE-S-S-PEG5000 in vivo enabling RES evasion and 
prolonged circulation times.  
 
 
Figure 6.3.  DSPE-S-S-PEG5000 enables triggered uptake of DXR encapsulated within liposomal 
nanocarriers by glioma cells.  Confocal images demonstrate DXR uptake (red) by cells and delivery to 
DAPI-stained cell nuclei (blue).  Cells received either unaltered formulations (A-D) or those pre-treated 
with cysteine (E-H). Treatment with Stealth NT formulations (A and E) resulted in negligible DXR uptake, 
whereas cells treated with conventional FRT (B and F) demonstrated bright red staining indicative of DXR 
uptake.  The addition of non-cleavable FRT liposomes did not result in DXR uptake by cells (panels C and 
G).  Cleavable FRT liposomes were not taken up by cells (D) unless pre-treated with cysteine to remove 
PEG chains and expose folate (H).  Cells receiving cysteine-treated cleavable FRT liposomes demonstrated 
bright red staining which was co-localized with DAPI (blue) indicating nuclear localization similar to that 
exhibited by cells treated with conventional FRT nanocarriers (B and F).  Scale bars represent 20 µm. 
 
In vitro studies were performed to evaluate our ability to precisely control ligand 
presentation and cellular uptake and cytotoxicity using 8% cysteine-cleavable DSPE-S-S-
PEG5000.  9L glioma cells were exposed to DXR encapsulated in Stealth NT liposomes, 
conventional FRT liposomes, non-cleavable FRT liposomes, or cleavable FRT liposomes 
(see Table 6.1 for formulation details).  Treatments were either applied directly to cells or 
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 after pre-treatment with cysteine.  In addition, excess folate was added to a subset of 
treatments before being applied to cells.  Images of cells were obtained through confocal 
microscopy after 1 hour treatment exposure (Figure 6.3).  Cells treated with Stealth NT 
formulations demonstrated negligible uptake with or without cysteine pre-treatment, 
while those treated with conventional FRT liposomes exhibited substantial uptake and 
nuclear localization of DXR under both conditions.  These data demonstrate the need for 
active targeting to facilitate uptake and nuclear localization of liposomal therapeutics.  
When applied without cysteine pre-treatment, “masked” FRT formulations containing 
either non-cleavable or cleavable DSPE-PEG5000 were not internalized by cells.  Pre-
treatment with cysteine, however, considerably enhanced cellular uptake of cleavable 
FRT liposomes.  When treatments were applied in the presence of excess folate, uptake 
of conventional FRT and cysteine-treated cleavable FRT liposomes was considerably 
reduced (data not shown).  The outcome of these studies indicates that removal of 
PEG5000 chains is necessary to expose folate and promote cellular uptake of FRT 
formulations.  In addition, these data prove that cleavage of PEG5000 and controlled 
exposure of folate is achievable with cysteine and subsequently results in uptake of 
liposomes by glioma cells.   
Cytotoxicity of each formulation was determined by evaluating cell viability after 
treatment exposure to ensure that not only targeted uptake was achieved but that the 
extent of DXR uptake was cytotoxic (Figure 6.4).  Cells exposed to Stealth NT liposomal 
DXR remained largely unaffected by treatment application and exhibited approximately 
100% viability under all four conditions.  Conventional FRT liposomal DXR 
demonstrated a significant (p<0.0001) increase in cytotoxicity exhibited by a dramatic 
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 reduction in cell viability.  The addition of excess folate significantly (p<0.0001) reduced 
the cytotoxicity verifying that uptake occurred via the folate receptor.  Cysteine had no 
effect on cytotoxicity, and the results obtained from cells receiving cysteine treated 
conventional FRT liposomes in the presence of excess folate were comparable to those 
resulting from treatment application (without cysteine pre-treatment) in the presence of 
excess folate.  “Masked” formulations (both cleavable and non-cleavable FRT) did not 
demonstrate any cytotoxic effects with or without excess folate, and cysteine had no 
effect on the cytotoxicity of non-cleavable FRT liposomes.  Pre-treatment with cysteine, 
however, did significantly (p<0.0001) decrease viability of cells treated with cleavable  
 
 
Figure 6.4.  Cytotoxicity of liposomal DXR is controllably altered through the inclusion of DSPE-S-S-
PEG5000.  Percent viability of cells after treatment with liposomal DXR formulations is shown.  Treatments 
were applied alone ( ) , with excess folate ( ) , cysteine-treated ( ) , or with excess folate and cysteine 
pre-treatment ( ) .  Stealth NT nanocarrier DXR did not demonstrate any cytotoxic effect on 9L glioma 
cells under any of these conditions.  Conventional FRT DXR was considerably cytotoxic except in the 
presence of excess folate verifying that uptake occurred via the folate receptor.  Cells treated with non-
cleavable FRT liposomal DXR did not exhibit any decrease in viability.  Treatment with cleavable FRT 
nanocarrier DXR did not alter cell viability unless the formulations were pre-treated with cysteine.  The 
addition of excess folate to cells receiving cysteine-cleaved FRT liposomes resulted in a significant 
increase in cell viability indicating that folate sufficiently blocked uptake via folate receptors.  Data 



















Formulation LC50 (µM) 
Free DXR 1.6 
Conventional FRT 4.17 
Non-cleavable FRT >60 
Cleavable FRT >60 
Cleavable FRT + Cysteine 9.22 
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 FRT liposomes verifying that the application of cysteine allows for controlled release of 
PEG5000 and exposure of folate to facilitate cellular uptake of drug.  When excess folate 
was applied to cells exposed to cysteine treated cleavable FRT liposomal DXR, 
cytotoxicity was significantly (p<0.0001) decreased due to competitive inhibition 
confirming that uptake of ‘unmasked’ FRT formulations occurred via the folate receptor.  
Cleavable NT formulations were also investigated and did not demonstrate any effect on 
cellular viability with or without cysteine pre-treatment (see supplementary data).  These 
results support the data obtained from in vitro uptake studies and clearly demonstrate that 
cytotoxic effect of targeted liposomal DXR can be manipulated through the inclusion of 
cleavable PEG conjugates that conceal targeting ligands.   
Results from studies conducted to determine the lethal concentration that kills 
50% of the cells (LC50) of select formulations corroborate the outcome of the cytotoxicity 
studies (Figure 6.4 inset).   The LC50 of free DXR on 9L glioma cells was very low (1.6 
µM) as was the LC50 of conventional FRT liposomal DXR (4.2 µM).  Masked 
formulations, however, were not cytotoxic at any of the concentrations tested (0-60 µM).  
Upon the addition of cysteine, cleavable FRT liposomal DXR exhibited a substantial 
reduction in LC50 (9.2 µM) verifying successful removal of PEG5000 and exposure of 
folate due to cysteine cleavage of the conjugate disulfide bridges.  These studies 
demonstrate that cleavable phospholipid-PEG conjugates can be inserted into targeted 
nanocarriers to enable precise control over cytotoxic effects.   
To determine intracellular uptake of systemically delivered nanocarriers by tumor 
cells in vivo and the ability to control uptake using cleavable PEG, we performed studies 
on brain tumor-bearing rats (9L/LacZ glioma model) receiving either Stealth NT 
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 liposomes or cleavable FRT liposomes encapsulating a fluorochrome (ADS645WS) and a 
subsequent infusion of either saline or cysteine.  Animals were euthanized, tumors were 
dissociated and stained for β-gal production, and cells were analyzed through flow 
cytometry.  Cultured 9L/LacZ cells and nontransfected 9L glioma cells were stained and 
served as positive and negative controls, respectively, for β-gal production.  Cytometric 
detection of β-gal in the 9L/LacZ glioma tumors delineated two populations of cells, β-
gal(+) tumor cells and β-gal(-) nontumor cells.  The β-gal(-) populations exhibited 
similar, minimal ADS645WS staining intensity per cell regardless of treatment type (NT 
+/- cysteine, FRT +/- cysteine) indicating that the uptake of liposomes by nontumor cells 
was nominal (Figure 6.5).  The β-gal(+) population of cells obtained from animals 
receiving cleavable FRT liposomes followed up by a cysteine infusion, however, 
demonstrated a significant shift in liposome uptake indicated by an increase in 
ADS645WS signal detected in the APC channel (Figure 6.5d).  β-gal(+) cells obtained  
 
Figure 5.5.  In vivo cellular uptake of liposomes is enhanced when folate on FR-targeted nanocarriers 
is masked during circulation and ultimately exposed after extravasation into tumor.  Uptake of 
liposomes represented by APC staining intensity, is shown for A) Stealth NT/saline treated (n=8), B) 
Stealth NT/cysteine treated (n=6), C) cleavable FRT/saline (n=6), or D) cleavable FRT/cysteine treated 
(n=6) rats after gating the non-tumor ( ) and tumor ( ) populations.  Saline treated animals (n=3) served 
as a negative control for APC staining ( ).  There was no significant difference in uptake between 
treatment groups by non-tumor cells.  However, a significant shift in the APC peak was observed in tumor 
cells of animals treated with cleavable FRT liposomes and a subsequent cysteine infusion (see Table 6.2 for 
quantitative analysis). 
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 from the other treatment groups showed comparably low uptake of liposomally 
encapsulated dye with only a minimal shift in uptake compared to β-gal(-) cells (Figure 
6.5a-c).  Frequency profiles of β-gal and liposome signal intensity on two-dimensional 
graphs also demonstrated a shift in the β-gal(+) cell population obtained from animals 
treated with cleavable FRT liposomes and cysteine into higher liposome signals (Figure 
6.6).  The percentage of tumor cells from these animals that demonstrated liposome 
uptake (APC+/FITC+) was significantly (p<0.0001) greater than that of other treatment  
  
Figure 6.6.  Cysteine cleavage of PEG and exposure of folate on FRT liposomal nanocarriers at the 
target site significantly increases frequency of drug uptake by tumor cells.  Two dimensional event 
density profiles of disaggregated tumor cell suspensions obtained from animals receiving Stealth NT (B 
and C) or cleavable FRT (D and E) liposomal nanocarriers display β-gal (FITC channel) and ADS645WS 
staining intensity (APC channel).  Animals received a saline (B and D) or cysteine (C and E) infusion 
following treatment administration.  A mixture of untransfected 9L glioma cells and transfected 9L/LacZ 
glioma cells obtained from in vitro culture was stained for β-gal production to identify β-gal(-) and β-gal(+) 
populations (A).  A shift in the β-gal(+) (tumor) population obtained from cleavable FRT/cysteine treated 
animals demonstrates a significant increase in the percentage of target cells positive for liposome uptake 
(p<0.0001, ANOVA).  Data represent mean ± SEM. 
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 groups, with the percentage of tumor cells demonstrating liposome uptake in cleavable 
FRT/cysteine treated animals being approximately 2.7 times that of Stealth NT/saline 
treated animals.   
Increased uptake of cleavable FRT formulations by tumor cells obtained from 
animals receiving a cysteine infusion is indicative of PEG removal in vivo.  Further 
verification of cleavage was obtained through analysis of blood samples obtained from 
animals immediately prior to euthanasia.  Fluorometric detection of liposomal 
ADS645WS in blood samples demonstrated a 25-30% reduction in liposome blood levels 
of animals receiving FRT liposomes and a cysteine infusion compared to other treatment 
groups confirming that cleavage of PEG, leading to immune recognition of exposed 
folate, was achieved in vivo. 
Cytometric data allowed for quantitative analysis of the results obtained from 
treated animals (Table 6.2).  The shift in fluorescent intensity representing liposomal 
uptake per cell observed in the group receiving cleavable FRT nanocarriers and a 
cysteine infusion was significant compared to the remaining treatment groups.  In 
addition, mean liposome associated fluorescence in tumor cells obtained from FRT 
liposome/cysteine treated animals was about 2.8 times greater than that of host cells  
Table 6.2.  Flow cytometric analysis of uptake of liposomal formulations by 
tumor cells recovered from 9L/LacZ tumors in rats. 
 APC Median Signal Intensity ± SEM 
Formulation Tumor Cells  Tumor/Host Ratio 
Stealth NT + Saline 1.371 ± 0.099  1.355 ± 0.099 
Stealth NT + Cysteine 1.425 ± 0.110  1.411 ± 0.109 
Cleavable FRT + Saline 1.398 ± 0.102  1.384 ± 0.101 
Cleavable FRT + Cysteine 2.845 ± 0.160*  2.715 ± 0.180* 
 *p<0.0001  *p<0.0001 
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 verifying specificity for tumor cells.  This tumor/host uptake ratio was significantly 
greater than that obtained from other treatment groups, which did not demonstrate 
selectivity for tumor cells.  These results verify that cleavage of the PEG5000 chains o
cleavable FRT nanocarriers is achievable at the tumor site in vivo using an i.v. cyste
infusion.  This cleavage is sufficient to allow for increased binding and internalization o
liposomes by tumor cells due to exposure of the targeting ligand, folate.  Animals that 
received cleavable FRT liposomes that were ultimately ‘unmasked’ demonstrated a 
significantly higher uptake of liposomes per tumor cell as well as a significantly greater
percentage of tumor cells internalizing liposomes.  These data were obtained from 
animals that were euthanized only 1.5 hours after PEG5000 chains were detached.  At late
time points, when cells have had a longer exposure to the targeted liposomes, the 
difference may be even greater.  Even considering the fact that circulating levels of 
cleavable FRT nanocarriers will decrease after cysteine infusion, longer exposure 
the tumor site should allow for a further increase in specific uptake (tumor/nontumor
uptake ratio) compared to Stealth NT liposome treated rats. 
We have previously demonstrated and discussed the importance of circulation 








 targeted nanocarriers [16].  
With th es 
s 
 as 
e knowledge that passive accumulation is critically dependent on circulation tim
[10], it is imperative that prolonged circulation of nanocarriers is uncompromised upon 
inclusion of targeting moieties.  Here, we have shown that cleavable phospholipid-PEG 
conjugates can be used to enable precise control over ligand exposure, effectively 
concealing ligands to prolong liposomal circulation times and exposing targeting moietie
at the desired time point upon administration of an in vivo safe cleaving agent such
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 cysteine.  Appropriate PEG lengths and percentages included in each liposomal 
formulation need to be considered for various applications (i.e. utilizing an alternative 
targeting moiety) as these parameters greatly affect the ability to conceal targetin
and prolong circulation times.  Utilizing the system described here for FRT liposomal 
formulations, we are confident that we have succeeded in satisfying the criteria for 
maximizing passive targeting of liposomal formulations containing targeting ligands an
preventing the offset of active targeting.   
Through these studies, we have also demonstrated that cleavable phospholipid-
PEG conjugates can be utilized to promote
g agents 
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 the ability to regulate uptake and cytotoxicity of targeted nanocarriers.  In vitro
cleavage of the PEG conjugates on FRT formulations was achieved with cysteine a
resulted in nuclear localization of drug payloads, a mandate for DXR efficacy.  In 
addition, treatment with cleaved FRT formulations resulted in a significant enhanceme
of uptake and cytotoxicity, which approached values attained with conventional FR
liposomes.  Conventional FRT liposomes have been shown to outperform FRT liposomes
with adjacent DSPE-PEG chains in vitro [42], however, until now, DSPE-PEG has bee
present on FRT liposomes at the tumor site in vivo because it is mandatory to prolong 
circulation time.  Removal of adjacent PEG chains in vivo, a feat made possible with this 
multifunctional liposomal system, should promote uptake of these formulations beyond
that previously achieved, thereby maximizing active targeting of liposomal formulations.  
In vivo, we demonstrated a significant increase in uptake compared to Stealth NT 
liposomes both in the number of tumor cells positive for liposomes and the number of 
liposomes per cell when animals received FRT liposomes followed by a cysteine 
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 infusion.  This data confirms that cysteine is capable of cleaving phospholipid-PEG 
conjugates, exposing targeting ligands, and promoting uptake in vivo.  In addition,
studies demonstrate that utilization of these cleavable conjugates in targeted nanocarr
formulations reduces the detrimental effects of targeting ligand incorporation and enables
true optimization of both passive and active targeting to tumors.  These findings should 
allow for a significant enhancement in treatment efficacy of targeted nanocarrier 




6.4.  METHODS 
6.4.1.  SYNTHESIS OF DSPE-S-S-PEG5000 






pyridyldithio]-propionamido (SPDP) as a cros
hoethanolamine (DSPE) and PEG5000-SH. In brief, DSPE (790 mg, 1.05 mmol) 
was dissolved in chloroform (22 mL) with triethylamine (900 µL) at 55 °C.  SPDP (263 
mg, 0.844 mmol) was dissolved in 3 mL of chloroform and then added to the DSPE 
solution.  The reaction mixture was stirred for 5 hours at room temperature.  The reaction
progress was monitored by thin-layer chromatography (TLC) which demonstrated the
conversion of DSPE to a faster running product.  PEG5000-SH (1.75 g, 0.351 mmol) was 
then dissolved in 9 ml of chloroform before being added to the solution of PDP-DSPE.
The mixture was allowed to react overnight at room temperature.  The reaction progress 
was monitored by the UV absorbance at 343 nm of the pyridyl-2-thione byproduct 
released from the DSPE-PDP intermediate once the disulfide bridge between the lipid 
and the PEG was formed.  TLC was also utilized to monitor the reaction progress.  
Following evaporation of the organic solvents, excess DSPE was then removed by 
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 precipitation in acetonitrile and centrifugation.  The supernatant was recovered, and
acetonitrile was then removed by rotary evaporation.  The residue was dissolved in 
dichloromethane and applied to a silica gel column.  The column was washed with 20
mL of each of the following concentrations of methanol in dichloromethane: 4%, 6%
9%, 12%, and 15%.  During chromatography, 4 mL fractions were collected, and those 
determined by TLC to contain product were pooled and lyophilized.  The product (DSP
S-S-PEG5000) was characterized by matrix assisted laser desorption ionization time-of-
flight mass spectroscopy (MALDI-TOFMS), high performance liquid chromatography 
(HPLC), and thin layer chromatography (TLC).  TLC confirmed the presence of the fin
product (Rf=0.25 in CHCl3:MeOH=85:15). MALDI-TOFMS resulted in a bell-shaped 
spectra verifying the expected molecular weight of ~6,210 Da with lines spaced at 44 Da. 
1HNMR (DMSO-d6, solvent): δ 0.83 (t, CH3, 6H), 1.2 (s, CH2, 56H), 1.6 (br, CH2 
CH2C=O, 56H), 2.24 (2xt, CH2C=O, 4H), 2.5 (2xt, S=CH2 CH2CON, 4H), 2.85 (t, 
CH2CONHDSPE, 4H), 3.22 (s, CH3O, 3H), 3.5 (s, PEG, ~456H), 3.7 (t, NCH2CH2







6.4.2.  THIOLYTIC CLEAVABILITY OF DSPE-S-S-PEG 
The thiolytic cleavability of the conjugate was confirmed by treating 1 mM 
in PBS for 30 min at 37°C.  
The deg LC 
6.4.3.  IN VIVO CIRCULATION STUDIES 
To form the folate conjugate, a DSPE-PEG2000-amine was mixed with folate 
cted with pyridine and dicyclohexyl 
micellar conjugate with cysteine of 10 mM concentration 
ree of cleavage was monitored by TLC and quantified via normal-phase HP
analysis.   











imide, rotary evaporated, and rehydrated with water to form micelles.  DSPE-
PEG3350-folate conjugates were synthesized in a similar manner [16].  Non-targe
liposomes were composed from a 62:35:3 molar ratio of DPPC:cholesterol:DSPE-
mPEG2000, and liposomes with detachable PEG were prepared using 
DPPC:cholesterol:DSPE-S-S-PEG5000 where the percentage of DSPE-S-S-PEG5000
varied (2%, 6%, 8%) with a corresponding decrease in DPPC content
100 nm liposomes were formulated following previously described methods [11, 16, 43]
Targeted formulations received 0.15 mol% of either DSPE-PEG3350-folate or DSPE-
PEG2000-folate for insertion following established procedures [11, 16].  DXR (120 mg 
DXR/mmol lipid) was then remotely loaded into liposomes according the previously 
described methods [16, 44].  Prior to administration, treatments were sterilized by passi
through a 0.2μm filter.  Final doxorubicin content was assessed by lysing the liposomal 
nanocarriers with 5% Triton X-100 at 60°C and measuring the UV absorbance at 480 nm. 
Plasma clearance studies were conducted under a protocol approved by the 
Institutional Animal Care and Use Committee (IACUC) at Georgia Institute of 
logy.  Adult, male Fisher 344 rats were given an i.v. injection of liposomal D
(10 mg/kg DXR; ~60 mg/kg lipid).  Each group received one of the following 
formulations: non-targeted with DSPE-PEG2000 (n=3), FR-targeted with DSPE-PEG3350-
folate and DSPE-PEG2000 (n=5), or FR-targeted with DSPE-PEG2000-folate and
S-PEG5000 (n=3 for each level of cleavable PEG incorporation).  Blood was collected 
from the orbital sinus immediately before injection and at 1.5, 7, 18.5, 25, 43, 53.5, and 
74.5 hours after injection.  Plasma was isolated by centrifugation.  Liposomes were lys
by diluting plasma 1:10 with 5% Triton X-100 and heating to 60ºC.  Total DXR content 
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 of each sample was analyzed (λex=485, λem=590) using a fluorescence spectrometer.  
Plasma samples obtained immediately prior to injection were used to correct for 
background fluorescence.   
6.4.4.  IN VITRO STUDIES 
A 9L glioma cell line received as a generous donation from the Neurosurgery 






d then incubated at 37°C for 5 days in folate-free 
RPMI m
Tissue Bank at UCSF was m
vine serum and 0.05 mg/mL gentamicin.  Liposomal DXR was prepared as 
describe above using 0% DSPE-PEG (conventional), 3% DSPE-PEG2000 (Stealth), or 8%
DSPE-S-S-PEG5000 (cleavable).  FR-targeted formulations received 0.15% DSPE-
PEG2000-folate for insertion.  Prior to applying to cells, formulations were split in half and 
mixed with either cysteine (10:1 molar ratio of cysteine:lipid) or an equivalent volu
saline for 30 minutes at 37°C and then dialyzed. 9L glioma cells were washed with 
folate-free RPMI medium, and then treatments were applied (10 µM DXR) in RPMI 
medium containing either 0 or 2 mM folate for 2 hours at 37°C.  Cells treated on cha
slides for uptake imaging were then washed three times with ice cold PBS containing 
calcium and magnesium before fixing with 4% paraformaldehyde/1.5% methanol in PBS 
for 20 minutes.  Cells were then washed with PBS and stained with DAPI for 10 minut
before a final PBS wash.  Images of the treated cells were obtained on a Zeiss confocal 
microscope (LSM 510). 
Cells treated for cytotoxicity analysis were washed three times with folate-free 
RPMI after treatment application an
edium.  Viability was then determined using a formazan based cell counting kit 
(CCK-8).  Untreated cells served as live controls for normalization of the data.  LC50 
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 values were determined in a similar manner with cells exposed to increasing 
concentrations of liposomal doxorubicin (1.56, 3.13, 6.25, 12.5, 25, 50 µM).  The best
line of at least 3 points in the linear range of cell viability was then used to de
LC50. 




llular drug and to distinguish uptake between tumor and non-tumor cells.  For 
these st ter 
 out 
ds 
6.4.5.  TUMOR INOCULATION 
A 9L glioma cell line transfected with the bacterial β-galactosidase encoding 




6.4.6.  FLOW CYTOMETRIC STUDIES 
Animals were allowed to recover from surgery, and 21 days later, saline sham, 
vable FRT (8% cleavable DSPE-PEG5000) 
udies, liposomes were fabricated as described above and loaded with a wa
soluble fluorophore, ADS645WS (American Dye Source).  Encapsulation was carried
by mixing the lipids with 10 mg/mL ADS645WS in 0.9% NaCl after dissolving in 
ethanol.  Formulations were extruded to 100 nm and then loaded onto a Sepharose CL-4B 
chromatography column to remove unencapsulated dye.  Insertion of targeting ligan
was conducted as described above.   
gene, LacZ, was maintained in M
serum and 0.05 mg/mL gentamicin.  A rat glioma model was established by 
orthotopic inoculation of 2 x 106 9L/LacZ glioma cells following established metho
[16].  Animals were fed a folate-free diet containing 1% succinylsulfathiozole for 
approximately 18 days prior to surgery to eliminate competitive inhibition of FR-target
liposome uptake and prevent down-regulation of folate receptors in vivo.  













al ADS645WS (1.77 mg/kg ADS645WS; ~70 mg/kg lipid) treatments were 
administered i.v.  After 28.5 hours, either 0.9% NaCl or a solution of 60 mg/ml cys
in 0.9% NaCl was infused over 15 minutes at a dose of 2 ml/kg.  Animals were 
anesthetized with 5% isoflurane 1.5 hours later and decapitated immediately after 
obtaining a cardiac blood sample.  Tumors were dissected from explanted brains
mechanically fragmented, and treated for 60 minutes at 37°C with a solution of 
collagenase (0.1 U/ml PBS) and dispase (0.8 U/ml PBS) to dissociate cells.  The c
solution was resuspended in 4% fetal bovine serum in PBS and treated with a 
FluoReporter® lacZ flow cytometry kit.  Tumor cells expressing the lacZ reporter gen
product, beta-galactosidase, hydrolyzed the fluorogenic beta-galactosidase sub
allowing fluorescent detection of expression to distinguish tumor cells from non-tumor 
cells.  A LIVE/DEAD® fixable red dead cell stain kit was also used separately to iden
dead cell populations during flow cytometric analysis.  Flow cytometry was conducted 
using a Becton-Dickinson DLSR digital flow cytometer equipped with a 488 nm 
excitation laser using the APC channel for detection of liposomal ADS645WS, the FITC
channel for tumor cell (lacZ) detection, and the Texas Red channel to identify dea
populations.  Liposome uptake by lacZ+ (tumor) cells and lacZ- (non-tumor) cells was 
then quantified.  Tumor cells obtained from saline treated animals served as a negative 
control for ADS645WS while untransfected 9L glioma cells stained with the 
FluoReporter® lacZ flow cytometry kit were utilized as a negative control for lacZ 
staining.  Blood samples were analyzed for liposome content after centrifugat
isolate plasma and treatment with 10% SDS to lyse liposomes.  Fluorescent signal o
samples was then quantified to determine liposome concentration.  
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 6.4.7.  STATISTICAL ANALYSIS 
Means were determined for each variable in this study and the resulting values 
from each experiment were subjected to an analysis of variance (ANOVA) with Tukey 
post-hoc pairwise comparisons.  Significance was determined using a 95% confidence 
level.  Normality of each data set was confirmed using the Ryan-Joiner test. 
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 6.7.  SUPPLEMENTARY INFORMATION 
 
Figure 6.7.  Matrix assisted laser desorption ionization time-of-flight mass spectrum (MALDI-
TOFMS) of DSPE-S-S-PEG5000.  A bell-shaped spectrum is shown verifying the expected molecular 
weight of ~6,210 Da.  Lines are spaced at 44 Da, the molecular weight of PEG monomer, due to the 
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Figure 6.8.  Supplement to Figure 6.2: Inclusion of 8% DSPE-S-S-PEG5000 prolongs circulation of 
FR-targeted nanocarriers.  Circulating levels of DXR in the bloodstream, expressed as a percentage of 
initial DXR concentration, over time in animals receiving an i.v. injection of Stealth NT ( ) (n=3) or 
cleavable FRT containing 8% DSPE-S-S-PEG5000 ( ) (n=3) liposomal DXR.  This plot also displays data 
obtained from the treatment group receiving cleavable FRT containing 6% DSPE-S-S-PEG5000 ( )  (n=3) 
liposomal DXR, which was omitted from Figure 6.2.  An increase in circulating levels of drug was 
observed when the DSPE-S-S-PEG5000 percentage was increased from 6% to 8% indicating an 



















Figure 6.9.  Supplement to Figure 6.4: Cytotoxicity of liposomal DXR is controllably altered through 
the inclusion of DSPE-S-S-PEG5000.  Percent viability of cells after treatment with liposomal DXR 
formulations is shown.  Plot displays additional control treatment groups (free DXR, conventional NT, 
noncleavable NT, cleavable NT) omitted from Figure 6.4.  Treatments were applied alone ( ) , with excess 
folate ( ) , cysteine-treated ( ) , or with excess folate and cysteine pre-treatment ( ) .  Free DXR 
demonstrated significant cytotoxicity to cells, while the 3 additional NT control treatment groups 
(conventional NT, noncleavable NT, cleavable NT) did not demonstrate a substantial cytotoxic effect under 





























Figure 6.10.  Cytotoxicity of liposomal DXR as a function of applied DXR concentration.  9L glioma 
cells were exposed to increasing numbers of DXR-loaded liposomes for 2 hours, washed, and then 
incubated for 5 days before assessing viability to determine the LC50 of each liposomal formulation.  The 
best fit line of at least 3 points in the linear range of cell viability was used to calculate LC50.  Conventional 
NT ( ), noncleavable NT ( ), noncleavable FRT ( ), and cleavable FRT ( ) did not demonstrate any 
cytotoxic effect over the range of DXR concentrations tested (up to 60 µM).  After pre-treatment with 
cysteine, however, the cleavable FRT formulation ( ) e hibited a dramatic effect on cell viability, reducing 
the LC50 to 9.22 µM.  Conventional FRT liposomal DXR ( ) and free DXR ( ) also exhibited cytotoxic 
effects on 9L glioma cells with LC50s of 4.17 µM and 1.6 µM, respectively.  Data represents mean ± SEM.  
x
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 CHAPTER 7.  SUMMARY OF FINDINGS 
7.1.  INTRODUCTION 
Liposomes have been studied extensively since their initial discovery in the 
1960’s.  By the 1970’s, realization of their potential use as therapeutic nanocarriers 
spurred thorough investigation toward drug delivery applications.  Soon afterward, 
sterically stabilized liposomes were introduced with the potential to passively target 
tumors due to the combination of 1) prolonged circulation in the bloodstream resulting 
from RES evasion and 2) the enhanced permeability and retention effect attributed to the 
intrinsic properties of the tumor vasculature and compromised lymphatics.  Today, 
despite the fact that several “Stealth” liposomal formulations have been clinically 
approved, little progress has been made toward the clinical approval of an actively 
targeted liposomal chemotherapeutic.    
 The inclusion of targeting agents into liposomal nanocarriers to promote active 
targeting to tumors has been studied extensively.  In vitro studies with a wide variety of 
targeting agents have demonstrated considerable success in facilitating specific binding 
and uptake by tumor cells [1-9].  In vivo, however, actively targeted liposomal 
nanocarriers have failed to meet the expectations established by the promising outcomes 
of in vitro studies.  Disappointing in vivo results have been attributed to the fact that the 
delivery of liposomes to solid tumors is limited by elevated interstitial pressures and 
inability to diffuse beyond the perivascular space [10].  This certainly is a valid 
explanation, however diffusion limitations only partially account for in vivo failure of 
actively targeted liposomal nanocarriers.   
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 It has been shown that the inclusion of targeting agents in liposomal formulations 
results in reductions in circulation time within the bloodstream due to RES recognition 
and clearance.  Since passive accumulation to tumor is directly related to circulating 
levels in the bloodstream, accelerated clearance of actively targeted liposomal 
formulations reduces passive targeting to tumor.  This decrease in passive targeting 
effectively offsets the benefits of active targeting to tumor. 
The global objective of the body of work described here was to further investigate 
the impact of targeting ligand incorporation into sterically stabilized liposomes and to 
explore a possible solution to the negative effects of ligand insertion using cleavable 
phospholipid-PEG conjugates.  To accomplish this objective, this study was divided into 
two parts.  Preliminary experiments were conducted to gain a more thorough 
understanding of the in vivo effects of folate insertion in liposomes, and subsequent 
studies explored the ability to modulate folate exposure in vitro and in vivo using 
detachable PEG chains. 
7.2.  EVALUATION OF ALTERNATIVE TARGETING AGENTS TO IMPROVE TREATMENT 
EFFICACY 
Through in vivo studies utilizing both a small peptide targeted to APN and a large 
antibody targeted to TfR in liposomal DXR formulations, the impact of targeting agent 
selection was investigated.  Survival studies performed on tumor-bearing animals 
demonstrated the importance of administration time point selection.  When treatment was 
administered at an earlier time point, a more favorable response in treatment efficacy was 
achieved.  Delaying the treatment administration by 8 days resulted in the complete 
inability to prolong survival beyond that achieved with saline sham treated animals.  At 
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 this time point, the tumor size had progressed to a point where a response to any 
treatment was unattainable.  Additional survival studies were performed to investigate 
alternative treatment regimens.  The results of these studies showed that a single 
treatment with liposomal DXR at a dose of 10 mg/kg was superior to the administration 
of 2 weekly treatments adding to a cumulative dose of 20 mg/kg.  Unfortunately, utilizing 
a single treatment regimen, neither the inclusion of NGR peptide or OX26 targeting 
agents in liposomal DXR formulations was able to improve the survival of tumor-bearing 
animals over the survival of animals receiving non-targeted liposomal DXR.   
Circulation studies emphasized the importance of careful consideration of 
targeting agent selection upon formulation of actively targeted liposomal nanocarriers.  
The small peptide investigated for APN targeting had no impact on liposome circulation 
times in the bloodstream, whereas the inclusion of as few as 4 OX26 antibodies had a 
severe detrimental effect on liposome performance in vivo.  The drastic dissimilarity in 
circulation of these targeted liposomal nanocarriers may be attributed to the 75-fold 
difference in targeting agent size; however, it is not size alone which determines the 
ability to evade the RES.  Other factors such as polarity, hydrophobicity, overall surface 
charge, and 3-dimensional configuration among other characteristics must also play a role 
in the ability of the RES to recognize these molecules on the surface of liposomal 
formulations and accelerate clearance from the bloodstream.  The primary reason 
suggested for the low immunogenicity of NGR has been its ability to mimic natural 
proteins in the bloodstream [11].  These studies have provided insight into additional 
factors which may be considered during targeting agent selection to ensure prolonged 
circulation in the bloodstream. 
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 Through biodistribution studies, we determined that an enhancement in drug 
delivery to the brain may be achieved using TfR-targeted liposomes, which is significant 
considering the drastic reductions in circulation time upon inclusion of OX26 antibody as 
a targeting agent.  These results further stressed the need to address reductions in 
circulation times of actively targeted liposomal formulations.  If, as shown here, 
enhanced drug delivery to the brain may be achieved with such low circulating levels of 
drug, improvements in circulation times should significantly increase delivery to the 
brain.  Therefore, it is imperative that circulation times of actively targeted liposomal 
nanocarriers are improved, and the use of smaller targeting agents or those able to mimic 
naturally occurring substances in the body may provide an option to do so in vivo. 
7.3.  DECREASED CIRCULATION TIME OFFSETS INCREASED EFFICACY OF PEGYLATED 
NANOCARRIERS TARGETING FOLATE RECEPTORS OF GLIOMA 
Experiments conducted to investigate the impact of targeting ligand insertion into 
passively targeted liposomes included the development and characterization of an 
orthotopic glioma model, in vivo blood circulation studies, biodistribution studies, and 
survival studies.  Previous reports have indicated a negative impact on targeting ligand 
inclusion through demonstrated reductions in circulating levels of actively targeted 
formulations in the bloodstream; however, the full consequences had not been directly 
addressed or investigated in detail [8, 10, 12-15].  The current studies reported here also 
revealed a dramatic and significant reduction in circulating levels of FR-targeted 
liposomes compared to passively-targeted Stealth liposomes.   
Intravascular administration of liposomal DXR demonstrated that the insertion of 
DSPE-PEG3350-folate into Stealth liposomes caused a 42% reduction in AUC and a 63% 
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 reduction in plasma half-life.  These results were attributed to recognition of folate, 
present on PEG chains (PEG3350) longer than those incorporated for steric stabilization 
(PEG2000), by the RES and subsequent acceleration of clearance from the bloodstream.  
Having successfully replicated results from previous work, we then conducted additional 
experiments to explore the effects of accelerated clearance from the bloodstream on the 
biodistribution and ultimate therapeutic efficacy of DXR encapsulated within FR-targeted 
liposomal nanocarriers.  
For these studies, an orthotopic glioma tumor model was developed in rats to 
assess FR-targeted liposomal DXR performance in vivo.  The majority of studies on FR-
targeted liposomes to date have utilized either subcutaneous [10, 13, 16, 17] or 
intraperitoneal [10, 18-21] tumor models for in vivo analysis.  These studies typically 
utilize cell lines, such as the human oral carcinoma KB cell line, which vastly 
overexpress the folate receptor compared to normal tissue [6].  We were interested in 
evaluating the ability to target and treat tumors which exhibit relatively moderate 
overexpression of the folate receptor compared to KB cells since this provides a better 
representation of the difficult to treat tumors presented in the clinic.  Therefore, a glioma 
cell line was selected for intracranial tumor inoculation.  An intracranial model was 
chosen for these experiments to more accurately represent the environment in which 
gliomas naturally occur.  The presence of the BBB is a major component of this 
environment and orthotopic inoculation of tumor ensured that the BBB remained a factor 
in our experimental studies.   
The 9L glioma tumor model was characterized by evaluating growth and 
angiogenesis.  Inoculated tumors proved to be aggressive demonstrating exponential 
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 growth with a doubling time of only 1.7 days.  Interventional euthanasia was required for 
all untreated animals on or before 22 days due to the onset of severe debilitating 
symptoms resulting from tumor growth and increased intracranial pressure.  There were 
no signs of metastasis in any of the euthanized animals confirming that symptoms 
resulted solely from rapid progression of the primary tumor.  Tumors were infiltrative 
and reproducible, therefore, this model was deemed appropriate for further studies.  
Angiogenesis of the tumor model was evaluated through histological examination.  The 
onset of angiogenesis was detected as early as 4 days following tumor inoculation.  These 
results helped to determine the proper time of treatment for survival studies evaluating 
therapeutic efficacy since established vasculature is mandatory for tumor delivery of 
treatments administered i.v.   
Studies were conducted on tumor-bearing animals to evaluate biodistribution of 
Stealth and FR-targeted liposomal DXR 20 and 50 hours after treatment administration.  
At both time points, the majority of DXR was located within the spleen and liver, the 
organs responsible for RES clearance.  There was no significant difference between the 
biodistribution of the two liposomal formulations with the exception of amount of drug 
detected within the liver.  Liver accumulation of FR-targeted liposomes was significantly 
greater than that of Stealth liposomes, accounting for the dramatic difference in 
circulating levels of DXR in the bloodstream between the formulations at each time 
point.  Tumor drug levels were not significantly different despite the vast disparity in 
bloodstream concentration of drug between the Stealth and FR-targeted nanocarriers, 
which may indicate that FR-targeted liposomes are retained within the tumor to a greater 
extent due to receptor binding and uptake.         
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 Survival studies investigating the therapeutic efficacy of each formulation were 
conducted on tumor-bearing animals receiving a single i.v. injection of liposomal DXR.  
Survival was prolonged for all animals receiving treatments compared to saline treated 
controls; however, there was no significant difference between the survival of animals 
treated with either Stealth or FR-targeted liposomal DXR.  This may simply be due to the 
aggressive nature of the tumor, where a single treatment is incapable of elucidating a 
detectable response in survival, however, the biodistribution results which demonstrated 
no difference in uptake by tumor between the 2 formulations, suggest that there are 
additional barriers in vivo preventing an increase in therapeutic efficacy of targeted 
formulations.  While diffusion limitations within solid tumors are certainly considered to 
be partially responsible, reductions in circulating levels of drug decreasing passive 
targeting to tumor may also play a role in the inability to realize a survival advantage 
using actively targeted formulations.  In fact, the only studies that have demonstrated 
prolonged survival using FR-targeted liposomes have involved i.p. administration of 
treatments to i.p. tumors thus bypassing the bloodstream and RES elimination [18, 22] or 
i.p. injection of treatments to athymic animals bearing s.c. tumors where the 
compromised immune system failed to accelerate clearance of targeted formulations [13].  
Another study demonstrated tumor growth reduction in tumors treated with FR-targeted 
liposomal DXR, however this study involved the administration of treatment ex vivo and 
subsequent implantation of treated cells thereby avoiding treatment exposure to the RES 
[3].  In addition, enhancement in tumor uptake of FR-targeted liposomes has only been 
demonstrated in i.p. tumor-bearing animals receiving the treatments i.p. [19-21].  As 
reported here, others have also shown that i.v. injection of FR-targeted treatments fails to 
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 result in an increase in tumor uptake [16, 17], however discussion regarding reductions in 
circulating drug and the impact this may have on delivery to tumor have been absent 
from the literature. 
The conclusions of this study have served to verify that the negative impact in 
targeting ligand insertion into Stealth liposomes, namely the recognition of nanocarriers 
by the RES and subsequent acceleration in plasma clearance, has a detrimental effect on 
tumor targeting.  Lower circulating levels of drug effectively reduce passive targeting to 
tumor thereby offsetting the benefits of active targeting.  This information should aid 
investigators in the design of future formulations where careful consideration regarding 
the effects of targeting agent insertion on circulation times should be made.  A 
compromise in passive targeting to tumor will likely be required unless an alternative 
solution such as transient masking of targeting agents from the RES is utilized. 
7.4.  MASKING AND TRIGGERED UNMASKING OF TARGETING LIGANDS ON NANOCARRIERS 
IMPROVES DRUG DELIVERY TO BRAIN TUMORS 
In an attempt to address the issue of accelerated clearance and reduction in 
passive tumor accumulation of targeted liposomes, we developed a controllable 
liposomal system by which exposure of folate may be modulated using detachable PEG 
chains.  Cysteine cleavable phospholipid-PEG5000 conjugates were formulated and 
characterized, the ability to mask folate with these conjugates was tested through in vivo 
circulation studies, controllable modulation of folate exposure on liposomes was tested 
and verified in vitro, and in vivo intracellular uptake of liposomal formulations was 
examined through flow cytometric analysis of explanted tumors. 
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 Following established methods, a cysteine cleavable DSPE-PEG5000 conjugate 
was formulated using SPDP, containing a reducible disulfide bridge, to crosslink DSPE 
and PEG5000-SH.  Mass spectroscopy, TLC, and 1H-NMR verified successful formation 
of the conjugate, and in vitro cleavage studies confirmed the ability to efficiently cleave 
the conjugate with as little as a 10-fold molar excess of cysteine. 
Blood circulation studies were performed on rats receiving FR-targeted liposomes 
with increasing concentrations of DSPE-S-S-PEG5000 to determine the minimum amount 
of cleavable conjugate necessary to adequately mask folate from the RES and enable 
prolonged circulation comparable to that achieved with Stealth liposomal nanocarriers.  
From this study, it was concluded that 8% DSPE-S-S-PEG5000 was sufficient to mask 
DSPE-PEG2000-folate from the RES while in circulation.  This formulation exhibited a 
3.8-fold increase in plasma half-life and a 65.5% increase in AUC compared to 
traditional FR-targeted liposomes containing 0.15% DSPE-PEG3350-folate and 3% 
DSPE-PEG2000.  The inclusion of detachable PEG5000 increased the half-life of FR-
targeted liposomes to 27.4 hours which was comparable to the half-life of non-targeted 
Stealth liposomes, 30.3 hours.  For the first 25 hours in circulation, concentrations of 
cleavable FR-targeted liposomes in the bloodstream actually surpassed the circulating 
levels of Stealth liposomes, however, the clearance of cleavable FR-targeted liposomes 
slowly increased over time presumably due to gradual cleavage and removal of PEG5000 
by endogenous cysteine.  Subsequent exposure of folate would likely trigger opsonization 
and clearance of the liposomes by the RES accounting for this reduction in circulating 
levels.  Fortunately, the AUC calculated between 0 and 25 hours was comparable 
between the cleavable FRT and Stealth liposomes indicating that passive accumulation to 
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 tumor should remain unaffected until much later when circulating cleavable FRT 
liposomes begin to clear at a faster rate, however, by that time the benefits of active 
targeting from triggered PEG removal and exposure of folate should surpass any gains 
from elevated circulating levels of drug.   
In vitro studies on cultured 9L glioma cells were conducted to verify the ability to 
modulate folate exposure using detachable PEG chains enabling control over uptake and 
cytotoxicity of FR-targeted liposomal DXR.  Confocal uptake images verified substantial 
uptake of conventional FR-targeted liposomes (0% DSPE-PEG) irrespective of cysteine 
pre-treatment.  Cells did not take up non-targeted Stealth liposomes or FR-targeted 
liposomes masked with non-cleavable DSPE-PEG5000 under either condition.  Cleavable 
FR-targeted formulations, however, demonstrated a distinct dependence on cysteine pre-
treatment.  In the absence of cysteine treatment, uptake of the liposomes was negligible, 
whereas after the application of cysteine, uptake by cells was substantially increased and 
resulted in nuclear localization of drug payloads.   
Cytotoxicity studies confirmed the in vitro uptake results.  DXR encapsulated 
within non-targeted liposomes and FR-targeted liposomes masked with non-cleavable 
DSPE-PEG5000 did not exhibit any cytotoxic potential.  Cytotoxicity of conventional FR-
targeted liposomal DXR was significantly increased.  Treatment with cysteine had no 
effect on the cytotoxicity, however, cell viability was significantly greater when excess 
folate was introduced indicating that uptake of the liposomal DXR was dependent on the 
availability of folate receptors.  Cytotoxicity of FR-targeted liposomal DXR formulated 
with detachable PEG chains demonstrated a significant dependence on cysteine pre-
treatment.  Only those formulations pre-treated with cysteine to remove PEG and expose 
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 folate demonstrated cytotoxicity to FR-expressing 9L glioma cells.  In the absence of 
cysteine pre-treatment, the LC50 of cleavable PEG FR-targeted liposomal DXR could not 
be determined since cytotoxicity was not observed at any of the tested concentrations up 
to 60 µM DXR. Cysteine pre-treatment, however, lowered the LC50 to 9.22 µM which 
approached the LC50 value of 4.17 µM obtained with conventional FR-targeted liposomal 
DXR.  The addition of excess folate significantly decreased the cytotoxic potential of 
cysteine treated FR-targeted liposomal DXR with cleavable PEG indicating that uptake 
occurred via the folate receptor.  These in vitro experiments verified the ability to 
modulate uptake and cytotoxicity of FR-targeted liposomal DXR using detachable PEG 
chains.   Cleaved formulations successfully regained the ability to bind and enter target 
cells with cytotoxicity approaching values attained with conventional FR-targeted 
liposomes, and uptake was shown to remain dependent on the folate receptor.    
To assess intracellular delivery in vivo, liposomal formulations were administered 
i.v. to tumor-bearing animals.  Treated animals then received either a saline or cysteine 
i.v. infusion.  Explanted tumors were dissociated and analyzed for liposomal content.  
This procedure enabled specific analysis of intracellular uptake in contrast to the previous 
study which simply measured bulk tumor uptake of liposomes.  Flow cytometry was 
utilized to distinguish between disaggregated tumor cells and host cells.  Animals treated 
with cleavable PEG FR-targeted liposomes followed by a cysteine infusion demonstrated 
a significant increase in uptake of liposomes by tumor cells and a significantly greater 
ratio of uptake between tumor and host cells compared to those animals treated with 
either Stealth liposomes or cleavable PEG FR-targeted liposomes followed by a saline 
infusion or Stealth liposomes followed by a cysteine infusion.  In addition, the percentage 
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 of tumor cells positive for liposome uptake was significantly greater in tumors explanted 
from animals treated with cleavable PEG FR-targeted liposomes and a cysteine infusion 
compared to the other treatment groups.  These results indicate that the removal of PEG 
and subsequent exposure of folate through an i.v. infusion of cysteine was sufficient to 
promote specific binding and internalization of liposomes by target cells within an 
intracranial tumor site.  This increase in uptake was dependent on cysteine removal of 
PEG chains since uptake was not increased in animals treated with cleavable PEG FR-
targeted formulations and a saline infusion.  Selectivity of cysteine-cleaved FR-targeted 
formulations was proven through the significant increase in uptake by tumor cells 
compared to host cells.   
 These studies verified the ability to ‘unmask’ folate on FR-targeted liposomes in a 
controlled manner in vivo to promote specific uptake by FR-expressing tumor cells.  This 
experiment was able to distinguish intracellular and extracellular liposomes and also 
differentiate uptake by tumor and host cells.  In this manner, it was determined that 
cysteine cleavage of PEG on FR-targeted formulations relays a distinct advantage for 
specific targeting to tumor cells since FR-targeted liposome treated animals receiving a 
cysteine infusion demonstrated a significantly higher uptake of liposomes per tumor cell 
as well as a significantly greater percentage of tumor cells internalizing liposomes.  In 
addition, uptake was proven to be controllable since it was dependent on exogenous 
administration of cysteine.  
Another potential benefit of PEG detachment from the liposomal surface is 
further diffusion of liposomes into the tumor and away from the perivascular space.  
Studies have shown that the presence of PEG inhibits diffusion within tumor [23, 24], 
180 
 and neutrally charged liposomes lacking a PEG coating have been shown to diffuse more 
deeply into spheroid structures [25].  Since surface modification is a requirement for 
prolonged circulation in vivo, PEG is invariably present upon long-circulating liposomes 
even after extravasation to tumor.  The cleavable PEG nanocarrier system presented here 
allows for controlled removal of PEG after extravasation to promote further diffusion 
within tumor and increased uptake by tumor cells. 
These studies have proven that the use of cleavable PEG on actively targeted 
liposomal nanocarriers is a viable solution to the negative impact of targeting agent 
insertion into liposomes.  With the knowledge that passive accumulation is critically 
dependent on circulation times [26], it is imperative that prolonged circulation of 
nanocarriers is uncompromised upon inclusion of targeting moieties.  Here, we have 
shown that cleavable phospholipid-PEG conjugates can be used to enable precise control 
over ligand exposure, effectively concealing ligands to prolong liposomal circulation 
times and exposing targeting moieties at the desired time point after extravasation to 
tumor to promote specific uptake by tumor cells.   
7.5.  CONCLUSIONS 
The studies presented here have provided further insight into the effects of 
targeting agent inclusion within passively targeted liposomal nanocarriers and 
demonstrated a potential solution to address the associated negative impact on circulation 
time in the bloodstream.  Inability to achieve enhanced delivery to tumor and prolonged 
survival times in vivo using actively targeted liposomal chemotherapeutics was shown to 
be due, in part, to the reductions in circulation time resulting from the use of targeting 
agents in liposomal formulations.  To address this issue, we successfully formulated a 
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 nanocarrier system which allows for precisely controlled exposure of targeting agents on 
the liposomal surface.  This liposomal system utilizing cysteine-cleavable phospholipid-
PEG conjugates was shown to restore prolonged circulation of FR-targeted liposomes by 
masking folate targeting ligands from the RES.  Modulation of uptake and cytotoxicity of 
these formulations through controlled removal of PEG was demonstrated and verified 
that liposomally encapsulated DXR reaches the cell nuclei in a functional active form.  In 
addition, enhancement of specific targeting to tumor cells was demonstrated in vivo.  
These findings should allow for increased efficacy of actively targeted nanocarrier 
chemotherapeutics in vivo. 
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 CHAPTER 8.  FUTURE PERSPECTIVES 
An actively targeted liposomal chemotherapeutic has yet to make it into the clinic 
despite promising in vitro results demonstrating the potential for increased cytotoxicity 
due to specific uptake by tumor cells.  In vivo studies have typically failed to exhibit 
enhanced efficacy with actively targeted liposomal chemotherapeutics because the 
inclusion of targeting agents results in accelerated clearance from the bloodstream and 
reductions in passive targeting to tumor.  The work reported in this dissertation has 
focused on the use of targeted nanocarriers engineered to allow controlled presentation of 
targeting agents.   Cleavable phospholipid-PEG conjugates were utilized to mask 
targeting ligands on nanocarriers and maintain RES evasion in an attempt to reestablish 
enhanced passive accumulation within tumors.  Unmasking of targeting agents was 
triggered by exogenous cysteine administration to promote specific uptake by tumor cells 
after the nanocarriers had passively extravasated to the target site.  This chapter is 
devoted to the discussion of additional aspects which may be investigated to further 
optimize this multifunctional liposomal system. 
8.1.  BIODISTRIBUTION STUDIES 
While the studies presented here included the examination and differentiation of 
uptake by tumor cells and host cells at the tumor site, additional studies need to be 
performed to evaluate whole organ distribution of drug.  These studies would determine 
whether the inclusion and subsequent removal of cleavable PEG chains in FR-targeted 
liposomes alters the biodistribution of drug.  It would be interesting to follow the 
progression of liver and spleen uptake to verify that it accounts for the slow acceleration 
in clearance of masked formulations over time.  In addition, levels of uptake by the liver 
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 of targeted liposomes formulated with detachable PEG at early time points (<25 hours) 
may be compared to the liver uptake of Stealth liposomal DXR to determine whether the 
inclusion of cleavable PEG chains reduces the significant difference in liver uptake 
previously observed between Stealth and traditional FR-targeted liposomes.  Bulk tumor 
uptake measurements would determine total intracellular and extracellular liposomal 
DXR delivered to the tumor.   
8.2.  SPATIAL DISTRIBUTION WITHIN TUMOR 
Histological examination of tumors explanted from animals treated with 
liposomal formulations could be performed to reveal the spatial distribution of drug 
within the tumor.  Vascular staining would serve to identify the perivascular regions to 
determine whether the treatments colocalize within this space.  Fluorescent microscopy 
following the administration of an encapsulated or membrane-inserted fluorophore may 
be utilized to determine spatial distribution of liposomes.  Alternatively, 
microdistribution within tumor tissue could be visualized using light microscopic 
examination of tissue sections obtained from animals treated with gold-loaded liposomes 
to compare tumor penetration and cellular localization. 
Ideally, uniform distribution of drug would ensure treatment delivery to the entire 
tumor; however, this is unlikely to occur for a number of reasons.  First, modifications 
introduced to achieve long-circulation, such as PEGylation, have been shown to inhibit 
diffusion within tumors and tumor spheroids [1-3].  Therefore, the diffusion of treatments 
within tumor prior to the removal of PEG from FR-targeted formulations may be limited; 
however, subsequent PEG detachment should facilitate transport within tumor.  Another 
reason to expect heterogeneous distribution of liposomes within tumor is due to the 
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 “binding site barrier”.  This refers to the condition where targeted agents bind to the first 
line of target cells after extravasation, are sequestered to the perivascular space, and 
consequently obstruct the extravasation of additional drug [4].  This phenomenon has 
been observed with antibodies targeted for cancer therapy where it was shown that the 
larger the antibody and higher its binding affinity, the lower its therapeutic efficacy [5].  
Fortunately, prior to cysteine administration, concealed folate should not participate in a 
binding site barrier; therefore, these formulations may diffuse further than other actively 
targeted liposomes.  Successive ‘unmasking’ of folate upon detachment of PEG, 
however, may serve to inhibit further transport within tumor.  This effect may counteract 
the enhanced diffusion benefit of PEG removal; however studies investigating spatial 
distribution within tumor are warranted to determine the overall effects of PEG removal 
at the tumor site.  Another major obstacle to uniform drug distribution of targeted agents 
within tumor is the fact that the interstitial fluid pressure is higher in the tumor center 
compared to the periphery and surrounding tissue [6-8].  This pressure differential along 
with heterogeneity in blood supply leads to lower fluid extravasation in the tumor core 
reducing drug delivery to this region.  In addition, this condition makes it difficult for 
macromolecules delivered to the periphery to diffuse into tumor since they have to 
overcome the outward convection of fluid from regions of high to low pressure [9].  
Spatial distribution studies would help to identify diffusion limitations within tumor.  
Possible methods to overcome transport barriers, should they have a major impact on 




 8.3.  IN VIVO CYTOTOXICITY 
Having investigated uptake by both tumor and host cells at the tumor site, 
additional studies should be performed to evaluate treatment cytotoxicity in vivo.  Ideally, 
cell populations would be differentiated either through histological staining or flow 
cytometry to distinguish cytotoxic effects among the different populations of cells at the 
tumor site.  It would be interesting to compare the cytotoxic effects after varying the time 
point of cysteine administration.  In this manner, the optimal time point for cysteine 
infusion following treatment administration could be determined.   
8.4.  TUMOR MODEL SELECTION 
The studies presented here investigated drug delivery to an intracranial glioma model.  It 
would be useful to determine the effectiveness of delivery utilizing this system with 
different tumor types and sites of implantation.   
8.4.1.  TUMOR TYPE 
With the ultimate goal of clinical application of this liposomal system, studies 
investigating its potential use to treat alternate tumor types would be beneficial.  The 
choice of targeting agent must be considered for different tumor types since expression 
profiles may differ between tumors.  This success of this system will be dependent on the 
type of tumor to be treated.  For example, treatment of tumors known to exhibit highly 
permeable vasculature should demonstrate greater success over tumors with vessels that 
are less “leaky” because it is the vascular permeability, in large part, which determines 
the extent of extravasation.  In addition, tumors expressing targets which facilitate 
transport of intact drug into the cell would be ideal for this delivery system.  Tumor types 
should be selected which display expression levels of target that are much higher than 
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 that of surrounding non-target cells.  Additional studies with this liposomal delivery 
system will warrant the use of human cell lines inoculated into nude animals to verify its 
clinical applicability for the future treatment of human tumors.  The studies reported here 
did not investigate delivery to human tumor xenografts because RES clearance of 
administered treatments was a major component of this experiment, and the lack of a 
competent immune system in the nude animals required for human tumor models would 
have compromised the experimental findings. 
8.4.2.  SITE OF IMPLANTATION 
The site of implantation, particularly for glioma models, should be carefully 
considered.  A human glioma, for example, has been shown to display high vascular 
permeability when grown subcutaneously in immuno-deficient mice, however, when 
grown in a cranial window, the same tumor demonstrated BBB characteristics [9].  
Therefore, orthotopic implantation provides the closest representation of the tumor 
microenvironment for glioma models.  Subcutaneous implantation may be appropriate for 
other tumor types, such as breast tumors.  Subcutaneous tumors are advantageous since 
they offer ease of measurement with a caliper and allow monitoring of growth 
progression in a live animal.  Alternatively, an intraperitoneal tumor model may be 
utilized to eliminate negative effects on delivery due to diffusional limitations.  An i.p. 
tumor model is not the best representation for brain tumors, especially due to the lack of 
the BBB; however, it could be utilized for the sole purpose of removing the reductions in 
tumor delivery due to diffusional limitations to gain a better understanding of this 
cleavable PEG liposomal system under optimal conditions. 
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 8.5.  IN VIVO THERAPEUTIC EFFICACY 
To analyze in vivo therapeutic efficacy, the ability to prolong survival or reduce 
tumor growth through the use of ‘masked’ FR-targeted liposomal DXR should be tested 
in vivo.  In these studies, treatments would be administered to tumor-bearing animals, and 
after sufficient drug is expected to accumulate at the tumor site, cysteine would be 
injected to cleave PEG chains from FR-targeted, cysteine-cleavable PEG nanocarriers 
and promote uptake by tumor cells.   
8.5.1.  TREATMENT REGIMEN 
Most studies investigating targeted chemotherapeutics have not demonstrated a 
positive impact on therapeutic efficacy unless an aggressive treatment regimen involving 
multiple administrations of treatment is followed.  For studies utilizing targeted 
liposomes with cleavable PEG, a single i.v. injection of treatment may be attempted 
initially to determine whether the advantages of this system are enough to convey a 
distinct improvement in efficacy resulting in either prolonged survival times or 
reductions in tumor growth.  If necessary, multiple treatments may be administered in an 
attempt to further distinguish survival advantages. 
The administration of cysteine should be performed via i.v. infusion.  While the 
length of infusion and amount of cysteine to be delivered for the studies presented here 
were determined through in vitro cleavage experiments, alternate durations of infusion 
and/or amounts of cysteine may be investigated for in vivo use since the cleavage 
experiments simply provide an approximation of the optimal cysteine dosage.  In 
addition, the time point of cysteine administration needs to be further investigated.  This 
may be done through in vivo cytotoxicity studies, biodistribution studies, or directly 
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 through survival studies.  In vivo cytotoxicity studies would identify the optimal time 
point for cysteine administration by determining the time point which results in the 
highest cytotoxicity toward tumor cells.  The optimal time point for cysteine infusion, 
presumably, would be at the time when passive delivery of liposomes to tumor occurs.  
Passive tumor accumulation may be measured through biodistribution studies at various 
time points.  The time at which maximum passive delivery to tumor occurs could then be 
determined and used as the time point for the administration of cysteine.  
It is acknowledged that the injection of cysteine will result in a reduction in 
circulating levels of targeted liposomes compared to non-targeted due to the exposure of 
the targeting agent and RES clearance.  To diminish the effects of this consequence, a 
booster dose of Stealth liposomal DXR equivalent to the amount of drug lost due to rapid 
cysteine triggered PEG detachment could be administered after cysteine administration in 
animals receiving FR-targeted liposomes.  
8.5.2.  OUTCOME MEASURES 
Therapeutic efficacy could be analyzed through evaluation of survival time 
following treatment administration or through determination of tumor size at a 
predetermined time point following treatment administration.  Evaluation of tumor size 
using an intracranial tumor model is not a straight-forward process; therefore, survival 
times are typically utilized for determination of therapeutic efficacy.  The drawback to 
this method is that reductions in tumor volume due to treatment may not be realized if the 
tumor is aggressive and growth recovers rapidly resulting in no significant change in 
survival times.  Using survival as the sole measure of treatment efficacy, therefore, may 
not be the best method to evaluate treatment efficacy.  
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 Tumor size may be estimated through histological means, medical imaging, 
changes in body weight, or caliper measurements.  With the exception of histological 
analysis, all of these approaches allow for tumor progression to be monitored over time 
after treatment administration.  The site of tumor implantation limits the choice of size 
estimation method since some of these techniques are unsuitable for certain tumors. 
8.6.  ADDRESSING EXTRAVASATION AND DIFFUSION LIMITATIONS 
Since it is acknowledged that extravasation and diffusion limitations also play a 
part in the in vivo failure of actively targeted formulations, the ideal targeted drug 
delivery system would include the multifunctional liposomal system presented here to 
prolong circulation times combined with methods to address extravasation and/or 
diffusion limitations.  As discussed in an earlier section, “leaky” tumors may be ideal 
candidates for this drug delivery system due to reductions in extravasation limitations.  
Alternative approaches to increase delivery to tumors which may not possess highly 
permeable blood vessels are presented here in addition to strategies to increase diffusion 
of treatments within tumor. 
8.6.1.  METHODS TO INCREASE EXTRAVASATION TO TUMOR 
Numerous techniques have been studied in an attempt to increase extravasation of 
nanocarriers into tumors.  The use of localized hypothermia, either by direct heating [10] 
or by the application of radio-frequency [11], has been shown to enhance extravasation 
and localization of liposomes to tumors.  Others have demonstrated that targeting to 
vascular receptors which undergo transcytosis, such as the transferrin receptor, increases 
delivery to tumors [12, 13].  Altering the vascular endothelial pore sizes through the use 
of agents such as mannitol [14], vascular endothelial growth factor [15], or tumor 
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 necrosis factor α [16] has been shown to promote extravasation to tumor.  Unfortunately, 
some of these agents may also affect the permeability of blood vessels within non-target 
tissue.  Another approach to improve delivery to tumors involves “normalization” of the 
tumor vasculature with antiangiogenic agents prior to treatment administration.  Tumor 
blood vessels are structurally abnormal with a haphazard pattern of connections and 
tortuous paths often terminating in ‘dead-ends’.  The basement membrane lining these 
vessels may be either unusually thick or entirely absent [17, 18].  Hyperpermeability 
leads to lack of pressure gradients and impairs the flow of fluids leading to the 
heterogeneous delivery of drug to tumors.  Normalizing the vasculature by pruning 
excess endothelial cells with judicious administration of antiangiogenic agents would 
alleviate some of these issues leading to more efficient delivery of drugs to tumor cells 
[19, 20].  Finally, extravasation to tumor has been shown to be size dependent [21, 22], 
therefore, future studies may investigate alterations in liposome size for this cleavable 
PEG system to optimize extravasation to tumor.     
8.6.2.  INCREASING DIFFUSION OF TARGETED AGENTS AFTER EXTRAVASATION 
Since diffusional barriers within tumors prohibit uniform drug delivery, numerous 
methods have been studied to overcome these limitations.  If the binding site barrier 
proves to be a major obstacle to diffusion beyond the perivascular space after PEG 
removal, studies may be conducted to establish the minimum number of targeting ligands 
required to enable specific binding and uptake by tumor cells.  Liposomal formulations 
utilizing this number of targeting ligands may then be investigated to reduce the binding 
site barrier effects.  Another means of promoting further diffusion within tumor is to 
utilize liposomes which may be destabilized.  Temperature-triggered destabilization has 
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 been shown to lead to rapid release of free drug from within nanocarriers [23, 24].  Free 
drug should not suffer from diffusion limitations due to its small size and will be able to 
penetrate more deeply into the tumor resulting in a more uniform intratumoral 
distribution.  
8.7.  ALTERNATIVE TARGETING AGENTS 
As discussed in Chapter 3, many different tumor targeting agents have been 
reported in the literature.  It would be worthwhile to investigate the use of alternative 
targeting ligands with this liposomal system.  In addition, this system may allow for or be 
modified to allow for the use of antibodies which tend to demonstrate higher binding 
affinities for tumor targets.  Antibodies presented on nanocarriers usually elicit immune 
responses resulting in accelerated clearance making them impractical for in vivo 
applications, however, masking with cleavable PEG may finally allow for their use in 
targeted formulations.  Due to the large size of antibodies compared to the folate 
targeting ligand utilized here, longer PEG chains may be necessary to adequately mask 
the antibodies from the RES.  To determine the optimal length, additional studies would 
need to be performed examining variation in PEG chain length and the resultant effects 
on circulation times.  Selection of specific agents for future studies would ultimately be 
dependent on the type of tumor to be treated. 
8.8.  CONTRAST AGENT DELIVERY 
The nanoscale delivery system presented here was designed for the delivery of 
chemotherapeutic agents.  Another promising application of this system would involve 
the encapsulation and delivery of contrast agents for medical imaging of tumors.  By 
targeting contrast agents to tumors, improvements in imaging would be achieved 
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 allowing for earlier detection of tumors.  In addition, images obtained before and after 
triggered removal of PEG could be compared to gain information on tumor vasculature, 
which tends to be difficult to resolve using traditional imaging techniques.  Images 
obtained prior to PEG cleavage would display contrast from both the tumor and the tumor 
vasculature while images subsequent to cysteine administration would simply display 
contrast at the tumor site since the unmasking of targeting agents results in clearance of 
liposomes from the bloodstream.  Image subtraction may then be performed to yield a 
clear picture of the tumor vasculature.  
8.9.  CONCLUSIONS 
While much progress has been made using the cleavable phospholipid-PEG 
conjugates presented here to successfully mask and unmask targeting agents on 
nanocarriers, additional studies must be performed before the multifunctional system is 
truly optimized for in vivo therapeutic use.  This chapter has presented some of the 
experiments which should yield a more thorough understanding of this system as well as 
some additional applications which may prove to be useful in the future. 
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The following text, figures, and tables comprise a manuscript submitted to 
Radiology related to the passive targeting of contrast agents to tumors using liposomes 
where the degree of extravasation is shown to be an accurate predictor of 
chemotherapeutic efficacy.  The manuscript is included for reference purposes in regards 
to the dissertational work provided in the main text. 
 
Advances in Knowledge:  
1. Imaging studies of a rat breast tumor model using a clinical digital 
mammography system identified a dose of a long-circulating 100nm-scale liposomal 
probe containing a high concentration of iodinated contrast agent (155 mg/mL) that 
produced undetectable signal from the blood while the accumulation of the agent in the 
tumor produced adequate signal for detection.  
2. Imaging of the extravascular, intratumoral accumulation of the nanoprobe 
allowed detection and quantification of the tumor vascular permeability which varied 
between animals. 
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 3. The imaging measurements of the tumor vascular permeability to the 
nanoprobe allowed prediction of the effect of a subsequent treatment with liposomal 
doxorubicin of similar composition and particle size as the nanoprobe. 
Implications for Patient Care:  
An a priori determination of the extent of tumor vascular permeability to 
nanoparticle-based therapy can facilitate personalized therapy, and spare potential non-
responders from the rigors of a chemotherapy regimen. 
A.1.  ABSTRACT 
Purpose: To prospectively predict the efficacy of a clinically used 
nanochemotherapeutic by detecting and measuring the intratumoral uptake of an X-ray 
contrast nanoprobe using digital mammography.  
Materials and Methods: All animal procedures were approved by the 
Institutional Animal Care and Use Committee. A long-circulating 100nm-scale injectable 
liposomal probe was developed encapsulating 155 mg/mL iodine. Preliminary studies 
were performed to identify the agent dose that would result in adequate tumor 
enhancement without enhancement of the normal vasculature in rats. This dose was used 
to image a rat breast tumor (n=14) over a period of three days using a digital 
mammography system, and subsequently the animals were treated with liposomal 
doxorubicin. The predictive capability of the probe was characterized by creating ‘good’ 
and ‘bad’ prognosis subgroups, based on the tumor enhancement found during imaging 
and analyzing the tumor growth after treatment of the animals in these two subgroups.  
Results: A dose of 455 mg I/kg body weight was found to produce an 
undetectable signal from the blood while achieving enough intratumoral accumulation of 
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 the probe so as to produce adequate signal for detection. The ‘good prognosis’ and ‘bad 
prognosis’ subgroups demonstrated differential tumor growth rates (p<0.003). An inverse 
linear relationship between the contrast enhancement rate constant during imaging and 
the tumor growth rate constant during treatment was found (slope=-0.576, R2=0.838).  
Conclusions: In this animal model, quantitative measure of vascular permeability 
enabled prediction of therapeutic responsiveness of tumors to liposomal doxorubicin 
treatment. 
A.2.  INTRODUCTION 
Nanoscale therapeutic interventions are increasingly important elements of cancer 
therapy [1, 2]. Nanoparticles [3, 4] can be effective delivery vehicles for toxic 
chemotherapeutic drugs, increasing delivery efficiency to the targeted tumor while 
reducing off-target delivery [5]. Liposomal anthracyclines were the first nanotherapeutics 
to be approved for clinical use as the first line for treatment of AIDS-related Kaposi’s 
Sarcoma and relapsed ovarian cancer [6] and are under numerous clinical trials (128 
active studies) for treatment of many types of cancer, especially breast cancer which 
accounts for 41 active clinical trials [7].  
In addition to the cytotoxic effect of the drug at the molecular level, the success of 
systemically delivered nanotherapeutics for solid tumors is critically dependent on the 
access that these agents have to tumors via the so-called leaky vasculature of the tumor 
microvasculature network. This network consists of an immature blood microvessel 
system with hypervascularization, abnormal vascular architecture, increased leakage 
through the vessel wall and lack of lymphatic drainage [8, 9]. Nanoparticles preferentially 
accumulate in solid tumors by passive convective transport through leaky endothelium 
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 (extravasation) that is due to pores varying from ~100 to 800 nm in size [10-12]. The 
phenomenon is termed the Enhanced Permeation and Retention (EPR) effect. To date 
however, to our knowledge, there exist no clinical tools to determine whether tumor 
blood vessels are permeable to nanoparticles in this fashion. For instance, the current 
clinical protocols for liposomal doxorubicin consist of a standard dose every 3-4 weeks 
[13]. No prior knowledge of tumor vessel status, especially leakiness, is taken into 
account for the dose scheduling. However, it is well-known that the degree of tumor 
vasculature leakiness differs not only among same type tumors but even spatially within 
the same tumor [14-16]. 
Our purpose was to prospectively predict the efficacy of a clinically used 
nanochemotherapeutic by detecting and measuring the intratumoral uptake of an X-ray 
contrast nanoprobe using digital mammography.  
A.3.  MATERIALS AND METHODS 
A.3.1.  FABRICATION OF THE NANOSCALE X-RAY PROBE  
A highly concentrated iodine solution (650 mg I/mL) was prepared by dissolving 
iodixanol powder (lyophilized from Visipaque 320; GE Healthcare, Milwaukee, WI) in 
ultrapure water under stirring and heating at 70°C. The rest of the procedures were 
similar to those described previously [17] (E.K., with 7 years of experience in 
nanoparticle fabrication). The liposomal probe contained 72 mg/ml lipids and 155 mg/mL 
iodine and 100% of the iodine was encapsulated within the liposomes. The average 
diameter of the liposomes was 96 nm (SD=8), a size known to prevent renal clearance. 
An in vitro leakage experiment against isotonic phosphate buffered saline exhibited very 
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 low leakage of the encapsulated iodine (less than 5% of the initial payload) over a period 
of 3 days.  
A.3.2.  ANIMAL MODEL 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee. Our study took place from February 15, 2007 to December 10, 2007. A 0.2 
mL aliquot containing 106 cancer cells (13762 MAT B III cell line (American Type 
Culture Collection, Manassas, VA), a mammary adenocarcinoma) was subcutaneously 
injected into the right flank of 53 8-9 weeks old female Fisher rats (Harlan, Indianapolis, 
IN). Caliper measurements were used to estimate tumor size and the tumor volume was 
calculated as: Vtumor=(d12 x d2)/2, where d1 and d2  are the minimum and maximum 
diameters (E.K., with 6 years of experience in animal handling and procedures). 
A.3.3.  X-RAY IMAGING  
Imaging was performed using a clinical digital mammography system 
(Senographe 2000D, GE Healthcare, Milwaukee, WI) (S.S. and I.S., with 10 and 6 years 
experience in medical physics, respectively). To maximize the number of photons with 
energies above the K-edge of iodine (~33.2  keV) [18], imaging was performed at 49 kVp 
and 63 mAs, using a rhodium target and the available 25 µm thick rhodium filter with an 
added 0.254 mm thick copper filter [19]. The resultant x-ray spectrum was estimated 
using the XSPECT simulation program (Henry Ford Health Systems, Detroit, MI), which 
uses semi-empirical models [20].   
To estimate the radiation dose to the animals during imaging, a previously 
validated Monte Carlo simulation for dosimetry studies [21] was modified to include a 
simplified version of the animal geometry (I.S.). In the simulation, the animals were 
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 represented as a 10 cm long cylinder of water with a 4 cm diameter. To estimate the dose 
to the cylinder from the x-ray spectrum used in the imaging studies, the Monte Carlo 
simulation was performed repeatedly with monochromatic x-rays with energies from 20 
keV to 49 keV in 0.5 keV steps. To achieve the necessary statistical accuracy, one million 
photons per energy level were simulated. The monochromatic results were combined 
with the x-ray spectrum obtained with the XSPECT simulation program using the method 
described by Boone [22]. 
A.3.4.  PRELIMINARY DOSE STUDY 
Initially, pilot imaging sessions were performed to determine the appropriate dose 
of the probe that would result in appropriate tumor enhancement with no detectable 
enhancement of the vasculature. For this task, 16 animals were injected with the probe at 
doses resulting in iodine concentrations in the blood ranging from 6 to 20 mg/mL with 2 
mg/mL intermediate steps (2 animals per dose) and were subsequently imaged at t=0.5, 1, 
5, 10 min and 24, 72, 120 h. From the acquired images the dose threshold above which 
the vasculature was not highlighted was identified by visual inspection by two reviewers 
in consensus (E.K., S.S.). 
A.3.5.  EFFICACY PREDICTION STUDY 
At day 6 after tumor inoculation (tumor volume ~300 mm3), 14 animals were 
imaged before (t=0) and at defined time points (t=2 and 30 min, 24 and 72 h) after 
intravascular (IV) injection of the probe at the dose identified in the preliminary dose 
study. As a control for the imaging portion of the study, 6 animals that were also 
inoculated with the tumor but only injected with 0.5 mL of saline were imaged at the 
same time points. Immediately after the last imaging session (at day 9 after tumor 
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 inoculation), the animals were IV injected with liposomal doxorubicin at a dose of 10 
mg/kg doxorubicin. As a control for the treatment portion of the study, 15 animals that 
underwent the same tumor inoculation and probe injection at the same time points as the 
study group was not injected with liposomal doxorubicin. Liposomal doxorubicin was 
prepared following established methods [23]. The tumor growth of each animal was 
monitored every day using caliper measurements. The maximum tumor size that was 
allowed was 3 cm. When the tumor reached this size or the animals showed signs of pain, 
prostration, labored breathing, sunken eyes, any skin ulcers, emaciation or anorexia, the 
animals were euthanized using a CO2 chamber. Otherwise the animals were euthanized 
21 days after tumor inoculation. 
A.3.6.  IMAGE ANALYSIS 
The sequential image acquisitions provided the dynamics of the probe’s 
intratumoral accumulation over time. The grey levels were measured in raw data 
(DICOM format) using ImageJ software (NIH, Bethesda, MD). An ellipsoid region of 
interest (ROI) was used for the measurements surrounding the entire tumor lesion (E.K.) 
and the average value of the grey levels in the ROI was used as the tumor enhancement. 
Since mammography is not a tomographic modality, the observed tumor enhancement 
represents the summation of the absolute enhancement due to the contrast agent and the 
enhancement of overlying tissue structures. To normalize with respect to the overlying 
tissues, a relative enhancement was computed by subtracting the pre-contrast 
enhancement value (t=0) from the post-contrast enhancement value (t>0). Tumors that 
presented a relative enhancement lower than 50 digital units in the 24 h post-injection 
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 image were assigned to a ‘bad prognosis’ subgroup, while tumors with a relative 
enhancement of 50 digital units or above were assigned to a ‘good prognosis’ subgroup. 
As a control, the relative enhancement of a normal section of tissue was also 
measured in each image by selecting a ROI that included only soft tissue and completely 
excluded the tumor (E.K.). The relative enhancement of this ROI was computed using the 
same methodology as that described for the tumor’s relative enhancement. 
For enhanced visibility of the images for publication, the images in Figures A.2, 
A.3, and A.4 , were histogram matched and sharpened using unsharp masking. Both 
processes were performed using ImageJ. This processing was performed for display of 
the images only; the quantitative analysis was performed with the original, unprocessed 
images. 
A.3.7.  IMMUNOHISTOCHEMISTRY AND HISTOLOGICAL EVALUATION OF EXPLANTED 
TUMORS 
For histological examination, animals (n=2) were injected at day 6 with the probe 
(455 mg I/kg) tagged with rhodamine. At 48-h post-injection, the animals were 
euthanized and the tumors were explanted. To visualize the tumor microvasculature, the 
tissue slices were immunohistochemically stained for the specific endothelial antigen 
CD31 (BD Biosciences Pharmingen, San Diego, CA). The tissues were also stained with 
the nuclear stain DAPI. The staining procedures followed established methods [24]. The 
tumor sections were imaged at 10x on the Nikon Eclipse 80i upright microscope using a 
Microfire CCD camera (Optronics, Golate, CA) that interfaced with the Neurolucida 
software (MicroBrightField Bioscience, Williston, VT) to obtain a montage of each 
section. The histological analysis was performed to verify the presence of extravascular 
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 intratumoral accumulation of the probe and its location with respect to the tumor 
vasculature (E.K.).  
A.3.8.  DATA AND STATISTICAL ANALYSIS 
To determine the significance of the grey levels variation and tumor volumes 
among the various animal groups at different time points, one-way ANOVA with post-
hoc Bonferroni test was performed (SPSS 15, Chicago, IL). A p-value less than 0.05 was 
used to confirm significant differences at the 95% confidence level. The Anderson-
Darling test was performed to verify that the data follow a normal distribution. The tumor 
enhancement profiles and tumor growth curves were fitted into an exponential function 
[25] using nonlinear regression (Levenberg-Marquardt algorithm) to compute the 
enhancement rate constant (Kenhancement) and the tumor growth rate constant (Ktumor growth), 
respectively (Polymath 5.0, Willimantic, CT) . The area under the curve of the signal 
enhancement profiles was estimated using the Gauss-Legendre orthogonal polynomial 
approximation. The correlation between the signal enhancement and the tumor growth 
rate was determined using linear regression. Besides the Pearson’s correlation, the 
correctness of the model was evaluated by examining the residuals plots and other 
statistical tests (SPSS 15, Chicago, IL).    
A.4.  RESULTS 
A.4.1.  IMAGING USING A CLINICAL MAMMOGRAPHY SYSTEM  
Figure A.1 shows the modeled x-ray spectrum resulting from the tube voltage and 
filter settings and the addition of the copper filter. Under these operating conditions, the 
animal received an estimated radiation dose of 0.39 mGy per imaging session. In the pilot 
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Figure A.1. Estimation of the 49 kVp rhodium/rhodium x-ray spectrum with the added 0.254 mm 
copper filter, according to the XSPECT simulation program. 
 
imaging sessions where animals were injected with different doses of the probe, the 
threshold for visualization of blood vessels was ~12 mg I/mL in the blood (or a dose of 
800 mg I/kg b.w.). For instance, while no vessels were visible pre-injection, they became 
clearly visible in normal tissue and at the tumor one minute after injection of the probe at 
a dose of 1344 mg I/kg body weight (bw) producing a concentration of ~20 mg I/mL in 
blood (Figure A.2). To eliminate signal from the blood vessels and probe the 
extravasation into the tumor, the dose selected for contrast-enhanced imaging was 455 
mg I/kg bw, producing a concentration of ~7 mg I/mL in blood; a concentration below 
the threshold for detection of iodine in the blood. This allowed detection of the 
extravasated nanoprobes as early as 24 h post-injection, with no interference from the 
vascular signal (Figure A.3). In the post-injection images no blood vessels were visible in 
the normal tissue while enhancement of the spleen, liver and the tumor can be clearly 
seen. Spleen and liver enhancement is consistent with clearance of liposomes via the  
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Figure A.2. Whole body images of a rat with a breast tumor in its right flank obtained using a clinical 
digital mammography system (a) before and (b) 1 minute after administration of a high dose (1344 mg 
I/kg) of the probe resulting in vasculature visualization of the tumor site and the normal tissues.  
  
Figure A.3. X-ray images display the 5-day intratumoral fate of the probe in a rat breast tumor model 
before and 24, 72, and 120 h after administration of the probe at a dose of 455 mg I/kg bw. In the post-
injection images no blood vessels were visible in the normal tissue while the spleen, liver and the tumor 
were clearly seen.  
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 reticulo endothelial system (RES).  Figure A.4 shows two examples of how tumors were 
enhanced by the extravasated probe. The spatial and temporal variability of this 
enhancement, suggesting that each tumor had different tumor vasculature leakiness, can 
be clearly seen. 
 
Figure A.4. X-ray images of two tumors before and after injection of the probe at a dose of 455 mg I/kg 
with signal enhancement in terms of grey levels of tumor A is higher that tumor B by 40 and 70 digital 
units at t=72 and 120 h post-injection respectively, a difference that is clearly visible in the images.  
A.4.2.  HISTOLOGICAL EVALUATION OF EXTRAVASATED PROBE TUMOR DISTRIBUTION  
The tumor was characterized by a highly vascularized peripheral rim and an 
internal core with low vascularization.  The extravasated liposomes were localized in the 
well-vascularized periphery of the tumor in a patchy distribution (Figure A.5).  
A.4.3.  TUMOR IMAGING  
During the 3-day time course of imaging, some tumors exhibited a rapid and 
substantial increase of the enhancement whereas other tumors showed a slow and low  
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Figure A.5. Microdistribution of the probe in a breast tumor lesion 48 h after IV injection of rhodamine-
tagged iodinated liposomes (appeared as red dots on fluorescent microscopy); (a) The liposomes localized 
in the periphery of the tumor showing a patchy distribution (DAPI was used as a nuclear stain; appeared as 
blue; 10x magnification); (b) Immuhistochemical microvascular staining was achieved by staining for the 
specific endothelial antigen CD31 (appeared as green) revealing a highly vascularized peripheral rim and a 
less vascularized inner core (top left quadrant of the lesion is shown; 10x magnification); (c) In the same 
histological slice, the probe was localized within the well-vascularized rim. 
 
increase (Figure A.6).  Overall, the tumor enhancement displayed a variation among the 
animals with the standard deviation of 55 digital units representing 50% of the mean 
value of 110 digital units 3 days post-injection (Figure A.6.b).  While the tumor displays 
substantial enhancement, no enhancement was observed in normal tissues confirming that 
the nanoprobe levels in the blood were below the detectable threshold by mammography. 
In contrast, tumors within the control group of rats not given a contrast agent remained 
unenhanced implying that no endogenous changes of the tumor tissue contributed to the 
enhancement. 
A.4.4.  QUANTIFYING TREATMENT EFFICACY AS A FUNCTION OF PROBE 
EXTRAVASATION 
Liposomal doxorubicin slowed the progress of the tumor displaying statistically 
significant effectiveness 3 days after initiation of treatment comparing the control to 




Figure A.6. (a) The 3-day pattern of the enhancement following injection of the probe (455 mg I/kg) to a 
group of rats (n=14) indicates a high variability of the tumors leakiness; (b) The tumor enhancement due to 
the probe was significantly higher than that of normal tissue (the region used for the measurement of 
normal tissue is indicated in the inset) which showed no substantial enhancement. Without administration 
of the probe, the tumor lesion of a control group of animals (n=6) showed no substantial enhancement (data 
presented as mean ± standard deviation); (c) Comparison of the tumor growth rate of an untreated group 
(n=15) and a group treated with liposomal doxorubicin (n=14) at day 9 (arrow) showed significance 
difference after day 12 (∗ indicates p<0.005; data presented as mean± standard deviation); (d) The tumor of 
each animal of the treated group responded differently to the nanotherapeutic as indicated by the variable 
tumor growth curves. 
 
the tumor growth curve having standard deviations ranging from 10-35% of the mean 
value. Higher uptake of the probe by the tumor indicating leakier vasculature was 
associated with a slower tumor growth rate suggesting a better therapeutic outcome of 
liposomal doxorubicin. While the tumors of five animals grew marginally, the rest of the 
animals had to be euthanized since their tumors reached notably large sizes affecting the 
animals’ quality of life.  
We found a strong correlation between Ktumor growth and Kenhancement with the less 




 Figure A.7. (a) The correlation of the tumor growth (Ktumor growth) and the prognostic assessment 
(Kenhancement) was statistically significant (R2=0.838; p<0.001). Based on the imaging-based prediction, the 
group of treated animals was divided into two subgroups:  ‘good prognosis’ (n=9) and ‘bad prognosis’ 
(n=5). (b) The tumor enhancement of the two subgroups was significantly different; (c) The response of the 
‘good prognosis’ subgroup to the chemotherapy was significantly better († and ‡ indicate statistical 
significance of p<0.0005 and p<0.002 compared to the control group and the ‘bad prognosis’ subgroup, 
respectively). The ‘bad prognosis’ subgroup showed decreased tumor growth when compared to the control 
group (∗ indicates p<0.005). 
 
versa (Fig 7). Besides the enhancement rate constant, the predictive power of other 
descriptive parameters (such as the area under the enhancement curve) were examined  
displaying similarly good correlations (R2=0.856). A better therapeutic outcome was 
observed in the ‘good prognosis’ subgroup from day 12 when compared to the untreated 
and the ‘bad prognosis’ subgroup. The ‘bad prognosis’ subgroup still benefited from the 
liposomal therapy; showing decreased tumor growth after day 14 when compared to the 
untreated control group.  
A.5.  DISCUSSION 
The variability in tumor enhancement found in our study is consistent with a 
published study where the standard deviation of the accumulation of liposomal 
doxorubicin in a rat brain tumor was 150% of the mean value [23]. Numerous studies 
with liposomal doxorubicin conducted in invasive and well-vascularized xenograft mouse 
models have shown substantial variation in intratumoral accumulation and antitumor 
effects [26-29].  Besides animal studies, the biodistribution of radiolabeled liposomes 
was studied in cancer patients showing a considerable heterogeneity of the liposomal 
intratumoral deposition between different cancer types and between patients with the 
same tumor type [30]. However, no attempt was made in that study to correlate the 
efficiency of a subsequent liposomal doxorubicin treatment. 
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 The variability of the intratumoral contrast agent uptake captured during the 3-day 
imaging sessions provided an accurate prognosis of the effect of liposomal doxorubicin 
on tumor growth rate. Since the timescale of extravasation of nanocarriers such as 
liposomal doxorubicin to tumors is in the order of few days, the 3-day imaging derived 
enhancement rate constant correlated well with the tumor growth. The variable tumor 
response to the treatment observed in our study is consistent with human breast tumor 
xenografts in nude mice treated with liposomal doxorubicin where the tumor growth 
curve had standard deviations of about 30% of the mean value [26]. The variability of 
tumor response to treatment depends on the type and the status of the tumor when 
treatment is initiated. Even in the aggressive model [31] used in our study where imaging 
probed the vascular permeability of a tumor growing at a fast rate, the prognosis and 
antitumor effect of liposomal doxorubicin were significantly correlated.  
Consistent with earlier reports [12, 27, 32], the liposomes showed a patchy 
distribution concentrated on the periphery of the tumor, where there is high 
vascularization, associated with high levels of angiogenic and permeability factors [33, 
34].  
It is important to note that the goal of our study was not to induce regression, but 
to be able to non-invasively probe EPR status of a given tumor in a given animal and 
correlate this to the extent of change in tumor growth rate with administration of systemic 
nanotherapeutic.  In this aggressive tumor model, the protocol to induce regression of 
tumor would require multiple injections of systemic nanotherapeutic but this would 
obfuscate the goals of the study which were to facilitate non-invasive probing of EPR 
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 status of tumors so as to predict the degree of extravasation of systemically administered 
nanotherapeutics.  
A limitation of our study is that the feasibility of the predictive capability of the 
nanoprobe was demonstrated on a single tumor model although human cancer as a 
disease is much more heterogeneous than one experimental tumor model in terms of both 
tumors and hosts. Further testing in more tumor models is required to fully assess the 
value of this approach in clinical practice.   
In summary, the nanoprobe’s extravasation was probed in a rat breast tumor using 
a clinical mammography unit, and the animals were subsequently treated with liposomal 
doxorubicin of similar composition and particle size as the probe (and as the clinically 
used liposomal chemotherapy), to evaluate the probe’s predictive efficacy. Imaging 
allowed the identification of two subgroups prior to treatment: a ‘good prognosis’ and a 
‘bad prognosis’ subgroup and indeed these demonstrated differential tumor growth rates 
following administration of therapeutic. Our study demonstrates a contrast agent with 
the potential of predicting the therapeutic outcome of a clinically used nanoparticle-
based chemotherapy. Taking under consideration that mammography prevails as the 
only method of low cost mass screening of the general population for non-palpable breast 
cancer, the visualization of the extravascular accumulation of the probe and at the same 
time invisibility of the vasculature makes mammography an attractive non-invasive 
method for prediction of cancer therapy. Finally, though planar x-ray imaging enabled 
prognosis in our study by employing a clinically relevant, breast cancer imaging 
modality, mammography, we hypothesize such strategy would also be possible with 
tomographic methods (e.g. CT) yielding further insights. 
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 A.6.  PRACTICAL APPLICATIONS  
Prediction of systemic liposomal chemotherapy efficacy with iodinated liposomal 
probes and clinical digital mammography would facilitate personalized treatment of 
breast cancer.  
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